<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" xml:lang="en"><front id="fb1221d7-335f-48df-81fd-41ad223653ad"><journal-meta id="b6fbab68-7aa8-484d-826e-86a16bd2b8d7"><journal-id journal-id-type="hwp" id="db71f000-aa2f-4c80-b9dc-31bbf73daac1">esmoopen</journal-id><journal-id journal-id-type="publisher-id" id="65fc3034-3730-4134-930e-ab93f33cca10">esmoopen</journal-id><journal-title-group id="1d304186-4c8d-438a-b2c8-423d924054fe"><journal-title id="6246845e-4818-4b38-ba92-80fe148a3710">ESMO Open</journal-title><abbrev-journal-title id="4d3a23d3-014f-410b-88b4-29949b7c270d">ESMO Open</abbrev-journal-title></journal-title-group><issn pub-type="ppub" id="2865204d-25c1-49e9-b3a4-2362fad62a81"/><issn pub-type="epub" id="a7177beb-efa9-464a-bc17-b675dab9c9d1">2059-7029</issn><publisher id="7ac7111d-a7f2-4224-bf16-7dda5ea2b859"><publisher-name id="a657c45e-f90b-46a3-9e57-4c51dae10ca0">ESMO Open</publisher-name><publisher-loc id="f54d0fa7-726d-47c0-98c4-d7ce2b9a749f">BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta id="71ce9b00-c5fd-427b-8c19-a3d5a39e4e51"><article-id pub-id-type="publisher-id" id="4e897bed-4d25-4cec-88c7-b7bd362b0aaa">10.1136/esmoopen-2019-000511</article-id><article-id pub-id-type="doi" id="1f1799ee-dcd5-41d1-a1d7-0887466989b1">esmoopen-2019-000511</article-id><article-id pub-id-type="paw-acronomy" id="9b4a964f-d015-4350-b198-c50aa1e073e5">esmoopen</article-id><article-categories id="0d9e167a-5254-4fb9-9aff-acf134be5da8"><subj-group subj-group-type="display-channel" id="d6903323-177e-457a-8cf2-3d28fab7e71e"><subject id="a13f7113-3f1f-40fe-ba46-26ab0b8f9441">Review</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" id="d838e3f4-df28-4d0b-a865-3b51f2a69afe"><subject id="944558f9-cc10-4710-ad44-e040ece66125">1506</subject></subj-group></article-categories><title-group id="5798bfc9-1a27-4382-981d-e688b118549c">  <article-title id="b3aa41ea-ca78-4806-87dd-2ced7dafc4ab"><named-content rid="1554706534046" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" content-type="jrnlQueryRef" specific-use="start" id="81b3e521-93e2-4037-9c6e-0cde7fe434d5" data-answered="true"/><named-content data-cid="1554706636" id="fd28912d-e763-4c98-abc3-d55bf3cea5cc" content-type="del cts-2" specific-use="1554707343091" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:39pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707343091">“How I treat” ESMO Open Special Issue </named-content>How I treat MSI<named-content data-cid="1554807099" id="961066f1-e72a-4e1a-bc17-66c5d4b464c2" content-type="del cts-3" specific-use="1554807216887" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:53pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807216887">-</named-content><named-content data-cid="1554807100" id="f59e3200-c7c8-4b88-9421-3e2f211a928f" content-type="ins cts-3" specific-use="1554807217073" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:53pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807217073"> </named-content>cancers with advanced disease</article-title></title-group><contrib-group section="front" node-xpath="article-meta" next-xpath="author-notes" data-group="author" id="c02c4e90-b144-428e-ac0d-4645feb994a1"><contrib contrib-type="author" id="author-45382089" data-id="author-45382089"><name id="1e3f1a81-252f-4b51-aea9-3529987491fe"><surname id="a1e37b5f-46c8-40e3-b294-5b3c920152cf">Kok</surname><given-names id="8811db05-8909-4686-89cf-5b16845274c3">Marleen</given-names><prefix id="bdac0dfb-afe0-4f37-92f4-0d562228ef96">Dr</prefix></name><xref rid="aff1" id="38c5f5c0-32a2-43e5-ad4f-05f787ba5104" ref-type="aff">1</xref><email id="f640fb6a-cbf3-4349-95ff-e30b2360a5fb">m.kok@nki.nl</email></contrib><contrib contrib-type="author" id="author-68703031" data-id="author-68703031" data-edited-node="true"><named-content rid="e8b4b55a-1a8a-4c64-9e1a-63f8bf3b482d" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="preeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="752abfe5-448b-400d-a1e6-5899ed6e67ac" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/><name id="fbccd961-fccd-4ac3-a70d-c3153ccc1705"><surname id="a03baf97-5a30-421c-aa79-f4089b7fc446">Chalabi</surname><given-names id="d472929c-4a72-4954-ab55-8eef036043af">Myriam</given-names><prefix id="6094d7f1-584d-41a4-a863-d81dca021f4f">Dr</prefix></name><xref id="a2a3a146-04e9-4b51-9563-7858271928b5" rid="aff1" ref-type="aff">1</xref><email id="68de58ce-42a3-45ac-99e1-76bdaec1993c">m.chalabi@nki.nl</email></contrib><contrib corresp="yes" contrib-type="author" id="author-45682448" data-id="author-45682448" data-order="last" data-correspondence-order="1"><name id="f4e3857e-7ba0-4ca0-935b-9b2ae2d1a76c"><surname id="a51237f2-da44-4119-ba07-e03dc83cad24">Haanen</surname><given-names id="0a52b4c8-5c18-4173-b03a-36e706466ff1">John</given-names><prefix id="c83bfda8-838b-4622-9b54-ff3e79a7ab89">Dr</prefix></name><xref id="149ef40a-3308-482c-9f70-6b94686185a0" rid="aff1" ref-type="aff">1</xref><xref ref-type="corresp" rid="cor1" id="3dd1175b-cc2d-4d01-b95e-7f10fcdd5c64"/><email id="5415ca27-8aaf-411f-af5b-17a8338a52d1">j.haanen@nki.nl</email></contrib><aff section="front" node-xpath="contrib-group" prev-xpath="contrib[last()]" id="aff1" data-id="aff1" data-edited-node="true"><label id="f20f4155-4c4e-4693-b122-50743eac705e">1</label><named-content content-type="dept" id="333507fd-61ba-4667-8f55-fe401bbba5c2">Medical Oncology</named-content>, <named-content content-type="institution" id="02c9ac03-0b33-4561-9080-b50cd0012b04">Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis</named-content>, <named-content content-type="city" id="48dad1e0-7aa6-4d05-a4e1-145482c3d3ad">Amsterdam</named-content>, <named-content content-type="country" id="6012816d-bcd9-4059-a01a-2b10802d806d">The Netherlands</named-content></aff><aff section="front" node-xpath="contrib-group" prev-xpath="contrib[last()]" id="aff2" data-id="aff1557330593688" data-track="del" data-cid="1554707474842" data-username="Gowtham Ram (PREEDITOR)" data-userid="preeditor gowthamram" data-time="1554707474842" data-callback="kriya.general.reorderLinks"><label id="a7470db9-b26a-44d6-941e-f4ece9f26304">2</label><named-content content-type="institution" id="6f50b1bb-d645-4f94-aefe-4fc3a6a242fe">Netherlands Cancer Institute</named-content>, <named-content content-type="city" id="89c9ae85-115a-48eb-88a2-b1b33debbd15">Amsterdam</named-content>, <named-content content-type="state" data-valid-state="false" id="06c8c2f6-0abe-4208-a7d0-316a44ba4d9e">Noord-Holland</named-content>, <named-content content-type="country" id="cce917cb-b1a3-4403-a9f5-13f886216047">Netherlands</named-content></aff></contrib-group><contrib-group content-type="section" id="5316da80-e943-46a7-9eba-19f1551efa80"><contrib contrib-type="editor" id="author-45383259"><name id="e55754ca-72b4-4dfc-836f-77b67cf5ec26"><surname id="77a0968a-8c7a-4802-93f9-81abd8935169">Zielinski</surname><given-names id="69b692de-0a5f-4113-a7b2-5f497dcbcb53">ChristophC</given-names><prefix id="53d2ccc2-881b-45bb-8043-2bf3a2749b9b">Professor</prefix><suffix id="661e5fc0-e62a-4254-89b4-68e3870425d5">M.D.</suffix></name><xref ref-type="aff" rid="ae-aff1" id="db40bec9-a369-4b56-b1b8-0086499a7939"/><xref ref-type="aff" rid="ae-aff2" id="9cb31c67-26c5-460b-8342-c0d3d9e5513a"/></contrib><contrib contrib-type="editor" id="author-45383259"><name id="7a0836f7-fcc8-4518-9381-6580b4c71b2a"><surname id="9cade339-4ba3-4971-9e1c-20f9663fabce">Zielinski</surname><given-names id="93448548-a3ad-4113-a53e-2a92cb6e8748">ChristophC</given-names><prefix id="924e76e3-06db-47e0-85f1-3f3519093a82">Professor</prefix><suffix id="b1f9fe55-9fd4-45bc-91c2-5d837415f207">M.D.</suffix></name><xref ref-type="aff" rid="ae-aff3" id="2cbe43d6-a8e3-4dfb-befd-ed54b86222d3"/><xref ref-type="aff" rid="ae-aff4" id="a1143d91-2888-49a9-8423-dc70e2778897"/></contrib><aff id="ae-aff1" data-id="ae-aff1"><department id="4979d0b8-0e6b-4310-a6c3-50c12595f9bd">Comprehensive Cancer Center</department>, <institution id="770d083e-9712-4982-8fca-1434ec46c70e">Medical University of Vienna</institution>, <city id="6d3b33d9-0633-456c-9029-583eacbddc99">Vienna</city>, <country id="fcf58813-89b5-40ac-b5e2-b4cb28d3c603">Austria</country></aff><aff id="ae-aff2" data-id="ae-aff2"><institution id="eadafd04-151f-4ffa-8a61-5a07e1c96f4d">Central European Cancer Center</institution>, <city id="263144a4-8aa9-4924-8da2-02ce9428b55b">Vienna</city>, <country id="f16f7250-c6b2-4d7f-a709-da34ceacf05d">Austria</country></aff><aff id="ae-aff3" data-id="ae-aff3"><department id="5cd51da3-f4c3-41a0-bd88-81ac362f531f">Comprehensive Cancer Center</department>, <institution id="8a937e82-d0ab-4d1c-b0bc-c02c02a43bf1">Medical University of Vienna</institution>, <city id="244280a0-ae28-400a-ab4e-da8f858964d5">Vienna</city>, <country id="154cb5e6-b6d8-434c-9ce8-63db097355ad">Austria</country></aff><aff id="ae-aff4" data-id="ae-aff4"><institution id="241805ff-ba23-4780-a6e0-3dd7dce2c57f">Central European Cancer Center</institution>, <city id="2a4ef5ba-9517-4d7e-a26e-99a98f18a374">Vienna</city>, <country id="cde11251-d6f7-46f2-bae1-6e02e676783d">Austria</country></aff></contrib-group><author-notes id="37b260e5-efd2-4e14-a803-1b10cd5150f5"><corresp section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" id="cor1" data-id="cor1"><name data-class="jrnlAuthor" id="c36222d8-7e3c-4020-9328-23e1286c50b1"><prefix id="10ad5044-0628-4bf8-873a-40f330a9a8b9">Dr</prefix> <given-names id="641a5677-5ee4-45d4-89e0-0a687ad8cc73">John</given-names> <surname id="9243dc1a-c13a-4da5-8fb7-5642417f907e">Haanen</surname></name>, <fn fn-type="corresp-address" id="b166a12e-092a-40a7-a31f-2ab7c84ef58b"><p id="1611af48-72fc-4ea6-9e83-bea35408ec2c"><named-content content-type="dept" id="38243800-7eb5-4e7a-abe0-768d4f408ebd">Medical Oncology</named-content>, <named-content content-type="institution" id="e637d601-4174-41af-b902-a00410b72785">Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis</named-content>, <named-content content-type="city" id="e2628f46-d615-43da-9edb-8b3db563ab0c">1066 CX Amsterdam</named-content>, <named-content content-type="country" id="b55751be-5481-4f90-aee5-dd32722fe461">Netherlands</named-content></p></fn>; <email id="3ffbd254-ea5c-41b7-ae0a-84ccdeda17ea">j.haanen@nki.nl</email></corresp><fn fn-type="con" section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" data-label="Contributors" id="fn1" data-id="fn1" data-edited-node="true"><label id="99ec5d15-1c79-4025-9fc5-5a679c47c0a6">Contributors</label><p id="f85bf8d5-5a6f-47c1-bdaa-abce766a3916">All authors contributed equally.</p></fn><fn fn-type="conflict" section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" data-label="Competing interests" id="fn2" data-id="fn2"><label id="78b1ecb8-1dd3-491e-bc2d-e8a6fc04afae">Competing interests</label><p id="e20600e7-2ce0-49db-b5c6-46535254541f">None declared.</p></fn><fn fn-type="provenance-and-peer-review" section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" data-label="Provenance and peer review" id="fn3" data-id="fn3"><label id="d26652ce-13c3-4d34-bc00-8a89085795f1">Provenance and peer review</label><p id="bd73a69c-4759-4946-a7ab-dd261b10ae89">Commissioned; internally peer reviewed.</p></fn><fn fn-type="prepub" section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" data-label="Prepub" id="fn4" data-id="fn4" data-edited-node="true"><label id="44f65690-284a-45c7-99c1-54827aba8b84">prepub</label><p id="dbbcfb26-4c5f-4839-9006-b4f17e84b7bf">Prepublication history for this paper is available online. To view these files, please visit the journal online (<ext-link data-class="jrnlExtLink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/esmoopen-2019-000511" id="fb593d0a-e335-42a0-ab27-67934f470d63">http://dx.doi.org/10.1136/esmoopen-2019-000511</ext-link>).</p></fn><fn fn-type="consent" section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" data-label="Patient consent" id="e5eaa23b-3cdd-4ba8-bf10-f02122459dff" data-track="ins" data-cid="1554707894385" data-username="Gowtham Ram (PREEDITOR)" data-userid="preeditor gowthamram" data-time="1554707894385"><label id="723efff7-104c-4556-90e4-703ee6b888a3">Patient consent for publication</label><p id="eb070ad5-a07d-4a1c-8628-e8796aecd542">Not required.</p></fn></author-notes><pub-date section="front" node-xpath="article-meta" node-prev-xpath="//author-notes" node-next-xpath="//history" pub-type="ppub" id="54ba7f6f-1cdb-4b57-ac34-0fbc39f04d6f"><day id="7b7b3645-f63f-44a2-8201-312d98fa9fb4">21</day><month id="9df0f27b-b011-4238-842a-faa47a47f8bb">05</month><year id="a583ab10-cbd9-4545-ac7b-9da6f61b6009">2019</year></pub-date><pub-date section="front" node-xpath="article-meta" node-prev-xpath="//author-notes" node-next-xpath="//history" pub-type="epub" id="d6c637d1-223f-44ee-a5ad-8f00e9aaf197"><day id="b0bcbb82-306b-48bf-8849-2ca55e8858e5">21</day><month id="28adb588-e713-4f5f-8f59-991a05bd3c74">05</month><year id="3c25fa67-3a22-43f9-a6c4-179da1d20df4">2019</year></pub-date><volume section="front" node-xpath="article-meta" node-next-xpath="//history" id="f78fab9c-0c39-401d-a2dd-6f5a2a6033a6">4</volume><issue section="front" node-xpath="article-meta" node-next-xpath="//history" id="73455461-443a-4ee3-b3d3-32a343b2e726">Suppl_2</issue><elocation-id section="front" node-xpath="article-meta" node-next-xpath="//history" id="405405b4-60b8-43a9-a5ce-9a7490c33ae1">e000511</elocation-id><history id="29da1168-45e8-4aa0-b37f-859f7aa868ab" data-edited-node="true"><date date-type="received" id="1147e560-c724-4e69-86c4-243f6e063510"><day id="731f82fc-94dc-4999-8730-4ad27af29639">11</day><month id="6b00e7a8-362f-40fc-843d-034a81910931">03</month><year id="11b361bb-d75c-4393-aae4-bf4edaa7af71">2019</year></date><date date-type="rev-recd" id="4148a47d-6198-4364-ac65-b349e7e1a9f9"/><date date-type="accepted" id="6879070e-5da8-40cc-8de9-c41ccc3ba967"><day id="3b8b66fb-cce8-4432-a1b0-836cd472965d">19</day><month id="56783879-fafc-4875-9a25-5c89582db02f">03</month><year id="510bf572-55f5-432a-81bb-2697e63b4ac6">2019</year></date></history><permissions data-type="ccbync40" id="63cb3c22-d379-4ed6-ac9e-63d8b58875db"><copyright-statement data-statement="new" id="0f775f3a-7924-4b1b-86fa-e7177ed6601e">© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.</copyright-statement><copyright-year id="4555a741-e19b-4280-98e9-1788ea81260e">2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" id="9204ec2f-ab08-4900-9982-b4ca312a83c9"><license-p id="801c922b-dfc4-4a6e-9988-27e0dfa07a48">This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" id="d16a0577-8689-4730-97d0-a75d3e53be92">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><files id="71c9f29d-244f-444b-b64f-6e0de4973ab1"><file file-type="Main Document" file_category="" file_name="esmoopen-2019-000511-File001.docx" submission_medium="online" id="151f65eb-05b4-4f22-bfb7-0d86e8ddef07"><file_createddate id="7ea8c39f-1e75-43fe-8eb4-bfe8434ea36d">2019-03-11 05:23:26.26</file_createddate><file-format id="718507b1-ddcd-4990-bbf5-4f691abc865f">docx</file-format><file-extension id="9d0a04f9-d314-4de9-a20b-f07caa68e006">docx</file-extension><file-name id="abba2d9a-622e-4330-a64b-61247769381d">How I treat_MSI_NKI.docx</file-name><file-caption id="f1775e70-518f-411b-bf85-5c1ef5c8fe98"/><file_tag id="aa3c838e-744a-45e3-b39e-7a1f5c5023fc"/><attribute attr_name="File Designation" id="959c4cdd-7c4f-470c-b461-c4f94b439128">Main Document</attribute></file><file file-type="Mono Image" file_category="" file_name="esmoopen-2019-000511-File002.JPG" submission_medium="online" id="32b8b6b0-324c-4a1e-98ae-a384944f69d5"><file_createddate id="ece85040-8923-4023-8974-74ed1eafa6b1">2019-04-05 07:44:31.31</file_createddate><file-format id="5ce4a149-ab1a-4e90-b0eb-c7650c76b703">JPG</file-format><file-extension id="afeab05a-fdcc-4a68-839c-6687dc638033">JPG</file-extension><file-name id="fd036310-8685-4647-b1cd-01ee1517f886">MSI FOR ESMO OPEN.JPG</file-name><file-caption id="cdbe395f-5bd8-4a34-b38a-65d360bcc80f"/><file_tag id="90f0e2b8-3b48-4d24-b910-72a9e1e33401"/><attribute attr_name="File Designation" id="fd4764bf-66e1-4ced-b981-f3e798b06bdd">Mono Image</attribute></file></files><abstract id="12d66e4f-5b1d-4dd0-9975-75c1cb661644"><title data-level="1" id="1bc28622-cb2a-4e57-be2b-e68c1dddb3a7">Abstract</title><p id="8cd36464-a932-467f-ab3e-6b0a249ba992">Mismatch repair deficiency (<named-content id="5336f3b0-2adb-4781-9add-3f2e800f7cce" data-cid="5336f3b0-2adb-4781-9add-3f2e800f7cce" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="28" data-match=" (dMMR)" data-pattern="" data-tag-index="1_1" data-time="" data-username="" data-userid="">dMMR</named-content>) results in microsatellite instability (<named-content id="1ddf1967-0f33-4f97-b81b-0a8b3b75e245" data-cid="1ddf1967-0f33-4f97-b81b-0a8b3b75e245" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="73" data-match=" (MSI)" data-pattern="" data-tag-index="1_2" data-time="" data-username="" data-userid="">MSI</named-content>) and is strongly associated with responsiveness to <named-content data-cid="1557330183" id="3456eaf7-95ce-49fe-a283-554f570b5214" content-type="ins cts-4" specific-use="1557330960804" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 4:56pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557330960804"><named-content rid="bb06f602-964a-46a6-aaa3-e15dc0c10f86" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="publisher" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="a08b0a65-469a-42d1-9109-d59301fb5ecf" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>programmed death-1 receptor (</named-content>PD-1<named-content data-cid="1557330232" id="b05846b3-5b45-4986-be39-f8b46c558f7a" content-type="ins cts-4" specific-use="1557331160537" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 4:59pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331160537">)</named-content>-blocking antibodies<named-content data-class="jrnlQueryRef" rid="bb06f602-964a-46a6-aaa3-e15dc0c10f86" data-type="end" id="a3f9b6e8-2730-4116-b3d4-fff5a1f23928" content-type="jrnlQueryRef" specific-use="end"/>. Probably the main driver for the observed high efficacy of immune checkpoint inhibitors in dMMR <named-content data-cid="1554706534010" id="cdef1710-86f4-41ab-be5f-05ec7ed69de7" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content data-cid="1554706534010" id="c71a6b61-2eea-4c52-b35f-f8a2ee8c4bb2" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="250" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="1_4" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> is the remarkably high <named-content id="6bdad4f4-76be-4e4b-95d2-8e571d98d73f" data-cid="6bdad4f4-76be-4e4b-95d2-8e571d98d73f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="280" data-match="tumor mutational burden" data-pattern="" data-tag-index="" data-abbr="TMB" data-time="" data-username="" data-userid=""><named-content data-cid="1554706534011" id="18ed4092-8dab-47aa-aefd-db21a670b67d" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content data-cid="1554706534011" id="4d17d804-220f-4b40-959b-908790fc50fe" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="280" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="1_5" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> mutational burden</named-content>. MSI can be detected using immunohistochemistry and/or PCR. In addition, next-generation sequencing <named-content data-cid="1554807237" id="38d99845-641a-4363-9ff4-b91fc7759af8" content-type="del cts-3" specific-use="1554811393559" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:03pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811393559">(</named-content><named-content id="0f964d19-4111-4619-b99d-6447647defb1" data-cid="0f964d19-4111-4619-b99d-6447647defb1" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="405" data-match=" (NGS)" data-pattern="" data-tag-index="1_3" data-time="" data-username="" data-userid=""><named-content data-cid="1554807236" id="19ea8d05-899d-4c3d-88e5-c26365267691" content-type="del cts-3" specific-use="1554811393392" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:03pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811393392">NGS</named-content></named-content><named-content data-cid="1554807236" id="dba8cdf5-15d5-408e-814f-95243f080423" content-type="del cts-3" specific-use="1554811393392" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:03pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811393392">) </named-content>is becoming increasingly available to clinical laboratories as a cost-effective and scalable method to evaluate multiple genetic aberrations including MSI.<named-content data-cid="1554706637" id="fd143200-2376-483d-b742-20f7e67d0e99" content-type="ins cts-2" specific-use="1554707750412" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Inserted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:45pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707750412"> <named-content data-cid="1554706638" id="72f222a2-9666-432b-a862-2f0e7e7db618" content-type="ins cts-2" specific-use="1554707751114" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Inserted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:45pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707751114">Efficacy of PD-1-blockade in MSI <named-content data-cid="1554807097" id="f4779d9e-9425-4645-bdf3-5bf6d27c6e0c" content-type="del cts-3" specific-use="1554807181631" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:53pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807181631">tumors</named-content>tumours is similar for patients with colorectal cancer (CRC<named-content data-cid="1554807268" id="3c305e6c-a535-44fd-a7b4-5d1f3cedd122" content-type="ins cts-3" specific-use="1554811548084" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:05pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811548084">;</named-content><named-content data-cid="1554807269" id="d89fc332-2cfa-4617-9c23-18a5e889cdf0" content-type="del cts-3" specific-use="1554811548710" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:05pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811548710">,</named-content> <named-content data-cid="1554807262" id="8c0b227d-8a7f-447a-b1fb-99d3700c647d" content-type="ins cts-3" specific-use="1554811537272" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:05pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811537272"><span id="fa6f225e-6532-4e75-be2e-cdc554084fc4"><named-content data-cid="1557330131" id="c5121d29-8f0f-4b4f-8fad-6406a7cc9a62" content-type="del cts-4" specific-use="1557330734833" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Deleted by Tasnia (BMJ) - May 8 2019 4:52pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557330734833">overall</named-content><named-content data-cid="1557330132" id="91a7521c-d73f-40c8-99b9-1e32ef2d5d56" content-type="ins cts-4" specific-use="1557330734871" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 4:52pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557330734871">objective</named-content> response rate</span> (</named-content>ORR<named-content data-cid="1554807265" id="bee8166f-6f13-4c8e-96cb-5c9d4f31fb86" content-type="ins cts-3" specific-use="1554811539958" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:05pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811539958">)</named-content> 36%) or a different cancer type (ORR 46% across 14 other cancer types). Based on these results, PD-1-blocking antibody pembrolizumab was the first tumo<named-content data-cid="1554807098" id="8ec1289d-65a9-4a46-b271-75a702954f8b" content-type="ins cts-3" specific-use="1554807197092" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:53pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807197092">u</named-content>r-agnostic treatment to be granted <named-content data-cid="1554807281" id="3503c372-a03e-4c0c-82c8-894ed1d17414" content-type="ins cts-3" specific-use="1554811985330" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:13pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811985330"><span id="a6a73335-4f06-4920-8ae4-37564e5f3592">Food and Drug Administration</span></named-content><named-content data-cid="1554807283" id="d987d332-1b9f-4e5c-ad46-50d117cc3a12" content-type="del cts-3" specific-use="1554811986916" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:13pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811986916">FDA</named-content> approval based on the presence of MSI as a biomarker. <named-content data-cid="1554706640" id="4c8b44aa-3e55-4704-80e3-75b2cf4bbe60" content-type="ins cts-2" specific-use="1554707758760" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Inserted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:45pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707758760">Currently, there is no approved PD-1-blocking antibody for MSI cancers in Europe. Here, we present our experience with the screening for MSI<named-content data-cid="1554813304" id="8c5ca027-aa8b-475a-a6d6-c295d6bdd587" content-type="del cts-3" specific-use="1554813957019" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:45pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554813957019">,</named-content> and the treatment of patients with advanced disease of MSI CRC and non-CRC with immunotherapy.</named-content></named-content></named-content></p> </abstract><kwd-group section="front" node-xpath="article-meta" next-xpath="funding-group" id="c542b443-1085-470a-a53c-49eee601f03d"><kwd data-class="jrnlKeyword" id="5de72a9a-0cc4-4e40-a845-fcb6fdb4b7d6">msi</kwd><kwd data-class="jrnlKeyword" data-track="ins" data-cid="1555312045467" data-username="John Haanen (AUTHOR)" data-userid="author 976668088" data-time="1555312045467" data-title="Inserted by John Haanen (AUTHOR) - Apr 15 2019 9:07am" id="ef8e2fe8-d4fb-4633-b4bb-c2edcab89928">deficient MMR</kwd><kwd data-class="jrnlKeyword" id="81ca09f2-79ab-4b39-8b90-a6bc8c59620d">advanced cancer</kwd></kwd-group><custom-meta-group id="d0df6548-037f-4dc1-9fd8-ba5d365d1b0f"><custom-meta id="780a5136-9725-42a9-95b6-575b42c08e96"><meta-name id="78cc4256-e584-40f6-93ff-c8632aede3bf">Copy editing requirement</meta-name><meta-value id="79573273-d546-43d9-95ed-b1addfd7ecc7">2</meta-value></custom-meta><custom-meta id="de9fea03-5ca0-43e8-8ace-2449d5f98869"><meta-name id="71eda16a-0d34-4156-a99d-44204d8691a9">Author requirement</meta-name><meta-value id="bf6d7183-9d4e-4ff3-a44b-fef01a296f4b">2</meta-value></custom-meta><custom-meta id="65b5a9d9-adac-4dc6-87d7-ac637da32e7a"><meta-name id="876a8695-e149-404b-a216-4fac5f9c03db">payment method</meta-name><meta-value holdtype="NoHold" id="0a51f29b-9a42-455d-a2b1-226b23143c17">APC Waived</meta-value></custom-meta><custom-meta id="a14cafdf-73fc-4b1e-b7b4-308482f5d346"><meta-name id="ee56919d-0333-4d97-8dbf-c1aa4a386cfe">license type</meta-name><meta-value id="567c8d78-8657-4e73-9838-e449d766c3b9">CC-BY-NC</meta-value></custom-meta><custom-meta id="00b47180-ba65-43b7-b8e0-726927b3ae33"><meta-name id="3627220f-dda8-4893-b642-747ea2a87047">Spelling language</meta-name><meta-value id="6a42a116-f018-4405-a1a5-3ab31dd47e0a">en-GB</meta-value></custom-meta><custom-meta section="article-meta" node-xpath="custom-meta-group" id="1a29f6a7-92cb-47fc-83dd-861e4ab079ac"><meta-name id="efcb9e52-bc60-48d1-a3d0-9d5dacfdba0d">Special issue</meta-name><meta-value id="6ca53f90-da3c-4870-989a-a270feada2fc">How I Treat Cancer</meta-value></custom-meta><custom-meta specific-use="query" id="1554706534046" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-answered="true"><meta-value id="7ab19ba4-f2f1-4f4c-9bfd-9eb2a5012f7c"><named-content xlink:title="Exeter Pre-editing" specific-use="Apr 08 2019 (12:25)" content-type="Author" alt="preeditor" id="4107e24b-3a2a-4978-a364-9e48fb6fa941">Corrections at this stage should be limited to those that are essential. Extensive corrections will delay the time to publication and may also have to be approved by the Editor. Changes can not be made after the article has published online. Please acknowledge that you have read this message.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:29)" content-type="answered" alt="author" id="0c505bf8-5014-46a6-991f-a8d60b30b314">have read this message</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="1554706534047" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-answered="true"><meta-value id="0e2ee803-f3ea-45d8-b054-f8957a9a05bd"><named-content xlink:title="Exeter Pre-editing" specific-use="Apr 08 2019 (12:25)" content-type="Author" alt="preeditor" id="fd6ac8af-bd78-48de-b558-c765ab78fa88">Please check all author names are spelt correctly, and that affiliations and correspondence details are accurate. Please confirm that these are correct.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:21)" content-type="answered" alt="author" id="0fdff5fd-a16f-480f-9862-b4435601c34f">Author names are spelled correctly and correspondence details: change Dr John Haanen to Prof John Haanen</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="bb06f602-964a-46a6-aaa3-e15dc0c10f86" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-answered="true"><meta-value id="ea1ca25b-0a5a-494d-bd3d-2c9101867267"><named-content xlink:title="Tasnia (BMJ)" specific-use="May 8 2019 5:00 PM" content-type="Author" alt="publisher" id="ef5e6c1c-b16c-46e7-9dd9-e963faaa37df">please confirm if this change is okay</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="May 8 2019 (22:02)" content-type="answered" alt="author" id="c001f894-c8c9-4355-a364-406bd62066c0">correct</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="b38c748e-a4ae-4351-bb25-0c50c8fca12d" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 775.75px; top: 213px;" data-answered="true"><meta-value id="6e9ee600-bbf7-41fc-9269-45b42f28c84a"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:51 PM" content-type="Author" alt="copyeditor" id="eaf4d057-c3ac-4523-82ed-28d23ff7a983">Please provide the expansion of PD-L1.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:25)" content-type="answered" alt="author" id="c3d9f503-7870-4a6f-bd30-b3061ccb4a20">Programmed Death receptor Ligand-1</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="65a5f656-0c30-4633-8000-cefdea3e2f4c" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 656.78125px; top: 656px;" data-answered="true"><meta-value id="930d37fe-5eb9-4763-89d9-b9434da19ed7"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:54 PM" content-type="Author" alt="copyeditor" id="60c46cea-2fc3-4f25-b26a-f8d8d04ee0f5">'Given that the number of immunotherapy trials entering individuals based on high TMB<sup id="ed55d17e-d183-4bcd-87c5-4fcbf6066f63">8</sup> or MSI status is increasing...'. In this sentence, please check the use of the word 'entering' and confirm this is correct, or can be modified to 'enrolling'.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:18)" content-type="answered" alt="author" id="6f300d24-3f83-4bb8-a0d6-c6b64ac30aa3">correct</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="9bc0c555-af32-4ed7-87d5-6a4495813bce" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 412.953125px; top: 652px;" data-answered="true"><meta-value id="478f8e66-5035-4517-9dae-f8b334067e10"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:01 PM" content-type="Author" alt="copyeditor" id="5052e2a1-bf09-4537-ad00-6d5c718110d3">Please note that 'microsatellite unstable' has been changed to 'microsatellite instability' as expansion of MSI in the main text. Please check and correct if necessary.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:10)" content-type="answered" alt="author" id="d05460f0-9086-4e4f-afaf-82c25ab3bc4e">perfect</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="1e213b78-2502-442c-a65a-df3abd79f5b3" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 115.5px; top: 699px;" data-answered="true"><meta-value id="21cce5af-ebc4-4394-86da-2276cf304849"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:02 PM" content-type="Author" alt="copyeditor" id="dfb1c210-770f-4262-b814-e578f2af2f10">Please provide the expansion of 'PD-1' at first mention in the abstract and in the main text.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:11)" content-type="answered" alt="author" id="0dee99a6-2eef-4d19-b9ee-dfa592ab8b57">Programmed Death-1 receptor</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="e20a7fe0-bdd5-478a-b262-f85beb296296" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 775.75px; top: 422px;" data-answered="true"><meta-value id="db819b98-17d3-4784-be8d-870c25133a4d"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:07 PM" content-type="Author" alt="copyeditor" id="cab0c154-88de-474f-94b5-66c6978a779d">Please provide the expansion of MCPyV.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:19)" content-type="answered" alt="author" id="94e0e0e4-dc8c-4890-b2f7-3586987b142d">Merkel Cell Polyoma Virus</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="2dc8f32c-35a5-46ad-b2f3-8912087c324b" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 775.75px; top: 604px;" data-answered="true"><meta-value id="f988623a-e62a-4639-9efe-156aa38eb6fa"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:10 PM" content-type="Author" alt="copyeditor" id="7e35abe8-622a-4453-b3e7-29e7855be710">Note that ORR has two expansions in the main text: 'objective response rate' versus 'overall response rate'. Please check and correct if necessary.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:09)" content-type="answered" alt="author" id="b6d43f8f-b978-438a-aee7-5f5c2c87bb95">Should be changed to objective response rate instead of overall response rate!</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="3e9fccdc-f1e3-49ac-ae4c-013597a43be3" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 335.796875px; top: 675px;" data-answered="true"><meta-value id="73dfe1b6-b8b1-4132-88ca-5c920587f43a"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:13 PM" content-type="Author" alt="copyeditor" id="f25f1912-ec3d-4f14-9cd0-231d8800c202">Please note that 'Food and Drug Administration' has been introduced in the main text and in the abstract as expansion of FDA. Please check and correct if necessary.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:10)" content-type="answered" alt="author" id="51359a82-da35-4bf9-8aa2-3c6cfb418883">accepted</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="8066ad22-9e71-43e0-8acd-60219ca97669" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 681.359375px; top: 710px;" data-answered="true"><meta-value id="5cd2ca50-7a78-43e0-8b6b-18b416361e6b"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:15 PM" content-type="Author" alt="copyeditor" id="6131f1fb-5caa-42d5-822e-68e88e3d9e84">Please provide the expansions of BAT-25 and BAT-26, if any.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:14)" content-type="answered" alt="author" id="5bf2bbc6-0625-4921-a663-ea066afd97b1">there are none</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="70fa2ea1-a465-44cd-a453-9b533793c671" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 24px; top: 634px;" data-answered="true"><meta-value id="1157a611-aa75-4ea1-b629-f8c749f8a582"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:17 PM" content-type="Author" alt="copyeditor" id="8896ff18-5a9c-419e-a3ee-8447d31c42b1">Please provide the expansion of CLTA-4.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:17)" content-type="answered" alt="author" id="8b6e55e8-1417-4f45-ba34-bc0c150c7f45">Cytotoxic T-lymphocyte associated protein-4</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="72a7d942-9650-4c9e-9652-4a927dd66d6d" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 24px; top: 658px;" data-answered="true"><meta-value id="afe84abf-5fd5-4dbc-b5ff-f7b65022801a"><named-content xlink:title="Maria (COPYEDITOR)" specific-use="Apr 9 2019 8:18 PM" content-type="Author" alt="copyeditor" id="2d5934e9-fe45-4140-9972-b3a92daa2552">Please provide the expansion of EMA.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:18)" content-type="answered" alt="author" id="3f89e685-609e-4c4f-992f-4e05e6eb42ce">European Medicines Agency</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="e8b4b55a-1a8a-4c64-9e1a-63f8bf3b482d" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-style="left: 682.234375px; top: 312px;" data-answered="true"><meta-value id="8b84589f-5348-4db8-92b1-da8c971a3977"><named-content xlink:title="Gowtham Ram (PREEDITOR)" specific-use="Apr 8 2019 12:52 PM" content-type="Author" alt="preeditor" id="035c70ec-a50f-4e82-94ba-507eb5fdcb6d">Please provide full first name of author M Chalabi.</named-content><named-content xlink:title="John Haanen (AUTHOR)" specific-use="Apr 15 2019 (9:06)" content-type="answered" alt="author" id="5943628c-cc16-42b4-9ba0-9078ed11c39e">Myriam Chalabi. Please change the order of authors to Marleen Kok, Myriam Chalabi, John Haanen</named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="a5cd8140-0d22-46a2-8ada-2cf259e914e6" xlink:title="29da1168-45e8-4aa0-b37f-859f7aa868ab" xlink:actuate="0b0ea00d-3c02-4ab4-9a81-09db426c9c05" xlink:role="typesetter" xlink:href="54ba7f6f-1cdb-4b57-ac34-0fbc39f04d6f"><meta-value id="9c9cef98-250a-4526-8cf8-0d1d097669d7"><named-content specific-use="historyContent" data-title="" id="1adc99b0-924c-4978-b4bb-1144f32c6c39"><named-content specific-use="change-person" data-title="" id="3142f053-8462-49ca-aeb0-6943b3d1686e">Usha</named-content> <named-content specific-use="" data-title="" id="b141742c-459c-4cb0-9260-0cd02e36cf7d">inserted</named-content> <named-content specific-use="newVal" data-title="" id="82685667-c000-46c2-99d2-7e9ecfe46d96">21052019</named-content> <named-content specific-use="" data-title="" id="6b7e1b3c-166e-4a8d-92f5-68f475283940"> in ppub field on</named-content> <named-content specific-use="change-time" data-title="" id="dee60f38-83d7-482b-b490-07dca3590967">21 May 2019 12:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="241e8b35-28a4-4246-ad7c-2bc6bfe39c79" xlink:title="29da1168-45e8-4aa0-b37f-859f7aa868ab" xlink:actuate="0b0ea00d-3c02-4ab4-9a81-09db426c9c05" xlink:role="typesetter" xlink:href="d6c637d1-223f-44ee-a5ad-8f00e9aaf197"><meta-value id="da113057-25f0-49e4-b6f5-ee7b0564eb40"><named-content specific-use="historyContent" data-title="" id="82b66103-5a93-4912-8348-9cbec019b0b8"><named-content specific-use="change-person" data-title="" id="e73bfd77-4416-40fd-b42e-252b3ec3cdbf">Usha</named-content> <named-content specific-use="" data-title="" id="a721dfc3-7386-43d9-a28c-2d1f37096c40">inserted</named-content> <named-content specific-use="newVal" data-title="" id="5f306736-a5ce-4c91-8356-a0148442720d">21052019</named-content> <named-content specific-use="" data-title="" id="d17d413f-bc41-4432-b7c8-59b8bad126e1"> in epub field on</named-content> <named-content specific-use="change-time" data-title="" id="4e75fbc4-7ed6-4c33-8434-151ca9f33d8f">21 May 2019 12:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="6e9fb0ef-b1bd-4fcd-a306-7eba46cfbb02" xlink:title="pubData" xlink:actuate="0b0ea00d-3c02-4ab4-9a81-09db426c9c05" xlink:role="typesetter" xlink:href="73455461-443a-4ee3-b3d3-32a343b2e726"><meta-value id="407c4cb8-87b0-4d92-8965-1b67062127d4"><named-content specific-use="historyContent" data-title="" id="dd84357f-71e6-4e9e-a9bd-14ff48eb8262"><named-content specific-use="change-person" data-title="" id="00f84a58-1942-4bf1-91ce-5ca2f839ef5c">Usha</named-content> <named-content specific-use="" data-title="" id="ae0fcc8c-56d3-4299-ae22-c55e5e3cd138">inserted</named-content> <named-content specific-use="newVal" data-title="" id="6a41297c-b963-44ac-925a-90924f2ccd1e">Suppl_2</named-content> <named-content specific-use="" data-title="" id="a7b0319a-7bba-4eb4-898f-ee88a94a20fa"> in Issue field on</named-content> <named-content specific-use="change-time" data-title="" id="3b5564d3-c706-4c9e-b0ff-112aa392b926">21 May 2019 12:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="8b66d917-1abd-454d-823f-00c24bac2f29" xlink:title="pubData" xlink:actuate="0b0ea00d-3c02-4ab4-9a81-09db426c9c05" xlink:role="typesetter" xlink:href="f78fab9c-0c39-401d-a2dd-6f5a2a6033a6"><meta-value id="e944a865-3bff-4372-9d39-df6c0195f803"><named-content specific-use="historyContent" data-title="" id="bba3ff77-e6f7-423a-978e-07b09cfa5ac4"><named-content specific-use="change-person" data-title="" id="6b13d57f-3e83-4416-a9f9-f0a84187e18d">Usha</named-content> <named-content specific-use="" data-title="" id="d8522002-e81b-4561-8318-589cf5997989">changed</named-content> <named-content specific-use="oldVal" data-title="" id="96a44afb-c221-41a3-af90-11b6683633ae">0</named-content> <named-content specific-use="" data-title="" id="7f81796f-256e-4059-89fb-d828877792ff">to</named-content> <named-content specific-use="newVal" data-title="" id="28257407-3a24-4963-b353-d08ab2b3dbec">4</named-content> <named-content specific-use="" data-title="" id="3751c6b8-f461-4165-8512-f31d1bcf555e"> in Volume field on</named-content> <named-content specific-use="change-time" data-title="" id="546d3eec-8390-436d-a957-1bc6fac73cef">21 May 2019 12:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="d7234f13-0a95-4172-802b-a0c4d0d40015" xlink:title="author-68703031" xlink:actuate="b86b70a7-dacf-4827-8162-0e4d003c05ac" xlink:role="publisher" xlink:href="d472929c-4a72-4954-ab55-8eef036043af"><meta-value id="0973a057-9831-41e8-be79-413962a9c6fd"><named-content specific-use="historyContent" data-title="" id="624c3636-fd8e-4e4a-b9e3-6acef3c04554"><named-content specific-use="change-person" data-title="" id="d48bfca8-8099-4ddc-9cf6-48993aa6a6cd">Tasnia</named-content> <named-content specific-use="" data-title="" id="0aa626ef-5e1f-4a50-a1da-d3738a78a3fe">changed</named-content> <named-content specific-use="oldVal" data-title="" id="a42034aa-1cbf-4f44-b53a-64bca75f784c">M</named-content> <named-content specific-use="" data-title="" id="a207deaf-314c-4a50-a71a-f835d5eb7288">to</named-content> <named-content specific-use="newVal" data-title="" id="208a6d87-52ba-4fac-846f-a5ff6c3c8e1e">Myriam</named-content> <named-content specific-use="" data-title="" id="e5150bdf-bc3f-478b-a8e2-588ec5faccf2"> in Given name field on</named-content> <named-content specific-use="change-time" data-title="" id="877e5830-12fc-4078-8e14-3113ccd682af">8 May 2019 4:42 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="e8e67dc4-4a90-4a92-a075-7812864112b2" xlink:title="ef8e2fe8-d4fb-4633-b4bb-c2edcab89928" xlink:actuate="976668088" xlink:role="author" xlink:href="ef8e2fe8-d4fb-4633-b4bb-c2edcab89928"><meta-value id="c0c42c42-864f-4d6c-b353-8839057ca03a"><named-content specific-use="historyContent" data-title="" id="d9010271-2a09-41cf-aeca-a0e7c69baed6"><named-content specific-use="change-person" data-title="" id="c70343cd-36d6-42ad-8849-4662ef1d7a39">John Haanen</named-content> <named-content specific-use="" data-title="" id="aff247b5-b277-4dba-a3d3-e40ddc2b751a">inserted</named-content> <named-content specific-use="newVal" data-title="deficient MMR; advanced cancer" id="e9d7b640-b9c8-4c92-9704-db577123da7a">deficient MMR; advanced cancer</named-content> <named-content specific-use="" data-title="" id="dd4900b5-0e5a-417f-bde5-7bd4a5cbb66d"> on</named-content> <named-content specific-use="change-time" data-title="" id="a362ca4f-6f83-445a-9b18-700f996f5223">15 Apr 2019 9:07 AM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="cd97d5f4-d66c-419f-a706-09eae174aa1e" xlink:title="pubData" xlink:actuate="gowthamram" xlink:role="typesetter" xlink:href="f78fab9c-0c39-401d-a2dd-6f5a2a6033a6"><meta-value id="a4b4cfed-008f-4d7b-8225-edf09760895e"><named-content specific-use="historyContent" data-title="" id="ba5704b6-2721-4705-a25c-4477fdc40996"><named-content specific-use="change-person" data-title="" id="d7132c9e-ba82-4c47-bfe1-9df63ec4c3a7">Gowtham Ram</named-content> <named-content specific-use="" data-title="" id="5ac0b2b7-25de-4dbe-b217-cedc216b723e">inserted</named-content> <named-content specific-use="newVal" data-title="" id="e73f041f-5ced-4193-b078-5a4fa9936cba">0</named-content> <named-content specific-use="" data-title="" id="a7ab22e3-c35e-45f3-abfe-285ff0b1aa5c"> in Volume field on</named-content> <named-content specific-use="change-time" data-title="" id="edef8dfe-6a11-4fe5-ade2-b5d53fae8a53">10 Apr 2019 11:13 AM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="61bfa018-c31f-466c-9ac8-2d1d6e9919eb" xlink:title="aff1" xlink:actuate="ff09adeb-0449-41e6-8404-dd7fc4dd50e6" xlink:role="copyeditor" xlink:href="6012816d-bcd9-4059-a01a-2b10802d806d"><meta-value id="b2cb051c-b855-484e-862e-c0160a165104"><named-content specific-use="historyContent" data-title="" id="96e294a6-a9f8-4d5f-977f-621e91ea0052"><named-content specific-use="change-person" data-title="" id="0b8ece20-75c8-43dc-b533-f48d23099b8a">Maria</named-content> <named-content specific-use="" data-title="" id="26279e8b-8b7b-42f6-ab0d-bc3a5a66227f">changed</named-content> <named-content specific-use="oldVal" data-title="" id="f9697fbd-5381-4fb6-b84f-78c52878135f">Netherlands</named-content> <named-content specific-use="" data-title="" id="6c57fbd2-e576-4f82-a086-3ffc12c467af">to</named-content> <named-content specific-use="newVal" data-title="The Netherlands" id="fa9224e3-7fad-4cb4-972a-f9704c3a1503">The Netherlands</named-content> <named-content specific-use="" data-title="" id="ac2c5eb0-613b-478d-bafc-ae7c44ba398f"> in Country field on</named-content> <named-content specific-use="change-time" data-title="" id="a80d922e-ea59-4d0a-ae92-76efb65673b0">9 Apr 2019 8:24 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="a64c0801-7a9e-4de9-bea6-c2136b6cfdc8" xlink:title="fn1" xlink:actuate="gowthamram" xlink:role="preeditor" xlink:href="fn1"><meta-value id="8e2b7df7-e20a-42da-93d6-3ff1c61bf9a7"><named-content specific-use="historyContent" data-title="" id="423c4846-0def-4c88-9efc-bfb1c1797f7a"><named-content specific-use="change-person" data-title="" id="b8e270a1-6340-4be6-9c70-6cc3115d4534">Gowtham Ram</named-content> <named-content specific-use="" data-title="" id="05905b8c-f3af-410c-bf37-fae60d24e0d8">changed</named-content> <named-content specific-use="oldVal" data-title="All contributed equally." id="8d79c216-43eb-4f36-9f71-78e4930d0234">All contributed equally.</named-content> <named-content specific-use="" data-title="" id="919351ad-ed22-47d8-b355-bbc6f50a6cbb">to</named-content> <named-content specific-use="newVal" data-title="All authors contributed equally." id="29d4c0ef-739a-468b-b2bd-4b04e4f7fcc2">All authors contributed equally.</named-content> <named-content specific-use="" data-title="" id="51a4d621-a493-4db4-8d06-2a1002a06932"> in Content field on</named-content> <named-content specific-use="change-time" data-title="" id="c9ba2e76-6ec6-484a-9518-e2c2d2e049e6">8 Apr 2019 12:47 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="984f2f08-183d-4ca2-9034-aa1205a2f71a" xlink:title="fn4" xlink:actuate="gowthamram" xlink:role="preeditor" xlink:href="fn4"><meta-value id="7f8945bd-3d5d-4ac4-95fa-37b1fe7d5a63"><named-content specific-use="historyContent" data-title="" id="e1b40a7a-127a-43ba-9fa3-ddda211cc5e9"><named-content specific-use="change-person" data-title="" id="55256baf-ad3f-48c6-a7ca-3a70d314c5ca">Gowtham Ram</named-content> <named-content specific-use="" data-title="" id="5e2439ec-3456-4804-a0ea-0662a71d282e">changed</named-content> <named-content specific-use="oldVal" data-title="Prepublication history for this paper is available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2019-000511)" id="7cb12f1d-7efa-4266-8619-ece5fd3e34a8">Prepublication history for this paper is available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2019-000511)</named-content> <named-content specific-use="" data-title="" id="d3cd2ac0-25e2-47b5-9763-07c849b185eb">to</named-content> <named-content specific-use="newVal" data-title="Prepublication history for this paper is available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2019-000511)." id="ec992920-b75d-4377-8df2-ebdcd83c01c1">Prepublication history for this paper is available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/esmoopen-2019-000511).</named-content> <named-content specific-use="" data-title="" id="78e55baa-1391-426c-a97d-f5ab57f34ed4"> in Content field on</named-content> <named-content specific-use="change-time" data-title="" id="786c5b96-d544-4454-85b8-90baa0c31ea5">8 Apr 2019 12:47 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="c9dba802-70ec-4c9e-8aee-ed01774fbe0b" xlink:title="b166a12e-092a-40a7-a31f-2ab7c84ef58b" xlink:actuate="gowthamram" xlink:role="preeditor" xlink:href="e2628f46-d615-43da-9edb-8b3db563ab0c"><meta-value id="d9d807fd-d12a-414e-926e-a70cf4cfe1a1"><named-content specific-use="historyContent" data-title="" id="6a80c8cb-f8a7-4e23-abfc-095f87fc69e0"><named-content specific-use="change-person" data-title="" id="680a29b7-7bbe-45df-88bd-93f19a6362b6">Gowtham Ram</named-content> <named-content specific-use="" data-title="" id="90cd247d-0c58-4c6c-b131-9d055a6692b9">changed</named-content> <named-content specific-use="oldVal" data-title="" id="7142f5e4-572a-4aa1-bdd7-0bf04744b238">Amsterdam</named-content> <named-content specific-use="" data-title="" id="5231c9cc-dae8-45d5-a508-fa683d07a470">to</named-content> <named-content specific-use="newVal" data-title="1066 CX Amsterdam" id="98192b58-e1e7-4801-9857-a736922eb79a">1066 CX Amsterdam</named-content> <named-content specific-use="" data-title="" id="d88c2e8a-90a9-41ed-8302-04cd7fd8a498"> in City field on</named-content> <named-content specific-use="change-time" data-title="" id="a99df1fb-73cd-4793-be93-9adb02617ccb">8 Apr 2019 12:43 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="a95be36c-856a-4f91-a651-4f1d866fd8e4" xlink:title="aff1" xlink:actuate="gowthamram" xlink:role="preeditor" xlink:href="38c5f5c0-32a2-43e5-ad4f-05f787ba5104"><meta-value id="86c75e3b-1f5f-4149-bf64-547fda970353"><named-content specific-use="historyContent" data-title="" id="7b677a2b-9715-4664-bdd9-262953586435"><named-content specific-use="change-person" data-title="" id="9352bdbb-b3c9-4d99-a36d-e7f3832639c6">Gowtham Ram</named-content> <named-content specific-use="" data-title="" id="8902c89f-705b-471a-88bc-dd7e46933755">inserted</named-content> <named-content specific-use="newVal" data-title="" id="bb14bffb-eba2-4e00-9a21-f3d9cb749494"> Dr Marleen Kok, Dr M Chalabi</named-content> <named-content specific-use="" data-title="" id="ea1d091a-991a-4ac6-bc16-73b807fc98c5">in Authors on</named-content> <named-content specific-use="change-time" data-title="" id="53d4c743-25fd-45f4-842d-7d8658f5e3ec">8 Apr 2019 12:41 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" id="8f08d0e5-f85c-4fc4-a273-4769617b2127" xlink:title="author-68703031" xlink:actuate="gowthamram" xlink:role="preeditor" xlink:href="d472929c-4a72-4954-ab55-8eef036043af"><meta-value id="28a20f82-68a8-4b8d-a6ad-9f59115cf350"><named-content specific-use="historyContent" data-title="" id="9fc11c20-d0b8-4f67-976b-a898a87ef668"><named-content specific-use="change-person" data-title="" id="979e764f-bd3d-4542-ba4e-6cd24dcc7d34">Gowtham Ram</named-content> <named-content specific-use="" data-title="" id="a0f3810b-5075-4411-8465-14c9d9c6d57d">changed</named-content> <named-content specific-use="oldVal" data-title="" id="bff04413-3050-4d18-9117-7832fdef5793">M.</named-content> <named-content specific-use="" data-title="" id="fe54f155-1884-4667-ac1c-af28b8af28b7">to</named-content> <named-content specific-use="newVal" data-title="" id="ab037f81-5f1d-40db-9ed5-7e4116d07b12">M</named-content> <named-content specific-use="" data-title="" id="cb6e6ff8-9dbd-4e51-9d34-e2632ef55d49"> in Given name field on</named-content> <named-content specific-use="change-time" data-title="" id="d2849295-5a73-4945-82ff-9c2bafa7c64b">8 Apr 2019 12:39 PM</named-content></named-content></meta-value></custom-meta><custom-meta id="846449db-d4d4-42e0-808f-7c4d76323375"><meta-name id="81874054-c48e-49ee-91f4-a0060a54c0a0">Copyediting_user_level</meta-name><meta-value id="fe5a2ccf-1b27-4901-b0b8-28761fd164f2">expert</meta-value></custom-meta></custom-meta-group><counts id="b2522170-9666-4324-a0c0-b7223b85d622"><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="15"/><page-count count="2.5"/><word-count count="2246"/></counts><funding-group id="6b4b4d91-8594-4103-a68e-79e138dbbcc8"><funding-statement section="article-meta" node-xpath="funding-group" next-xpath="custom-meta-group" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'addDataTempSelector', 'param' : {'component' : 'jrnlFN'}}" data-ele-type="funding-statement" fn-type="funding" data-label="Funding" id="408b147e-7f94-43d7-902c-5e57723fa734">The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</funding-statement></funding-group></article-meta></front><body id="642b857f-20f8-4f7f-bd58-aeed211cccd9"><p data-class="jrnlDeleted" colorcode="#" textdecoration=" underline" id="6780379a-5cb1-424c-ba3a-7a3c575590ce">Corresponding author: j.haanen@nki.nl</p><p data-class="jrnlDeleted" headweightage="41" id="27e23ceb-b501-4499-b262-449d9444f390">(175 words, max 300 words)</p><p data-class="jrnlDeleted" id="d46c6b15-6ce4-4947-a2f3-a004bd03fb11" old-class="jrnlSecPara" data-role="preeditor"><named-content data-cid="1554706642" id="1ebaf2e1-27b8-4239-bc4e-1c06c16cd18c" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423">Efficacy of PD-1-blockade in MSI </named-content><named-content data-cid="1554706534012" id="395df60c-7538-4abf-8117-8545da59a3ae" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="890f865b-da42-447c-b9a3-5911a955ec3a" data-cid="1554706534012" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="33" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="2_3" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000"><named-content data-cid="1554706642" id="b808e1c3-5be6-4326-aa37-4540153ba473" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423">tumours</named-content></named-content><named-content data-cid="1554706642" id="0863c589-3211-4c67-a3fb-ced1c5986108" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423"> is similar for </named-content><named-content id="a2981f96-be28-4f3d-94f0-621c71cea11c" data-cid="a2981f96-be28-4f3d-94f0-621c71cea11c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="55" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="2_2" data-function="addTrackChanges" data-time="" data-username="" data-userid=""><named-content data-cid="1554706642" id="7a49d725-72e1-46c1-a32c-715117ef172f" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423">patients</named-content></named-content><named-content data-cid="1554706642" id="1b2ccfb9-3db3-4ee4-900f-7487c28fe93a" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423"> with colorectal cancer (CRC, ORR 36%) or a different cancer type (ORR </named-content><named-content id="3c494d0e-9e31-4973-9140-6e62a4eafa75" data-cid="3c494d0e-9e31-4973-9140-6e62a4eafa75" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="134" data-match="46%" data-replace="46" data-pattern="$1" data-tag-index="2_1" data-time="" data-username="" data-userid=""><named-content data-cid="1554706642" id="87e58ef1-ea4f-4a5b-9865-9dab096755d6" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423">46</named-content></named-content><named-content id="2c553bfa-30a7-4541-a3d3-cf2a0d4407f1" data-cid="2c553bfa-30a7-4541-a3d3-cf2a0d4407f1" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="136" data-match="46%" data-replace="%" data-pattern="%" data-tag-index="2_1" data-time="" data-username="" data-userid=""><named-content data-cid="1554706642" id="275ed994-7a45-4e53-a12e-8dda7549cd43" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423">%</named-content></named-content><named-content data-cid="1554706642" id="33e9301d-b96e-4cc5-bc0e-a409eb80c84e" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423"> across 14 other cancer types).</named-content><xref id="51ee80f6-9587-42c6-bee0-b90b4571af90" ref-type="bibr" rid="R1" data-citation-string=" R1 " data-tag-type="BIBREF" data-track-change="1" data-track="del" data-cid="1554707774876" data-username="Gowtham Ram (PREEDITOR)" data-userid="preeditor gowthamram" data-time="1554707774876" data-cite-type="delete"><sup id="144f628c-1f34-47c7-9d14-650f03ca2798">1</sup></xref><named-content data-cid="1554706642" id="6f7fd0d6-6ad8-40cb-b410-f39fe5491be0" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423"> Based on these results, PD-1-blocking antibody pembrolizumab was the first tumor-agnostic treatment to be granted FDA approval based on the presence of MSI as a biomarker.Currently, there is no approved PD-1-blocking antibody for MSI cancers in Europe. Here, we present our experience with the screening for MSI, and the treatment of </named-content><named-content id="329e095a-907a-48fc-9a23-cb3687cda12c" data-cid="329e095a-907a-48fc-9a23-cb3687cda12c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="163" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="3_1" data-function="addTrackChanges" data-time="" data-username="" data-userid=""><named-content data-cid="1554706642" id="e9839d08-dd33-4fb5-b91e-f956b183ac67" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423">patients</named-content></named-content><named-content data-cid="1554706642" id="7bd6ec97-fdbd-4ab8-86ea-554827bd5bc6" content-type="del cts-2" specific-use="1554707768423" xlink:title="Gowtham Ram (PREEDITOR)" alt="preeditor gowthamram" data-title="Deleted by Gowtham Ram (PREEDITOR) - Apr 8 2019 12:46pm" data-track-detail="" data-userid="preeditor gowthamram" data-username="Gowtham Ram (PREEDITOR)" data-time="1554707768423"> with advanced disease of MSI CRC and non-CRC with immunotherapy.</named-content></p><p data-class="jrnlDeleted" headweightage="41" id="c98dd729-0be9-42d3-b238-10308acec4b1">Body text (1345 words incl REFs, max 1500 words)</p><p data-class="jrnlSecPara" id="e6603a25-bd02-46cd-8110-4a946af5e8ee">Immunotherapy with immune checkpoint inhibitors has been very successful in a number of <named-content data-cid="1554706534013" id="0b0e9eba-24bc-4a06-947a-904db07f18fc" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="a79854c3-268d-4ce2-9ceb-8a415a588c7b" data-cid="1554706534013" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="88" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="4_27" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> types. <named-content data-cid="1554807101" id="87251d21-b431-47dc-9abd-d681805b6a7b" content-type="ins cts-3" specific-use="1554807226987" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:53pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807226987">The </named-content><named-content data-cid="1554807105" id="360fc309-4eb3-4754-90c1-350c04fa4b1e" content-type="del cts-3" specific-use="1554807228074" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:53pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807228074">H</named-content><named-content data-cid="1554807106" id="647cffc4-888d-468b-a99d-33292f435988" content-type="ins cts-3" specific-use="1554807228450" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:53pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807228450"><named-content rid="2dc8f32c-35a5-46ad-b2f3-8912087c324b" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="2aab1e33-895b-4bbe-9939-6ac819ab7237" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>h</named-content>ighest<named-content rid="2dc8f32c-35a5-46ad-b2f3-8912087c324b" data-class="jrnlQueryRef" data-type="end" id="044f0df4-e0d2-4488-b69c-1422a4dff7c7" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/> <named-content id="db06620d-36e7-4378-beb8-59454fd9fac3" data-cid="db06620d-36e7-4378-beb8-59454fd9fac3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="109" data-match="overall response rates" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid=""><named-content data-cid="1557330121" id="8cb202d4-c5a1-48e4-acd7-b478c7ef5027" content-type="del cts-4" specific-use="1557330640533" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Deleted by Tasnia (BMJ) - May 8 2019 4:50pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557330640533">overall</named-content><named-content data-cid="1557330122" id="5803fc0e-3a5c-4b91-9592-6604480fc1f4" content-type="ins cts-4" specific-use="1557330640582" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 4:50pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557330640582">objective</named-content> response rates</named-content> (<named-content id="f984db7a-5a1f-483c-9b96-a3281ae095e0" data-cid="f984db7a-5a1f-483c-9b96-a3281ae095e0" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="133" data-match=" (ORR)" data-pattern="" data-tag-index="4_5" data-time="" data-username="" data-userid="">ORR</named-content>) are observed <named-content data-cid="1554706534003" id="33f882f9-e1f4-4567-bf7b-73bb3837d70a" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">amongst</named-content><named-content id="b966d871-01bd-4d77-8dab-f06306f5966a" data-cid="1554706534003" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'amongst' to 'among'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="151" data-match="amongst" data-replace="among" data-pattern="among" data-tag-index="4_15" data-function="addTrackChanges" data-track-change="amongst" data-userid="preediting" data-username="Exeter" data-time="1554706534000">among</named-content> <named-content data-cid="1554706534014" id="793570d7-32bd-4992-8624-d02ac5c7030c" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="c091bd29-3851-42b7-8d80-0911c9aa7d68" data-cid="1554706534014" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="159" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="4_28" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> with high <named-content id="5f324c6b-499d-4673-8114-50ef602071b7" data-cid="5f324c6b-499d-4673-8114-50ef602071b7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="176" data-match="tumor mutational burden" data-pattern="" data-tag-index="" data-abbr="TMB" data-time="" data-username="" data-userid=""><named-content data-cid="1554706534015" id="caeb97df-d107-496f-bc4f-0a34dcc0d7e2" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="832a4c89-5f82-4360-bd8b-fa2dd437b50e" data-cid="1554706534015" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="176" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="4_29" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> mutational burden</named-content> (<named-content id="5d145315-7b9f-4968-bd25-31fb7f67f6b5" data-cid="5d145315-7b9f-4968-bd25-31fb7f67f6b5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="201" data-match=" (TMB)" data-pattern="" data-tag-index="4_6" data-time="" data-username="" data-userid="">TMB</named-content>), including melanoma, Merkel<named-content data-cid="1554807276" id="47a6b57d-34cd-4b86-bf07-db39d0ea3931" content-type="ins cts-3" specific-use="1554811611891" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811611891"> </named-content>cell carcinoma (<named-content data-cid="1557330141" id="30b0545f-460c-4932-a252-98bb163d2ccb" content-type="ins cts-4" specific-use="1557330832243" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 4:53pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557330832243">Merkel cell polyomavirus (</named-content><named-content rid="e20a7fe0-bdd5-478a-b262-f85beb296296" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="1ccc565a-47d3-4849-aac1-206aa5b016e3" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>MCPyV<named-content data-cid="1557330177" id="3aa05d0e-a5b4-48eb-a37d-53168ccc4ffd" content-type="ins cts-4" specific-use="1557330854951" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 4:54pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557330854951">)</named-content><named-content rid="e20a7fe0-bdd5-478a-b262-f85beb296296" data-class="jrnlQueryRef" data-type="end" id="91ed464b-1b30-4e03-810e-f64c344eb999" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/><named-content data-cid="1554807277" id="63846f45-0ddc-4039-8ebe-8be1ca2bc1d9" content-type="del cts-3" specific-use="1554811631962" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:07pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811631962"> </named-content><named-content data-cid="1554807278" id="3e0fb984-54ce-4948-b693-bb109e9ed008" content-type="ins cts-3" specific-use="1554811632192" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:07pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811632192">-</named-content>negative), cutaneous squamous cell carcinoma, a TMB-high subset of (non)-small-cell lung cancer <named-content data-cid="1554807280" id="fc0592db-3de0-42f4-98ef-46dd7652af55" content-type="del cts-3" specific-use="1554811667767" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:07pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811667767">(</named-content><named-content id="b473eed6-7d66-48ca-b451-b403fcc0cfb1" data-cid="b473eed6-7d66-48ca-b451-b403fcc0cfb1" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="352" data-match=" (NSCLC)" data-pattern="" data-tag-index="4_7" data-time="" data-username="" data-userid=""><named-content data-cid="1554807279" id="625787a8-a89c-4a49-af89-401e5ab1bff6" content-type="del cts-3" specific-use="1554811667594" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:07pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811667594">NSCLC</named-content></named-content><named-content data-cid="1554807279" id="69b1eb01-fdbc-4f06-bcdc-27cc3d9b233f" content-type="del cts-3" specific-use="1554811667594" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:07pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811667594">) </named-content>and <named-content rid="9bc0c555-af32-4ed7-87d5-6a4495813bce" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="a4336ce4-4f04-4cef-8808-518fe0e825a3" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>microsatellite<named-content rid="9bc0c555-af32-4ed7-87d5-6a4495813bce" data-class="jrnlQueryRef" data-type="end" id="4265a056-9f54-41cf-a6a9-837d38782b6b" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/> <named-content data-cid="1554807224" id="4db8f1ae-e671-4266-9d01-b2fe9483c7b2" content-type="ins cts-3" specific-use="1554811239606" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:00pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811239606">instability</named-content><named-content data-cid="1554807235" id="c2e06494-86de-41ad-8253-290eeb63afcf" content-type="del cts-3" specific-use="1554811242369" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:00pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811242369">unstable</named-content> (<named-content id="82b4e3b6-efde-4536-ae2e-09a6a4e51dbf" data-cid="82b4e3b6-efde-4536-ae2e-09a6a4e51dbf" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="388" data-match=" (MSI)" data-pattern="" data-tag-index="4_8" data-time="" data-username="" data-userid="">MSI</named-content>) cancers. MSI <named-content data-cid="1554706534016" id="75b77aec-8920-43db-aff8-0b5d32a63205" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="20aa38c2-184d-444b-8e57-cab7f850a29f" data-cid="1554706534016" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="406" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="4_30" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> may be sporadic or result from germ<named-content data-cid="1554807107" id="6fd50af8-1412-4706-9cc7-3a2a39aaf534" content-type="del cts-3" specific-use="1554807259345" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:54pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807259345">-</named-content>line mutations in mismatch repair (<named-content id="48b9b20e-8d09-4b01-9277-8a4d945f6102" data-cid="48b9b20e-8d09-4b01-9277-8a4d945f6102" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="484" data-match=" (MMR)" data-pattern="" data-tag-index="4_9" data-time="" data-username="" data-userid="">MMR</named-content>) genes (Lynch syndrome), and have by far the highest TMB of all cancers, with often<named-content id="cd234c48-d536-46b6-9a06-97698eb48ab9" data-cid="cd234c48-d536-46b6-9a06-97698eb48ab9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '␣&gt;' to '⍽&gt;'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="OPR" data-offset="571" data-match="often &amp;gt;1000" data-replace=" &gt;" data-pattern=" $2" data-tag-index="4_1" data-track-change=" &amp;gt;" data-time="" data-username="" data-userid=""> &gt;</named-content><named-content id="632a71c8-7920-4c71-ab76-a1f2c80f5aca" data-cid="632a71c8-7920-4c71-ab76-a1f2c80f5aca" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="VAL" data-offset="573" data-match="often &amp;gt;1000" data-replace="1000" data-pattern="1000" data-tag-index="4_1" data-time="" data-username="" data-userid="">1000</named-content> non-synonymous genomic mutations. It is very likely that the high TMB is the key driver for the observed high ORR in these <named-content data-cid="1554706534017" id="a846b8f0-f885-44e4-ad33-5d6b71b3918b" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="a5b34f95-d0c4-4fbf-ac83-9d890df3d387" data-cid="1554706534017" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="701" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="4_31" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content>, creating a permissive inflamed <named-content data-cid="1554706534018" id="d06276f5-c648-40cd-a6da-63058eb09d57" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="38f1d0ed-505f-4ff0-a0cd-47fe4e21cbae" data-cid="1554706534018" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="740" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="4_32" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> microenvironment. With the recent accelerated <named-content data-cid="1554807284" id="79ca5f2e-3f58-43d6-9939-42eaf4825e70" content-type="ins cts-3" specific-use="1554811992930" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:13pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811992930"><span id="90f8921f-7f49-437c-934f-d8bd7b093d61">Food and Drug Administration</span> (</named-content><named-content rid="3e9fccdc-f1e3-49ac-ae4c-013597a43be3" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="4b93923f-1d0c-414c-abc5-10fec14ad5c2" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>FDA<named-content rid="3e9fccdc-f1e3-49ac-ae4c-013597a43be3" data-class="jrnlQueryRef" data-type="end" id="8334e5d3-0c7c-4bbc-a010-6420773693b9" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/><named-content data-cid="1554807287" id="c99f2482-88b4-41b7-b81a-17c546e8b7dd" content-type="ins cts-3" specific-use="1554811995366" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:13pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811995366">)</named-content><named-content data-cid="1554807108" id="2727c304-49f4-4cf3-a50b-a1724143e2d9" content-type="del cts-3" specific-use="1554807281252" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:54pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807281252">-</named-content><named-content data-cid="1554807109" id="4fffd422-734a-4756-9879-c51786cb920e" content-type="ins cts-3" specific-use="1554807281412" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:54pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807281412"> </named-content>approval of pembrolizumab for the treatment of <named-content id="2711a4f4-b42c-4b42-a749-4b91d959ca55" data-cid="2711a4f4-b42c-4b42-a749-4b91d959ca55" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="843" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_16" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with advanced MSI <named-content data-cid="1554706534019" id="e6e91a7c-cb8d-4f8c-ac09-2f841b21e1e7" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="191c4275-3c24-42f5-993e-b887901f81b4" data-cid="1554706534019" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="870" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="4_33" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content>, regardless of <named-content data-cid="1554706534020" id="22b2ef39-ae1d-46e8-8214-9251763cbca0" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="3c76eb68-456f-4a95-a0f9-87310f7103fb" data-cid="1554706534020" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="892" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="4_34" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> site or histology, <named-content rid="1e213b78-2502-442c-a65a-df3abd79f5b3" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="047113c7-f864-4098-a675-5e38b555a711" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/><named-content data-cid="1557330233" id="27c865d9-12ab-488f-80bb-53bf59746cb0" content-type="ins cts-4" specific-use="1557331208837" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:00pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331208837">programmed death-1 receptor (</named-content>PD<named-content rid="1e213b78-2502-442c-a65a-df3abd79f5b3" data-class="jrnlQueryRef" data-type="end" id="f6795ca0-4131-4546-89e6-065a4c521561" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/>-1<named-content data-cid="1557330270" id="bbf5d7f3-a967-4dd4-a351-b0bee6d7ae9d" content-type="ins cts-4" specific-use="1557331221981" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:00pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331221981">)</named-content> blockade has become a highly relevant treatment option for this <named-content id="a6cb8adc-7992-44bd-9a64-b0583f5d0d05" data-cid="a6cb8adc-7992-44bd-9a64-b0583f5d0d05" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patient' to 'patient'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="986" data-match="patient" data-replace="patient" data-pattern="$1" data-tag-index="4_17" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patient</named-content> population. The registration of pembrolizumab in this setting was based on data from 149 <named-content id="46df0331-f920-431a-add8-3ba5a5bcdee9" data-cid="46df0331-f920-431a-add8-3ba5a5bcdee9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1083" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_18" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with MSI cancers enrolled across five uncontrolled, multi<named-content data-cid="1554807110" id="de7b39e9-95d9-4cbf-a5b9-30570430a16c" content-type="del cts-3" specific-use="1554807292293" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:54pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807292293">-</named-content>cohort, single-arm trials. Ninety <named-content id="ecc4a81b-82e1-480f-ba42-73b3d2d5bf98" data-cid="ecc4a81b-82e1-480f-ba42-73b3d2d5bf98" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1184" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_19" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> had colorectal cancer <named-content data-cid="1554807238" id="f71cf8f0-a8e7-430f-8102-a44ead150579" content-type="ins cts-3" specific-use="1554811434972" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:03pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811434972">(CRC) </named-content>and 59 <named-content id="e56c73d4-663d-4ae0-9965-f10df03743b3" data-cid="e56c73d4-663d-4ae0-9965-f10df03743b3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1222" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_20" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> were diagnosed with <named-content data-cid="1554807111" id="1790b3e5-f0a6-4eda-9c81-41e5da6c5cd5" content-type="ins cts-3" specific-use="1554807296803" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:54pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807296803">1</named-content><named-content data-cid="1554807112" id="5db33f8c-77fa-47aa-b77c-48169c6bd504" content-type="del cts-3" specific-use="1554807297583" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:54pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807297583">one</named-content> of 14 other cancer types.<xref id="b5978b87-eaab-4339-88ad-cff356bd88d6" ref-type="bibr" rid="R1 R2 R3" data-citation-string=" R1 R2 R3 " data-tag-type="BIBREF" data-track-change="1-3" data-anchor="true"><sup id="19f22895-5fc0-44a0-b588-7a025ff8ee5f">1–3</sup></xref> <named-content data-cid="1554807113" id="1f210aeb-896a-46f7-b3e8-a85b64eb655f" content-type="ins cts-3" specific-use="1554807304443" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:55pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807304443">The </named-content><named-content id="8df4b951-05d9-497d-a370-1cef51bd43c8" data-cid="8df4b951-05d9-497d-a370-1cef51bd43c8" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="1284" data-match="Objective response rate" data-pattern="" data-tag-index="" data-abbr="ORR" data-time="" data-username="" data-userid=""><named-content data-cid="1554807117" id="bbfc7be5-2691-4b8b-b85f-8c412252674a" content-type="del cts-3" specific-use="1554807305540" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:55pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807305540">O</named-content><named-content data-cid="1554807118" id="f3f6d40b-aee1-441c-8b48-7b344dfd955a" content-type="ins cts-3" specific-use="1554807305859" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:55pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807305859">o</named-content>bjective response rate</named-content> (<named-content id="4a76141f-c0bf-4956-8959-69c29653c67f" data-cid="4a76141f-c0bf-4956-8959-69c29653c67f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="1309" data-match=" (ORR)" data-pattern="" data-tag-index="4_10" data-time="" data-username="" data-userid="">ORR</named-content>) was <named-content id="e3de73f9-dab8-433e-b98d-d49b63957b43" data-cid="e3de73f9-dab8-433e-b98d-d49b63957b43" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="1318" data-match="36%" data-replace="36" data-pattern="$1" data-tag-index="4_3" data-time="" data-username="" data-userid="">36</named-content><named-content id="4f6a4216-8c94-4235-a3be-3fa68ebf9b20" data-cid="4f6a4216-8c94-4235-a3be-3fa68ebf9b20" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="1320" data-match="36%" data-replace="%" data-pattern="%" data-tag-index="4_3" data-time="" data-username="" data-userid="">%</named-content> for <named-content id="5fa09826-8fc6-429d-9819-aaf5f88bc408" data-cid="5fa09826-8fc6-429d-9819-aaf5f88bc408" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1326" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_21" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> diagnosed with <named-content data-cid="1554807244" id="3ef54db9-1418-4732-ad48-e0a76ee7b560" content-type="ins cts-3" specific-use="1554811439533" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:03pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811439533">CRC</named-content><named-content data-cid="1554807247" id="20edaae6-3d94-4a43-b7ec-777c491475a6" content-type="del cts-3" specific-use="1554811441248" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811441248">colorectal cancer</named-content> and <named-content id="c32d3f5a-4546-4800-9381-84b94b755845" data-cid="c32d3f5a-4546-4800-9381-84b94b755845" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="1372" data-match="46%" data-replace="46" data-pattern="$1" data-tag-index="4_4" data-time="" data-username="" data-userid="">46</named-content><named-content id="48ee6d00-b8e2-42ae-b496-8b62b60a32a6" data-cid="48ee6d00-b8e2-42ae-b496-8b62b60a32a6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="1374" data-match="46%" data-replace="%" data-pattern="%" data-tag-index="4_4" data-time="" data-username="" data-userid="">%</named-content> for <named-content id="28bbdbe7-fef7-4319-9952-6182b959f311" data-cid="28bbdbe7-fef7-4319-9952-6182b959f311" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1380" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_22" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with any of 14 other histology MSI <named-content data-cid="1554706534021" id="b4b0aa83-630c-4edb-9f63-ce01c275e513" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="6965b555-a53f-4966-9ff4-2c31d2a2be57" data-cid="1554706534021" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="1424" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="4_35" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content>. The identification of MSI status for the majority of <named-content id="0b43c086-f7a7-4a20-9706-e97a6f61ef41" data-cid="0b43c086-f7a7-4a20-9706-e97a6f61ef41" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1485" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_23" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> was prospectively determined using immunohistochemistry (<named-content id="e5087e18-a70a-4525-98ec-23fa7b22cd6d" data-cid="e5087e18-a70a-4525-98ec-23fa7b22cd6d" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="1551" data-match=" (IHC)" data-pattern="" data-tag-index="4_11" data-time="" data-username="" data-userid="">IHC</named-content>) tests for MMR proteins or local <named-content data-cid="1554706534009" id="626f923b-95bf-4e51-ad9d-7027b2fd12f6" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">polymerase chain reaction (PCR)</named-content><named-content id="5925eb7f-844f-44d6-8969-9c126dbf6663" data-cid="1554706534009" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'polymerase␣chain␣reaction␣(PCR)' to 'PCR'" data-track-detail="" data-tag-desc="ABBRV" data-tag-type="ABBRV" data-offset="1588" data-match="polymerase chain reaction (PCR)" data-replace="PCR" data-pattern="PCR" data-tag-index="4_14" data-function="addTrackChanges" data-track-change="polymerase chain reaction (PCR)" data-userid="preediting" data-username="Exeter" data-time="1554706534000">PCR</named-content> tests for MSI status. To date, there is no approval of any PD-1-blocking antibodies for MSI cancers in Europe. Here, we present our experience at the Netherlands Cancer Institute <named-content data-cid="1554807304" id="39dc98eb-8a87-44a8-a031-822a7af3a156" content-type="ins cts-3" specific-use="1554812264122" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:17pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554812264122">(NKI) </named-content>with screening for MSI, and treatment of <named-content id="4de5b3c9-e9c5-4c1b-a343-5bbf48652e93" data-cid="4de5b3c9-e9c5-4c1b-a343-5bbf48652e93" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1840" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="4_24" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with advanced disease of MSI non-CRC and CRC <named-content data-cid="1554706534022" id="c4e5224f-02d1-4be9-85bf-aab8ea492fde" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="a9becca2-3044-47c5-adc3-e34de2b79380" data-cid="1554706534022" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="1894" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="4_36" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> with immunotherapy, either within clinical trials or <named-content id="1de8900d-f11a-451f-ae83-3eb379486a3b" data-cid="1de8900d-f11a-451f-ae83-3eb379486a3b" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patient' to 'patient'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1954" data-match="patient" data-replace="patient" data-pattern="$1" data-tag-index="4_25" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patient</named-content> access <named-content data-cid="1554706534004" id="c52dbab2-088a-458b-a4a3-a4aeab4a12c6" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">programs</named-content><named-content id="818b369d-0dc8-4344-a7fd-225af018e41b" data-cid="1554706534004" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'programs' to 'programme'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1969" data-match="programs" data-replace="programme" data-pattern="programme" data-tag-index="4_26" data-function="addTrackChanges" data-track-change="programs" data-userid="preediting" data-username="Exeter" data-time="1554706534000">programme<named-content data-cid="1554807119" id="43f8acfb-e2a1-4d5c-a1a4-3fe2a5a92122" content-type="ins cts-3" specific-use="1554807336836" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:55pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807336836">s</named-content></named-content>.</p><p data-class="jrnlSecPara" id="aa756e84-c532-4486-aeaa-f1e79760135a" data-word-spacing="0.23w">Although not routinely tested, MSI can be found in other cancer types outside the more common Lynch<named-content data-cid="1554807120" id="dfba06a0-d063-4e0d-82fe-f8c3a1c19bcb" content-type="del cts-3" specific-use="1554807341315" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:55pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807341315">-</named-content><named-content data-cid="1554807121" id="26c1878f-1223-4814-bb77-8edd35db49bc" content-type="ins cts-3" specific-use="1554807341536" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:55pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807341536"> </named-content>syndrome-associated gastrointestinal and endometrial cancers, at a frequency of around <named-content id="9cd3fa2b-d79a-4d9d-aaa6-56200860a6be" data-cid="9cd3fa2b-d79a-4d9d-aaa6-56200860a6be" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '2' to '2%'" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="PRE" data-offset="187" data-match="2-4%" data-replace="2%" data-pattern="$2$6" data-tag-index="5_1" data-track-change="2" data-time="" data-username="" data-userid="">2%</named-content><named-content id="2d42ddc5-19f9-45a9-9bfe-9de711e52132" data-cid="2d42ddc5-19f9-45a9-9bfe-9de711e52132" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to '–'" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="RNG" data-offset="188" data-match="2-4%" data-replace="–" data-pattern="–" data-tag-index="5_1" data-track-change="-" data-time="" data-username="" data-userid="">–</named-content><named-content id="4f23032b-9af8-4770-bff3-6eae0f301e14" data-cid="4f23032b-9af8-4770-bff3-6eae0f301e14" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SUF" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="SUF" data-offset="189" data-match="2-4%" data-replace="4" data-pattern="$5" data-tag-index="5_1" data-time="" data-username="" data-userid="">4</named-content><named-content id="1002c348-7db8-4170-bd59-6b47d2fbd5ae" data-cid="1002c348-7db8-4170-bd59-6b47d2fbd5ae" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SREP" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="SREP" data-offset="190" data-match="2-4%" data-replace="%" data-pattern="$6" data-tag-index="5_1" data-time="" data-username="" data-userid="">%</named-content>.<xref id="9a8c2d01-4f8a-42c6-a672-548a25fc5891" ref-type="bibr" rid="R4 R5" data-citation-string=" R4 R5 " data-tag-type="BIBREF" data-track-change="4,5"><sup id="3047182c-75a5-492e-9dbb-ec6420ad03d1">4 5</sup></xref> Traditionally, identification of MSI has relied on immunohistochemical detection of loss of MMR protein expression (MLH1, MSH2, MHS6 and PMS2) or PCR-based analysis using five microsatellite markers, including <named-content rid="8066ad22-9e71-43e0-8acd-60219ca97669" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="418653b9-eb21-488d-b1f2-4d441c7c2982" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>BAT<named-content rid="8066ad22-9e71-43e0-8acd-60219ca97669" data-class="jrnlQueryRef" data-type="end" id="c9ecc054-4b8c-4d20-bcfe-81fda4d53d39" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/>-25 and BAT-26. Next-generation sequencing (<named-content id="e9ba8371-128a-4952-93af-32a68ca20e69" data-cid="e9ba8371-128a-4952-93af-32a68ca20e69" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="453" data-match=" (NGS)" data-pattern="" data-tag-index="5_3" data-time="" data-username="" data-userid="">NGS</named-content>) is becoming increasingly available to clinical laboratories as a cost-effective and scalable method to evaluate multiple genetic aberrations in parallel, allowing linking of MSI status to <named-content data-cid="1554807270" id="d0ccbded-4a20-4f19-9fa9-5e27ceb4dfad" content-type="ins cts-3" specific-use="1554811577871" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811577871">TMB</named-content><named-content id="69044c79-03b0-41d5-a0de-083979e3540a" data-cid="69044c79-03b0-41d5-a0de-083979e3540a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="646" data-match="tumor mutational burden" data-pattern="" data-tag-index="" data-abbr="TMB" data-time="" data-username="" data-userid=""><named-content data-cid="1554706534023" id="f4b0af47-fe08-4cfb-8d46-62a261055515" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="1a9c347a-dcea-447a-ae3a-881d23da3c43" data-cid="1554706534023" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="646" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="5_5" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000"><named-content data-cid="1554807273" id="745c91d8-4a04-4666-9c33-1996d1c0d743" content-type="del cts-3" specific-use="1554811579619" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811579619">tumour</named-content></named-content><named-content data-cid="1554807273" id="3c7afc3c-7b3d-4217-a463-82468e4b1948" content-type="del cts-3" specific-use="1554811579619" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811579619"> mutational burden</named-content></named-content>. Consequently, initiatives to incorporate MSI testing in NGS-based cancer<named-content data-cid="1554807124" id="e6dd46ce-0ba4-40ea-8837-c1590a40ef50" content-type="del cts-3" specific-use="1554807367935" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807367935">-</named-content><named-content data-cid="1554807125" id="e2cb3590-7e09-478c-8447-7d917da5f6d7" content-type="ins cts-3" specific-use="1554807368164" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807368164"> </named-content>gene<named-content data-cid="1554807122" id="5cfe8d94-ef5c-4c4d-a828-db5c298e76ac" content-type="del cts-3" specific-use="1554807366855" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807366855">-</named-content><named-content data-cid="1554807123" id="29bb5c6f-e409-4206-8ba7-50ac86a8f723" content-type="ins cts-3" specific-use="1554807367075" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807367075"> </named-content>panels have emerged,<xref id="a0601fc4-7ea2-4ba2-9ec7-2b6c6b3f6ed5" ref-type="bibr" rid="R6 R7" data-citation-string=" R6 R7 " data-tag-type="BIBREF" data-track-change="6,7"><sup id="a59c11d4-b5fb-4eae-848c-54ae4a982970">6 7</sup></xref> illustrated by two FDA-<named-content data-cid="1554706534024" id="6413e9af-2724-4b86-8e9a-6c853d9ee341" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">authorized</named-content><named-content id="1786a8c0-9c73-43e0-905d-b71dd7917242" data-cid="1554706534024" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'authorized' to 'authorised'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="797" data-match="authorized" data-replace="authorised" data-pattern="authorised" data-tag-index="5_6" data-function="addTrackChanges" data-track-change="authorized" data-userid="preediting" data-username="Exeter" data-time="1554706534000">authorised</named-content> NGS platforms now incorporating MSI-calling algorithms. These efforts allow the selection of individual <named-content id="4320f2a1-8128-4ae1-baef-a6f767d9fc84" data-cid="4320f2a1-8128-4ae1-baef-a6f767d9fc84" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="912" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="5_4" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with incurable metastatic disease for clinical immunotherapy trials via the screening for MSI.</p><title data-level="1" data-class="jrnlHead1" id="7ecc5557-a1d6-47f4-a250-9b3652a7da5f" data-top-gap="-4pt">Colorectal cancer</title><p data-class="jrnlSecPara" id="8e00d2e6-0a89-4c5e-abe7-68064b3e4f2f">MSI CRC comprise<named-content data-cid="1554813309" id="d0fdbd76-9b32-4836-aa91-5a82004c1d1d" content-type="ins cts-3" specific-use="1554814229078" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:50pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554814229078">s</named-content> around <named-content id="1943b79a-3e42-4807-b184-b66fcfbfbd8e" data-cid="1943b79a-3e42-4807-b184-b66fcfbfbd8e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="24" data-match="15%" data-replace="15" data-pattern="$1" data-tag-index="7_3" data-time="" data-username="" data-userid="">15</named-content><named-content id="7426e134-7c50-4dd9-99a7-048702f83eb5" data-cid="7426e134-7c50-4dd9-99a7-048702f83eb5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="26" data-match="15%" data-replace="%" data-pattern="%" data-tag-index="7_3" data-time="" data-username="" data-userid="">%</named-content> of all primary <named-content data-cid="1554807248" id="1d3a6b07-5cb3-417f-919d-f398e26379f3" content-type="ins cts-3" specific-use="1554811455007" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811455007">CRC</named-content><named-content data-cid="1554807251" id="c9149da1-8d40-456b-b03d-4a62f3cd4643" content-type="del cts-3" specific-use="1554811457061" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811457061">colorectal cancers</named-content><named-content data-cid="1554807252" id="53007398-21a1-4326-8883-5473dfec3007" content-type="ins cts-3" specific-use="1554811457338" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811457338">s</named-content>, of which <named-content id="012c7820-029b-4ef2-b664-ab39c970a63e" data-cid="012c7820-029b-4ef2-b664-ab39c970a63e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '2' to '2%'" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="PRE" data-offset="72" data-match="2-3% are" data-replace="2%" data-pattern="$2$6" data-tag-index="7_1" data-track-change="2" data-time="" data-username="" data-userid="">2%</named-content><named-content id="3b658c94-cd21-4e19-93d2-5303a119bdbd" data-cid="3b658c94-cd21-4e19-93d2-5303a119bdbd" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to '–'" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="RNG" data-offset="73" data-match="2-3% are" data-replace="–" data-pattern="–" data-tag-index="7_1" data-track-change="-" data-time="" data-username="" data-userid="">–</named-content><named-content id="e242653e-e255-4cfc-977d-227261dc7356" data-cid="e242653e-e255-4cfc-977d-227261dc7356" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SUF" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="SUF" data-offset="74" data-match="2-3% are" data-replace="3" data-pattern="$5" data-tag-index="7_1" data-time="" data-username="" data-userid="">3</named-content><named-content id="72bc27c7-96ac-47a8-b7e6-d652961ba7bc" data-cid="72bc27c7-96ac-47a8-b7e6-d652961ba7bc" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SREP" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="SREP" data-offset="75" data-match="2-3% are" data-replace="%" data-pattern="$6" data-tag-index="7_1" data-time="" data-username="" data-userid="">%</named-content> are the result of germ<named-content data-cid="1554807126" id="eecbec4d-f74a-43f7-84b2-847a3ecaf049" content-type="del cts-3" specific-use="1554807388209" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807388209">-</named-content>line mutations in one of the four MMR genes. In metastatic CRC (<named-content id="2279826c-a7b4-4fe3-8579-e38f7d293da6" data-cid="2279826c-a7b4-4fe3-8579-e38f7d293da6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="164" data-match=" (mCRC)" data-pattern="" data-tag-index="7_5" data-time="" data-username="" data-userid="">mCRC</named-content>), less than <named-content id="00bef320-0035-4f3b-9d4d-3816f1340a95" data-cid="00bef320-0035-4f3b-9d4d-3816f1340a95" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="181" data-match="5%" data-replace="5" data-pattern="$1" data-tag-index="7_4" data-time="" data-username="" data-userid="">5</named-content><named-content id="d33d492d-3f5f-46b4-9e33-4faafacd7f1b" data-cid="d33d492d-3f5f-46b4-9e33-4faafacd7f1b" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="182" data-match="5%" data-replace="%" data-pattern="%" data-tag-index="7_4" data-time="" data-username="" data-userid="">%</named-content> is MSI. Currently, several trials are ongoing in <named-content data-cid="1554807289" id="48c6e620-8a9e-4221-8567-748f689c2724" content-type="ins cts-3" specific-use="1554812195982" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:16pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554812195982">patients with </named-content>MSI mCR<named-content data-cid="1554807288" id="34ab8f44-d231-4d88-ba92-5c775c6c04d7" content-type="ins cts-3" specific-use="1554812191512" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:16pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554812191512">C</named-content><named-content data-cid="1554807127" id="501463de-dd86-4982-92f3-542ccf15f830" content-type="del cts-3" specific-use="1554807401993" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807401993">)</named-content><named-content data-cid="1554807303" id="c9afa6d5-b36a-40a3-b9a1-03e1a544f822" content-type="del cts-3" specific-use="1554812198544" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:16pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554812198544"> </named-content><named-content id="410bda9e-8b09-4169-922d-d7079dda1bdf" data-cid="410bda9e-8b09-4169-922d-d7079dda1bdf" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="242" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="7_6" data-function="addTrackChanges" data-time="" data-username="" data-userid=""><named-content data-cid="1554807303" id="bdfb4180-8315-4501-97e4-c1c91e59294d" content-type="del cts-3" specific-use="1554812198544" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:16pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554812198544">patients</named-content></named-content> with either single<named-content data-cid="1554807128" id="09154b3e-03ee-422d-b7cb-8478b2bb1b56" content-type="del cts-3" specific-use="1554807406498" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807406498"> </named-content><named-content data-cid="1554807129" id="25a61f01-c99f-4af0-be0d-e235caf54609" content-type="ins cts-3" specific-use="1554807406813" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:56pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807406813">-</named-content>agent PD-1/<named-content data-cid="1557330271" id="e0587fff-198e-4fff-915d-051e4921fd96" content-type="ins cts-4" specific-use="1557331273675" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:01pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331273675">programmed death receptor ligand-1 (</named-content>PD<named-content rid="b38c748e-a4ae-4351-bb25-0c50c8fca12d" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="d5cc62f1-9af5-4ad5-aeb5-ad6e5b97cc4a" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>-<named-content rid="b38c748e-a4ae-4351-bb25-0c50c8fca12d" data-class="jrnlQueryRef" data-type="end" id="c7f07de2-8484-4228-a01d-753fc829d782" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/>L1<named-content data-cid="1557330307" id="c644f536-60a6-4cb1-9dc8-d7b2be60d750" content-type="ins cts-4" specific-use="1557331286097" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:01pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331286097">)</named-content> inhibitors<named-content data-cid="1554813310" id="17dbe870-1de3-4a28-9f07-c57f89ed9347" content-type="ins cts-3" specific-use="1554814255421" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:50pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554814255421">,</named-content> or in combination with either <named-content rid="70fa2ea1-a465-44cd-a453-9b533793c671" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="9ef9f642-1fbb-4247-87ba-1f052e6e1481" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/><named-content data-cid="1557330308" id="27b1f864-74b3-4ce1-a99b-1a85a074c0cd" content-type="ins cts-4" specific-use="1557331324468" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:02pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331324468"><span id="a5e4fe5b-247a-4e90-99d3-70c5c81344aa">cytotoxic T-lymphocyte associated protein-4</span> (</named-content>CLTA<named-content rid="70fa2ea1-a465-44cd-a453-9b533793c671" data-class="jrnlQueryRef" data-type="end" id="2fa22371-efc2-4e58-96bc-b35d2a035dbb" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/>-4<named-content data-cid="1557330313" id="3bd2786c-e1bc-49a3-9a07-767ca181055a" content-type="ins cts-4" specific-use="1557331337040" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:02pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331337040">)</named-content> blockade, targeted therapies and/or chemotherapy. Since many of these studies include control arms, results are eagerly awaited and will hopefully lead to <named-content rid="72a7d942-9650-4c9e-9652-4a927dd66d6d" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="18e52b6e-f171-4262-be52-2360f50b2ca7" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/><named-content data-cid="1557330314" id="c760684e-d4a4-4552-8976-a4a64555536b" content-type="ins cts-4" specific-use="1557331373526" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:02pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331373526">European Medicines Agency (</named-content>EMA<named-content data-cid="1557330347" id="14cb1e39-727e-4533-a6e9-5216cfe384b5" content-type="ins cts-4" specific-use="1557331390024" xlink:title="Tasnia (BMJ)" alt="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-title="Inserted by Tasnia (BMJ) - May 8 2019 5:03pm" data-track-detail="" data-userid="publisher b86b70a7-dacf-4827-8162-0e4d003c05ac" data-username="Tasnia (BMJ)" data-time="1557331390024">)</named-content><named-content rid="72a7d942-9650-4c9e-9652-4a927dd66d6d" data-class="jrnlQueryRef" data-type="end" id="47f79a22-0ca9-4741-81ef-85b7d7d350d8" content-type="jrnlQueryRef" specific-use="end" data-answered="true"/> approval of immune checkpoint blockade as a standard of care for <named-content id="38fddadb-e4c9-4774-bbb7-7b5507089d9f" data-cid="38fddadb-e4c9-4774-bbb7-7b5507089d9f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="559" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="7_7" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with MSI mCRC. In the meantime, these <named-content id="cc625ee8-a19d-46e8-af2a-667826b3eba3" data-cid="cc625ee8-a19d-46e8-af2a-667826b3eba3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="606" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="7_8" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> are being treated with PD-1/PD-L1 inhibitors within clinical trials in the Netherlands. Another way of treating these <named-content id="d3c6d03b-cfbf-479f-9093-89d9d88852ee" data-cid="d3c6d03b-cfbf-479f-9093-89d9d88852ee" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="733" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="7_9" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with immunotherapy when they do<named-content data-cid="1554813311" id="beac83eb-b738-4db0-9423-1eee1a759ab8" content-type="ins cts-3" specific-use="1554814308166" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:51pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554814308166"> </named-content>n<named-content data-cid="1554813312" id="3fb31205-141b-47dd-9acf-5f74fe33bd49" content-type="del cts-3" specific-use="1554814308908" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:51pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554814308908">’</named-content><named-content data-cid="1554813313" id="49b83102-8004-445d-8d0d-494fb6aba1de" content-type="ins cts-3" specific-use="1554814309198" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:51pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554814309198">o</named-content>t <named-content data-cid="1554706534025" id="857a7651-69b9-45af-8b21-7bc38680e9cd" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">fulfill</named-content><named-content id="eb6ba860-70ef-4c3a-beff-c28540cd4db0" data-cid="1554706534025" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'fulfill' to 'fulfil'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="779" data-match="fulfill" data-replace="fulfil" data-pattern="fulfil" data-tag-index="7_12" data-function="addTrackChanges" data-track-change="fulfill" data-userid="preediting" data-username="Exeter" data-time="1554706534000">fulfil</named-content> <named-content data-cid="1554807130" id="6e850fb5-b07d-49db-9fb9-966eb9167f45" content-type="ins cts-3" specific-use="1554807431522" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807431522">the </named-content>criteria for clinical trials or when trials are not available<named-content data-cid="1554807134" id="e30db4e1-c1bd-464a-98bd-60021b12ab20" content-type="del cts-3" specific-use="1554807434084" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807434084">,</named-content> is by acquiring PD-1 blockade through <named-content id="e92354f0-5ead-45af-bcfc-17a7047a2810" data-cid="e92354f0-5ead-45af-bcfc-17a7047a2810" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patient' to 'patient'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="888" data-match="patient" data-replace="patient" data-pattern="$1" data-tag-index="7_10" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patient</named-content> access <named-content data-cid="1554706534005" id="c1c6fe80-e30a-4790-a138-69dd8a9dbc2b" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">programs</named-content><named-content id="2da36144-03df-47d4-b598-a8aa7b2da507" data-cid="1554706534005" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'programs' to 'programme'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="903" data-match="programs" data-replace="programme" data-pattern="programme" data-tag-index="7_11" data-function="addTrackChanges" data-track-change="programs" data-userid="preediting" data-username="Exeter" data-time="1554706534000">programme<named-content data-cid="1554807135" id="3230bc0c-52d9-42e9-b044-1c25fdd27bd4" content-type="ins cts-3" specific-use="1554807436744" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807436744">s</named-content></named-content>. Ultimately, checkpoint blockade in MSI mCRC provides clear benefit in a heavily pre<named-content data-cid="1554807136" id="f56c89e3-88a8-4b41-9a8d-fc9181c0b7e9" content-type="del cts-3" specific-use="1554807440611" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807440611">-</named-content>treated population, and data from <named-content data-cid="1554706534026" id="e0e98eaa-7b8f-494c-ad83-9103cac5c499" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">randomized</named-content><named-content id="d8f0d349-afa0-4899-801e-a25e930ef2e2" data-cid="1554706534026" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'randomized' to 'randomised'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="1031" data-match="randomized" data-replace="randomised" data-pattern="randomised" data-tag-index="7_13" data-function="addTrackChanges" data-track-change="randomized" data-userid="preediting" data-username="Exeter" data-time="1554706534000">randomised</named-content> controlled trials are needed for approval in Europe.</p><p data-class="jrnlSecPara" id="7deb83b3-d304-4766-a48e-8d163c2b14b3">At the NKI, all <named-content id="e8499dc3-a855-4a72-8914-378ecfd314fa" data-cid="e8499dc3-a855-4a72-8914-378ecfd314fa" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="16" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="8_2" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with mCRC undergo MSI testing, using IHC for all four MMR proteins. Often, MSI testing has already been done at the time of diagnosis as this is advised in national guidelines in all <named-content id="ee84da33-6e20-4612-900d-b375d3f9a352" data-cid="ee84da33-6e20-4612-900d-b375d3f9a352" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patient' to 'patient'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="208" data-match="patient" data-replace="patient" data-pattern="$1" data-tag-index="8_3" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patient<named-content data-cid="1554807137" id="7b3e42c9-2172-4899-8a0a-9ae8f26be20d" content-type="ins cts-3" specific-use="1554807457540" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807457540">s</named-content></named-content> under <named-content id="2e4d4bce-d778-4dcd-9361-284b8e5e1f29" data-cid="2e4d4bce-d778-4dcd-9361-284b8e5e1f29" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="222" data-match="70 years" data-replace="70" data-pattern="$1" data-tag-index="8_1" data-time="" data-username="" data-userid="">70</named-content><named-content id="60f18b3a-f300-4f8a-9d15-091f6d690f79" data-cid="60f18b3a-f300-4f8a-9d15-091f6d690f79" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="224" data-match="70 years" data-replace=" years" data-pattern=" $2" data-tag-index="8_1" data-time="" data-username="" data-userid=""> years</named-content> of age. In <named-content id="28652543-88e1-4bc6-86ef-7cb3250d24aa" data-cid="28652543-88e1-4bc6-86ef-7cb3250d24aa" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="242" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="8_4" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with MSI mCRC <named-content data-cid="1554706534027" id="5bb73073-e2d3-49de-91bf-029385c38961" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="847284e4-a6cc-41fa-bf4f-abc17b367123" data-cid="1554706534027" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="265" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="8_6" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> <named-content data-cid="1554706534028" id="3f1a45c0-ea62-4ca9-b99d-46f107249672" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">harboring</named-content><named-content id="90e47ccd-4d7f-4d16-92d3-b7e49d57bfdb" data-cid="1554706534028" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'harboring' to 'harbouring'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="272" data-match="harboring" data-replace="harbouring" data-pattern="harbouring" data-tag-index="8_7" data-function="addTrackChanges" data-track-change="harboring" data-userid="preediting" data-username="Exeter" data-time="1554706534000">harbouring</named-content> BRAF mutations, immunotherapy is preferred over tyrosine-kinase inhibitors when possible. <named-content id="25a03101-9a10-42ef-bb85-d7792eeeb718" data-cid="25a03101-9a10-42ef-bb85-d7792eeeb718" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'Patients' to 'Patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="372" data-match="Patients" data-replace="Patients" data-pattern="$1" data-tag-index="8_5" data-function="addTrackChanges" data-time="" data-username="" data-userid="">Patients</named-content> with stage I<named-content data-cid="1554807138" id="e20fe593-041f-472b-9230-a67b7c1de750" content-type="del cts-3" specific-use="1554807470026" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807470026">-</named-content><named-content data-cid="1554807139" id="d90759f2-8f53-4da1-9a61-c9f93a04c833" content-type="ins cts-3" specific-use="1554807470362" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807470362">–</named-content>III colon cancers are routinely tested for MSI, and within the NKI and other participating <named-content data-cid="1554706534029" id="7e029a2b-f56b-44ed-9889-e77be36f6429" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">centers</named-content><named-content id="f568e29e-d5d9-456a-afbb-4f0adc20f608" data-cid="1554706534029" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'centers' to 'centres'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="485" data-match="centers" data-replace="centres" data-pattern="centres" data-tag-index="8_8" data-function="addTrackChanges" data-track-change="centers" data-userid="preediting" data-username="Exeter" data-time="1554706534000">centres</named-content> in <named-content data-cid="1554807140" id="0597e146-535e-4dc4-b333-0efcadc5c30a" content-type="del cts-3" specific-use="1554807474578" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807474578">T</named-content><named-content data-cid="1554807141" id="b927a8c5-a914-4c2d-94cf-4186d736a01a" content-type="ins cts-3" specific-use="1554807474974" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:57pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807474974">t</named-content>he Netherlands<named-content data-cid="1554813314" id="3170443f-4707-4e95-a99a-f3a2f9d99a21" content-type="del cts-3" specific-use="1554814365902" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:52pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554814365902">,</named-content> the possibility of neoadjuvant immunotherapy in a clinical trial setting is discussed.</p><title data-level="1" data-class="jrnlHead1" id="f0e66cff-7c8e-4872-83bd-0f93dc5c4ce6">Non-<named-content data-cid="1554807253" id="f69e94d4-d516-470f-8ea7-c4bb9c65591d" content-type="ins cts-3" specific-use="1554811460608" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811460608">CRC</named-content><named-content data-cid="1554807256" id="c6e9c418-cde6-4f86-9473-2e4ab1fb0243" content-type="del cts-3" specific-use="1554811462230" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811462230">colorectal cancer</named-content></title><p data-class="jrnlSecPara" id="0550ed2b-dfb8-430b-8aac-00e5d5409b49">To date, PD-1-blocking antibodies are not approved for treatment of MSI cancers in Europe. Therefore, <named-content id="d671708c-41bf-4dc5-bb10-ab19a7e7de91" data-cid="d671708c-41bf-4dc5-bb10-ab19a7e7de91" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="102" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="9_3" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with advanced MSI cancers are entirely dependent on access to clinical trials or <named-content id="8de5b33c-e89e-4d59-9786-b6c6901ac121" data-cid="8de5b33c-e89e-4d59-9786-b6c6901ac121" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patient' to 'patient'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="192" data-match="patient" data-replace="patient" data-pattern="$1" data-tag-index="9_4" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patient</named-content> access <named-content data-cid="1554706534006" id="fd544765-6edc-485d-897d-d0050626c5e0" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">programs</named-content><named-content id="39ac50ea-7202-423e-bc0d-add750033116" data-cid="1554706534006" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'programs' to 'programme'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="207" data-match="programs" data-replace="programme" data-pattern="programme" data-tag-index="9_5" data-function="addTrackChanges" data-track-change="programs" data-userid="preediting" data-username="Exeter" data-time="1554706534000">programme<named-content data-cid="1554807142" id="bff60d95-a04d-4280-8cc8-13971ceebfed" content-type="ins cts-3" specific-use="1554807485565" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807485565">s</named-content></named-content> with immune checkpoint inhibitors. <named-content rid="65a5f656-0c30-4633-8000-cefdea3e2f4c" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="32c26215-e118-4e47-b7b0-b706dca883f9" content-type="jrnlQueryRef" specific-use="start" data-answered="true"/>Given<named-content rid="65a5f656-0c30-4633-8000-cefdea3e2f4c" data-class="jrnlQueryRef" data-type="end" id="b93660c0-0213-4f4b-b75e-09161a494a04" content-type="jrnlQueryRef" specific-use="end" data-query-type="action" data-answered="true"/> that the number of immunotherapy trials entering individuals based on high <named-content id="3c0c3bc3-6058-4714-9778-31d8cdf05b33" data-cid="3c0c3bc3-6058-4714-9778-31d8cdf05b33" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="332" data-match="tumor mutational burden" data-pattern="" data-tag-index="" data-abbr="TMB" data-time="" data-username="" data-userid=""><named-content data-cid="1554706534030" id="448a35bb-c0ac-4c92-85fb-4de0455116dd" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="8cff35ff-8c51-4008-8a85-7488183b529f" data-cid="1554706534030" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="332" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="9_11" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000"><named-content data-cid="1554807274" id="2eed30b5-faff-4df8-8ecf-9eb58dd9833f" content-type="del cts-3" specific-use="1554811583916" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811583916">tumour</named-content></named-content><named-content data-cid="1554807274" id="08f82ba8-6334-4946-afd6-549093d8df1e" content-type="del cts-3" specific-use="1554811583916" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811583916"> mutational burden</named-content></named-content><named-content data-cid="1554807274" id="05716116-3665-4c44-9bbd-068b7dfac2fa" content-type="del cts-3" specific-use="1554811583916" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811583916"> (</named-content><named-content id="162c183e-9a5a-4ddc-8e2d-5c6ec77121df" data-cid="162c183e-9a5a-4ddc-8e2d-5c6ec77121df" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="357" data-match=" (TMB)" data-pattern="" data-tag-index="9_1" data-time="" data-username="" data-userid="">TMB</named-content><named-content data-cid="1554807275" id="4c0ad429-dfef-4e31-af66-d97470b43f2b" content-type="del cts-3" specific-use="1554811584938" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:06pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811584938">)</named-content><xref id="93b612d8-1db6-4e1b-9333-e6b7e5dbf16f" ref-type="bibr" rid="R8" data-citation-string=" R8 " data-tag-type="BIBREF" data-track-change="8"><sup id="8b7eb636-1c55-407a-a9d4-6521e649679d">8</sup></xref> or MSI status is increasing, it is becoming more customary and worthwhile to screen certain <named-content id="4a05fbdd-b575-4722-adde-f16bbd2786ee" data-cid="4a05fbdd-b575-4722-adde-f16bbd2786ee" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patient' to 'patient'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="455" data-match="patient" data-replace="patient" data-pattern="$1" data-tag-index="9_6" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patient</named-content> subgroups for MSI. At the NKI, we consider MSI screening for <named-content id="6254ab6c-a9d2-49a7-b1e2-2628b8a51107" data-cid="6254ab6c-a9d2-49a7-b1e2-2628b8a51107" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="524" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="9_7" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> fulfilling the following criteria: <named-content data-cid="1554807143" id="a9c76688-59d5-4d3b-aad8-94b58707c387" content-type="ins cts-3" specific-use="1554807497652" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807497652">(</named-content><named-content data-cid="1554807144" id="2f684107-6770-4561-a775-fc405bb671a8" content-type="del cts-3" specific-use="1554807498665" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807498665">i</named-content><named-content data-cid="1554807145" id="98b7f15f-1a3d-4dce-9655-238e4f77214f" content-type="ins cts-3" specific-use="1554807498705" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807498705">1</named-content>) advanced disease, <named-content data-cid="1554807146" id="86d79842-a70c-49f2-8ee0-2bfe3b2d3e0e" content-type="ins cts-3" specific-use="1554807500775" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807500775">(</named-content><named-content data-cid="1554807147" id="8e4db9c0-234f-40b9-aa66-b4edca98ec60" content-type="del cts-3" specific-use="1554807501795" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807501795">ii</named-content><named-content data-cid="1554807148" id="0fa4c568-1a78-4784-b008-588ac09e4f32" content-type="ins cts-3" specific-use="1554807501829" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807501829">2</named-content>) no standard treatment options or only treatment options for which limited efficacy can be expected, <named-content data-cid="1554807149" id="bd9cfd6d-7bf6-47fe-9784-75e5c64c8a39" content-type="ins cts-3" specific-use="1554807506629" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807506629">(</named-content><named-content data-cid="1554807150" id="7de07e6f-3a5d-4ca5-9250-83f181e28e5b" content-type="del cts-3" specific-use="1554807507635" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807507635">iii</named-content><named-content data-cid="1554807151" id="59e433dd-caa5-4f30-8983-37cb61a61210" content-type="ins cts-3" specific-use="1554807507668" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807507668">3</named-content>) histologies outside <named-content data-cid="1554706534031" id="3993fb14-14ed-46f8-9887-52e9a62762b4" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="3c090047-9449-4b76-937a-5b730a1d1859" data-cid="1554706534031" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="718" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="9_12" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> types for which PD-1/PD-L1-blocking antibodies have been approved (melanoma, lung cancer, bladder cancer, renal cell carcinoma <named-content data-cid="1554807152" id="0b9f8690-2762-43ef-b4fe-d32d3e609863" content-type="del cts-3" specific-use="1554807513280" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807513280">etc</named-content><named-content data-cid="1554807153" id="3a791011-b18b-4a75-8f3e-9215f3cf2386" content-type="ins cts-3" specific-use="1554807513317" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807513317">and so on</named-content>), <named-content data-cid="1554807162" id="324d940d-7ebc-4857-887c-5e6bedacdd60" content-type="ins cts-3" specific-use="1554807515828" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807515828">(</named-content><named-content id="95bb6cef-3844-4089-9576-94c8a9e7c954" data-cid="95bb6cef-3844-4089-9576-94c8a9e7c954" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'iv' to 'iv'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="857" data-match="iv" data-replace="iv" data-pattern="$1" data-tag-index="9_8" data-function="addTrackChanges" data-time="" data-username="" data-userid=""><named-content data-cid="1554807163" id="0b03c5e0-ec0e-4b08-9fcd-86f939f582bf" content-type="del cts-3" specific-use="1554807516948" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807516948">iv</named-content></named-content><named-content data-cid="1554807164" id="24af5e1f-65d6-44bd-a6d0-e87c3545a98a" content-type="ins cts-3" specific-use="1554807516987" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807516987">4</named-content>) no severe auto<named-content data-cid="1554807165" id="19c6c98f-8592-4977-897e-bf4d2bc94008" content-type="del cts-3" specific-use="1554807518397" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807518397">-</named-content>immune disease, <named-content data-cid="1554807169" id="aa22aed8-256c-4b32-9c39-d2087e9696b1" content-type="ins cts-3" specific-use="1554807525640" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807525640">and </named-content><named-content data-cid="1554807166" id="726a77a3-6a8d-4c10-87a9-1fb1d835e68c" content-type="ins cts-3" specific-use="1554807520078" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807520078">(</named-content><named-content data-cid="1554807167" id="c48b4a04-e25b-4285-b553-f584a4b0e940" content-type="del cts-3" specific-use="1554807521125" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807521125">v</named-content><named-content data-cid="1554807168" id="adec5867-1c94-40a7-9d9e-119f53ffdd31" content-type="ins cts-3" specific-use="1554807521163" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807521163">5</named-content>) WHO performance status and laboratory findings that allow participation in a clinical trial. In <named-content id="1dac66d9-8b1d-4810-8bc4-dd75ceb07b4e" data-cid="1dac66d9-8b1d-4810-8bc4-dd75ceb07b4e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="991" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="9_9" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with gastrointestinal cancers other than CRC, subgroups of breast cancer, prostate and endometrial cancers who <named-content data-cid="1554706534032" id="99e68626-658b-4ce4-b911-5f3294af7194" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">fulfill</named-content><named-content id="1b47e988-3a53-4b9e-b924-95d7e782ff4e" data-cid="1554706534032" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'fulfill' to 'fulfil'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="1111" data-match="fulfill" data-replace="fulfil" data-pattern="fulfil" data-tag-index="9_13" data-function="addTrackChanges" data-track-change="fulfill" data-userid="preediting" data-username="Exeter" data-time="1554706534000">fulfil</named-content> these criteria, it has become common practice to test for MMR deficiency. Also, MSI testing is performed in <named-content id="72fc0cef-fce2-4773-889d-a5ea84e460d7" data-cid="72fc0cef-fce2-4773-889d-a5ea84e460d7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1227" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="9_10" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with non-metastatic gastro-<named-content data-cid="1554807173" id="f53feb55-53ae-4e22-b747-5a2c0eae395f" content-type="ins cts-3" specific-use="1554807536288" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:58pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807536288">o</named-content>esophageal junction and gastric cancers due to the availability of neoadjuvant immunotherapy trials (NCT03448835). With the emergence of neoadjuvant immunotherapy trials, <named-content data-cid="1554807174" id="ebc7f077-1897-4240-8ffb-1de5898d1d79" content-type="del cts-3" specific-use="1554807545923" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807545923">like </named-content>for example breast cancer, it is expected that there will be a significant increase in MSI testing in a broad spectrum of <named-content data-cid="1554706534033" id="46a37d75-82bd-47bd-bb21-a7a6ae237d44" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="aa75f1f5-7283-4c40-8cad-e334da6058e0" data-cid="1554706534033" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="1561" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="9_14" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> types in the early<named-content data-cid="1554807175" id="00e2c6c5-227e-402f-a320-6ba62ce522a3" content-type="del cts-3" specific-use="1554807551848" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807551848"> </named-content><named-content data-cid="1554807176" id="e9d5ea9c-8945-4202-820e-5e742692cc5f" content-type="ins cts-3" specific-use="1554807552130" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807552130">-</named-content>stage disease setting.</p><p data-class="jrnlSecPara" id="595e5e24-1b70-4ccd-982f-9f6231c7cdd0">The method of choice for screening for MSI depends on (cancer<named-content data-cid="1554807177" id="b1ed0b16-735a-456a-89ce-9f0670b6c96b" content-type="del cts-3" specific-use="1554807556560" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807556560">-</named-content><named-content data-cid="1554807178" id="f6f60df2-3b48-408e-8cd4-6baf9e2cedf9" content-type="ins cts-3" specific-use="1554807556799" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807556799"> </named-content>gene panel) sequencing options available in the hospital laboratory or at affiliated (commercial) institutes. Besides, certain trials offer screening for high TMB or MSI as part of the pre<named-content data-cid="1554807179" id="827b3fb8-5b9d-464b-b13a-e3156cc980e0" content-type="del cts-3" specific-use="1554807565430" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807565430">-</named-content>screening. However, given that IHC for MMR proteins and/or PCR for MSI detection is widely available, in most cases screening for MSI will start with IHC for the four MMR proteins and/or the PCR-based test. Of note, although these immunohistochemical and PCR assays are highly sensitive methods for the identification of MSI in <named-content data-cid="1554807257" id="998e2a56-3dcd-4611-95c4-21b0ef19db43" content-type="ins cts-3" specific-use="1554811466375" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811466375">CRCs</named-content><named-content data-cid="1554807261" id="467476b5-bf4b-4da2-bf85-ed1771f14139" content-type="del cts-3" specific-use="1554811468271" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 8:04pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554811468271">colorectal cancers</named-content>, little<named-content data-cid="1554807180" id="01347a2a-5a50-44c1-a408-62a8b065c4bf" content-type="del cts-3" specific-use="1554807576289" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807576289">,</named-content> is known about the likelihood of false-negative results and heterogeneity of the IHC staining in other <named-content data-cid="1554706534034" id="8b6e7eb4-f230-4bf7-9d27-21af021a92fd" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="b48e16d4-853c-4743-b6f4-53149359c28c" data-cid="1554706534034" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="710" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="10_2" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> types. NGS studies in which IHC<named-content data-cid="1554807181" id="a37dbc5e-aa9e-4ca6-99ea-26641b8e1d3e" content-type="del cts-3" specific-use="1554807582191" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807582191">-</named-content><named-content data-cid="1554807182" id="989033db-925b-4ecb-aba9-10a8e1d779b0" content-type="ins cts-3" specific-use="1554807582514" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807582514"> </named-content>analyses for MMR<named-content data-cid="1554807183" id="bf7a7d5d-4025-42bd-bab6-21f2c8ffa7ac" content-type="del cts-3" specific-use="1554807583970" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807583970">-</named-content><named-content data-cid="1554807184" id="2023a58d-9fba-4a5c-8df1-adbfe403e285" content-type="ins cts-3" specific-use="1554807584395" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 6:59pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807584395"> </named-content>protein expression are directly compared with NGS data suggest that MSI calling is highly concordant between these <named-content data-cid="1554706534000" id="a28b57bf-eaae-444e-a40b-eeb2fdee2941" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">2</named-content><named-content id="7ebe6627-697d-4615-bd8c-e2259341a9c1" data-cid="1554706534000" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from '2' to 'two'" data-track-detail="" data-tag-desc="SNUM" data-tag-type="SNUM" data-offset="880" data-match="2" data-pattern="" data-tag-index="10_1" data-function="numberToText,addTrackChanges" data-track-change="2" data-userid="preediting" data-username="Exeter" data-time="1554706534000">two</named-content> assays.<xref id="750933ab-f810-4375-8f59-a0c3f59ddb69" ref-type="bibr" rid="R9" data-citation-string=" R9 " data-tag-type="BIBREF" data-track-change="9"><sup id="5e8fa493-6760-4751-9400-faa5f12d7876">9</sup></xref></p><p data-class="jrnlSecPara" id="fe7605cc-21d2-430f-b9db-fd5cc754541c">In addition, given that MSI is predictive of Lynch syndrome across a much broader <named-content data-cid="1554706534035" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" id="91cbbe24-fa18-4751-96b3-cdc5fed6b031">tumor</named-content><named-content id="a6cb7674-d30c-4bca-8459-af4d7704336a" data-cid="1554706534035" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="82" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="11_3" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> spectrum than is currently appreciated, germline assessment for Lynch syndrome should be considered for <named-content id="fecd14c7-c914-4db4-aabc-9bd681118de7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="192" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="11_1" data-function="addTrackChanges">patients</named-content> with an MSI <named-content data-cid="1554706534036" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" id="da340f9f-5768-452a-89e7-b9e81d41ac0c">tumor</named-content><named-content id="bdec1385-9b7b-4ace-abf7-11f41cffdb69" data-cid="1554706534036" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="213" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="11_4" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content>, regardless of cancer type or family history.<xref id="98dc6cff-2f7e-4bd4-87e8-aa2b3bcbbe0a" ref-type="bibr" rid="R10" data-tag-type="BIBREF" data-citation-string=" R10 " data-track-change="10"><sup id="3934832e-2db0-4695-bb62-28319e1f055f">10</sup></xref> At the NKI, <named-content id="9fc08742-3b01-4faa-a316-41aefeb7b95f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="279" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="11_2" data-function="addTrackChanges">patients</named-content> with MSI <named-content data-cid="1554706534037" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" id="ed93a4ee-8530-4b9d-8b2f-50fd093d728f">tumors</named-content><named-content id="8432aad1-dbab-4604-bc27-924cc3fc22b9" data-cid="1554706534037" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="297" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="11_5" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> of any origin without an underlying (somatic) MLH1 hypermethylation are referred for genetic <named-content data-cid="1554706534038" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" id="aefee38a-3ff9-4cf8-809e-a110afc10c4c">counseling</named-content><named-content id="9c6e5fae-cd90-4f42-ac9f-73549ce2d114" data-cid="1554706534038" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'counseling' to 'counselling'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="397" data-match="counseling" data-replace="counselling" data-pattern="counselling" data-tag-index="11_6" data-function="addTrackChanges" data-track-change="counseling" data-userid="preediting" data-username="Exeter" data-time="1554706534000">counselling</named-content>.</p><title data-level="1" data-class="jrnlHead1" id="5ae20c85-2f1b-466f-b9f2-feb0436e796e"><named-content data-cid="1554706534045" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" data-reason="truecase" id="657c8501-8762-4faf-838b-e36584431c0e">Future Perspective</named-content><named-content data-cid="1554706534045" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" data-reason="truecase" id="010d6ed5-3fc1-40e3-88b0-80462e87f9b8">Future perspective</named-content></title><p data-class="jrnlSecPara" id="cda6711d-1e21-49d5-89b8-1ef5bf31f280">Immunotherapy with immune checkpoint inhibitors for <named-content id="ce97195f-958a-4ed9-a2dc-72930ace4e05" data-cid="ce97195f-958a-4ed9-a2dc-72930ace4e05" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="52" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="12_3" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> in Europe with advanced MSI <named-content data-cid="1554706534039" id="37d450c5-c1d6-4629-828d-c2a07c17dc48" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="2628ca66-0dad-475f-a88e-bd4da08ff64a" data-cid="1554706534039" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="89" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="12_11" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> will largely depend on EMA approval. Based on the current landscape of clinical trials in CRC <named-content id="1e106d82-6b44-4b70-b9e8-0b5e34384b61" data-cid="1e106d82-6b44-4b70-b9e8-0b5e34384b61" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'versus' to 'vs'" data-track-detail="" data-tag-desc="VERSUS" data-tag-type="VERSUS" data-offset="190" data-match="versus" data-replace="vs" data-pattern="vs" data-tag-index="12_10" data-track-change="versus" data-time="" data-username="" data-userid="">v<named-content data-cid="1554807185" id="2e3badd3-6208-4d10-b8d3-65f12d661d09" content-type="ins cts-3" specific-use="1554807615106" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 7:00pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807615106">ersu</named-content>s</named-content> non-CRC, the timing and details of this approval might come earlier for advanced CRC <named-content data-cid="1554706534007" id="ca77a85a-1028-4f08-af5f-8cc1989c92bc" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">compared to</named-content><named-content id="1e3d6b66-1ca0-4b15-b993-1feb907aeffc" data-cid="1554706534007" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'compared␣to' to 'compared with'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="282" data-match="compared to" data-replace="compared with" data-pattern="compared with" data-tag-index="12_5" data-function="addTrackChanges" data-track-change="compared to" data-userid="preediting" data-username="Exeter" data-time="1554706534000">compared with</named-content> the tumo<named-content data-cid="1554807189" id="685e5501-97b8-4a33-bbde-50bcce547f15" content-type="ins cts-3" specific-use="1554807621656" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 7:00pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807621656">u</named-content>r-agnostic indication. Awaiting the data of ongoing trials, two fields of research are of particular interest for <named-content id="6c47556e-b939-4ed7-852f-0a73c61fd35f" data-cid="6c47556e-b939-4ed7-852f-0a73c61fd35f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="416" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="12_6" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with MSI cancers. First, although the ORR with anti-PD-(L)1 monotherapy is high <named-content data-cid="1554706534008" id="738347be-b5ed-4978-8e3e-4464ec5f2dba" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">compared to</named-content><named-content id="0784f52c-e802-4cc1-a7c2-c52408d7f05b" data-cid="1554706534008" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'compared␣to' to 'compared with'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="505" data-match="compared to" data-replace="compared with" data-pattern="compared with" data-tag-index="12_7" data-function="addTrackChanges" data-track-change="compared to" data-userid="preediting" data-username="Exeter" data-time="1554706534000">compared with</named-content> other <named-content data-cid="1554706534040" id="158ccaa3-7ff5-49fd-84bf-e47254f27945" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="3e49f10e-fded-4be3-9e0a-2841e5df7c94" data-cid="1554706534040" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="523" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="12_12" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> subtypes, there is still a substantial proportion of <named-content id="5f7632a4-4952-454a-b1d2-fde2a941a15f" data-cid="5f7632a4-4952-454a-b1d2-fde2a941a15f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="582" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="12_8" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with advanced MSI <named-content data-cid="1554706534041" id="e38ae05d-490e-485f-af82-600754f4aabf" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumors</named-content><named-content id="a4d7ea3d-6b45-4068-adc0-efd2240ecbdf" data-cid="1554706534041" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumors' to 'tumours'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="609" data-match="tumors" data-replace="tumours" data-pattern="tumours" data-tag-index="12_13" data-function="addTrackChanges" data-track-change="tumors" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumours</named-content> that do not benefit from PD-(L)1<named-content data-cid="1554807190" id="3e3a7d9a-ed5e-44eb-b014-f25a0e455afb" content-type="ins cts-3" specific-use="1554807636312" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 7:00pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807636312">-</named-content><named-content data-cid="1554807191" id="cdee9c7d-4857-45f6-a609-1d870df2cf2b" content-type="del cts-3" specific-use="1554807637069" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 7:00pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807637069"> </named-content>blocking antibodies. Progress in more fundamental immunological research should provide further insight into both the exact mechanism of <named-content data-cid="1554706534042" id="5a5d58fb-a0e6-4069-8944-76c299917a13" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="e8cdf99a-e8ad-41a6-86b3-1a67e6f8d636" data-cid="1554706534042" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="786" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="12_14" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> recognition as well as the immune cell types involved in <named-content data-cid="1554706534043" id="a2cd96a3-0d13-49d9-945e-90644d673c5d" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumor</named-content><named-content id="7f8d3377-2e5d-4e6c-83d8-419696252827" data-cid="1554706534043" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="849" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="12_15" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554706534000">tumour</named-content> control of MSI cancers.<xref id="b8d72ce5-3782-473b-a24b-99de07654314" ref-type="bibr" rid="R11" data-citation-string=" R11 " data-tag-type="BIBREF" data-track-change="11"><sup id="1d48ec8f-1082-4585-a310-44c055d08c2a">11</sup></xref> These data should thereby provide rationale for novel immunomodulatory approaches for MSI cancers. Second, neoadjuvant trials in melanoma<xref id="65925b35-236f-4f3e-ad4e-bb9a5b5c38c0" ref-type="bibr" rid="R12 R13 R14" data-citation-string=" R12 R13 R14 " data-tag-type="BIBREF" data-track-change="12-14"><sup id="cd98f330-ce22-4210-b9a6-38da3ecee64d">12–14</sup></xref> and lung cancer<xref id="047e97dc-ee32-4820-94b9-20058654cf2c" ref-type="bibr" rid="R15" data-citation-string=" R15 " data-tag-type="BIBREF" data-track-change="15"><sup id="32824858-3ed8-4df9-9dd9-8062552ae5b8">15</sup></xref> have now shown that the response rate to immune checkpoint inhibition may be substantially higher when these treatments are given early in the disease course. Importantly, our preliminary data suggest that pre<named-content data-cid="1554807192" id="4c29a56a-62e6-4365-8b27-22acf33a51d8" content-type="del cts-3" specific-use="1554807658217" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 7:00pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807658217">-</named-content>operative immunotherapy in <named-content data-cid="1554807193" id="8d17af71-e54b-4b76-94c5-73f127924c15" content-type="ins cts-3" specific-use="1554807660624" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Inserted by Maria (COPYEDITOR) - Apr 9 2019 7:01pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807660624">patients with </named-content>MSI colon cancer <named-content id="ed1e8f7f-d723-4a34-9576-c9fcc657de17" data-cid="ed1e8f7f-d723-4a34-9576-c9fcc657de17" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1296" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="12_9" data-function="addTrackChanges" data-time="" data-username="" data-userid=""><named-content data-cid="1554807223" id="54d4f0b4-b322-401a-8312-51aca8b2f3d6" content-type="del cts-3" specific-use="1554807668657" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 7:01pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807668657">patients</named-content></named-content><named-content data-cid="1554807223" id="a7b5e996-a3d4-46df-947c-ec3e2d013036" content-type="del cts-3" specific-use="1554807668657" xlink:title="Maria (COPYEDITOR)" alt="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-title="Deleted by Maria (COPYEDITOR) - Apr 9 2019 7:01pm" data-track-detail="" data-userid="copyeditor ff09adeb-0449-41e6-8404-dd7fc4dd50e6" data-username="Maria (COPYEDITOR)" data-time="1554807668657"> </named-content>(NCT03026140) can result in an extremely high major pathological response rate and has the potential to change the standard of care for early MSI-related cancers.</p></body><back id="7b955f72-2738-4982-af88-b9ec3a2ee410" data-edited="true"><ref-list section="back" node-xpath="back" id="7469bc43-af63-444f-9b59-fa385a4187d4"><title data-level="1" id="e9d9acd2-9e39-45dd-a495-7f1d61d7c134"><named-content data-cid="1554706534044" content-type="del cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" id="1531ae09-7aa8-466f-86d2-9d449f945029">References (max 15)</named-content><named-content data-cid="1554706534044" content-type="ins cts-1" specific-use="1554706534000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554706534000" id="9c0bfe75-f7a5-45ba-b9e8-f8ac788133eb">References</named-content></title><ref data-class="jrnlRefText" seqid="R1" id="R1" data-id="R1" data-styled="RefText" data-reftype="Journal" data-valid-id="R1" data-validated="true"><label id="7d25f60e-7826-407e-a836-2566b90cd7fe">1.</label><element-citation publication-type="journal" id="5fe36bec-7344-477f-890f-2e65dc797ce8"><person-group person-group-type="author" id="f6e47538-6402-42f1-a262-99610e1a4e67"><name id="2db19a73-6e95-4064-a8ff-bb5d7f5d33d1"><surname id="17a53790-f174-4266-85c4-a24b06a8579a">DT</surname> <given-names id="f22611c5-0a97-4139-b7ff-0b3826b1a9ec">L</given-names></name><x>, </x><name id="b7fe4179-88b5-4958-b8b1-81bf4ada419b"><surname id="651fd6cd-1cc7-4045-b087-58b1ac5d8af2">Durham</surname> <given-names id="a1a66cec-7d01-4b0a-bc77-135cee065ba3">JN</given-names></name><x>, </x><name id="90f687da-b0d4-44c1-a834-80d26a378d1e"><surname id="2b9ebf38-e26f-4b69-8747-8d154d5a32da">Smith</surname> <given-names id="1d96d60f-fcfd-4c68-9d5d-d5612dede004">KN</given-names></name><x>, </x><etal data-class="RefEtal" id="1b986f4d-9df2-4dd8-ab0f-8ccf7ccd0cde">et al</etal></person-group><x>. </x><article-title id="58b86a24-3edd-4026-b5c2-925d3c7dae3f">Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade</article-title><x>. </x><source id="b647b87a-df25-4ff3-a5b7-3e3c1014dfe9">Science</source><x> </x><year id="70ab7c7a-8a81-4d99-805b-41fa4518fd5d">2017</year><x>.</x></element-citation></ref><ref data-class="jrnlRefText" seqid="R2" id="R2" data-id="R2" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R2" data-validated="true"><label id="b3a7f53e-3dbc-4296-8545-0d8935e46105">2.</label><element-citation publication-type="journal" id="b6046a39-c172-4046-8473-76c0081cad06"><person-group person-group-type="author" id="592dc058-e9c0-40f0-b6ad-38a7617b37f8"><name id="529dd517-bbca-4df7-bd4c-02a7bb33ff17"><surname id="e5e7f878-3d66-45e7-ae68-617d6609ff10">Diaz</surname> <given-names id="ca173eda-b65b-4391-8055-24b95d2fa158">LA</given-names></name><x>, </x><name id="661b8c0c-e3a2-49a3-ae61-d5e862a2a110"><surname id="1268c6d3-c6fb-4078-bab0-93de35da8a05">DT</surname> <given-names id="b76019dd-83a0-40d0-9470-105be1458537">L</given-names></name></person-group><x>. </x><article-title id="98de6d78-d9b2-4656-8732-a3be11ecded7">PD-1 <named-content data-cid="1554706553002" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R71" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="d2cb4627-d775-48af-af0e-3cf6dda0c55d">Blockade</named-content><named-content data-cid="1554706553002" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R71" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="cb2c2ae4-926b-43eb-86b4-70582c8fad35">blockade</named-content> in <named-content data-cid="1554706553003" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R72" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="3481050d-db1d-4834-8085-0fb45b1639cd">Tumors</named-content><named-content data-cid="1554706553003" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R72" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="b7e55ae2-ce79-4e19-a127-e0de5e4ea038">tumors</named-content> with <named-content data-cid="1554706553004" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R73" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="989ad732-82c6-4b8f-b02c-0fbb9a0317d8">Mismatch</named-content><named-content data-cid="1554706553004" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R73" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="d3e39d8c-2fa9-48ba-92a1-7347f10959e7">mismatch</named-content>-<named-content data-cid="1554706553005" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R74" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="78c34cd5-4105-4141-9abf-35f0aea93f36">Repair</named-content><named-content data-cid="1554706553005" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R74" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="ba3a3561-3433-49ed-8d31-ea140d139842">repair</named-content> <named-content data-cid="1554706553006" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R75" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="aa6ee1d5-6606-44ce-baa8-9d373f47cbcc">Deficiency</named-content><named-content data-cid="1554706553006" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R75" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="4092fc3a-6732-4178-9c45-1a556a0b8c31">deficiency</named-content></article-title><x>. </x><source id="e1e19ef4-d556-44ed-9dad-2bdb833009ba">N Engl J Med</source><x> </x><year id="59e1e0ea-9440-4395-af93-e893c9fbdce7">2015</year><x>;</x><volume id="ee8c76c2-c9cb-45eb-822c-d092489f59c0">373</volume><x>.</x></element-citation></ref><ref data-class="jrnlRefText" seqid="R3" id="R3" data-id="R3" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R3" data-doi="10.1158/1078-0432.CCR-18-4070" data-validated="true"><label id="da4ef0ac-1d71-4804-98b4-78d5b8ccd98b">3.</label><element-citation publication-type="journal" id="06064cf7-812e-422f-b10a-9a1dcaac3226"><person-group person-group-type="author" id="9c35c622-8818-4ae4-a49e-6b1a21d31366"><name id="661b00fb-958a-4708-845d-e281acb5e296"><surname id="baf2af40-f0c1-4637-b837-94543dc1fa1d">Marcus</surname> <given-names id="190d9557-2111-429c-bc5d-87cc7b4d0aca">L</given-names></name><x>, </x><name id="1641ec63-83e6-4a08-bdea-f34bc59cee13"><surname id="aebdd1b3-4055-4575-ae21-4dd8f88b1259">Lemery</surname> <given-names id="ad4c1b39-8967-45de-aeed-335057f956a9">SJ</given-names></name><x>, </x><name id="51fb8dc2-b6ab-4728-b789-ce1f5dd71834"><surname id="ca845095-9c64-4b17-9916-faa2efc0dca0">Keegan</surname> <given-names id="6cb40875-f803-4b26-b096-5043c0a1ca73">P</given-names></name><x>, </x><etal data-class="RefEtal" id="5b243d24-f762-4009-b7e1-12d90da70008">et al</etal></person-group><x>. </x><article-title id="a905d999-c429-46f9-9da4-74b0c18536ea">FDA <named-content data-cid="1554706553007" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R71" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="11881631-3f19-45c8-a000-c4505dec1c9d">Approval</named-content><named-content data-cid="1554706553007" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R71" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="c11116d2-c316-4d74-94b2-8980ac4ada1a">approval</named-content> <named-content data-cid="1554706553008" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R72" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="55605c26-9b33-460e-ad55-96c2fe60ebcb">Summary</named-content><named-content data-cid="1554706553008" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R72" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="e399559c-70eb-43fa-95ef-91e4673444c6">summary</named-content>: <named-content data-cid="1554706553009" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R73" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="8ac6b2ff-eb4e-4e67-bdc3-87cbcba6bd14">Pembrolizumab</named-content><named-content data-cid="1554706553009" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R73" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="99b134a7-2336-4d15-8289-161638e85485">pembrolizumab</named-content> for the treatment of microsatellite instability-high solid tumors</article-title><x>. </x><source id="b570de6f-a2a0-4c7f-9028-180a81f6d5dd">Clin Cancer Res</source><x> </x><year id="a543ee9e-3e1c-447c-8267-621d4b4dd2ff">2019</year><x>.</x><pub-id pub-id-type="doi" id="1b4a75e8-093b-4dbc-b05a-0ac885abdea9">10.1158/1078-0432.CCR-18-4070</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R4" id="R4" data-id="R4" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R4" data-doi="10.1038/nature12477" data-validated="true"><label id="9af2a692-4160-487e-b841-a1e0a4096086">4.</label><element-citation publication-type="journal" id="7a07f9ed-f3f6-43ef-8a74-a2d4ef5355f9"><person-group person-group-type="author" id="eb8b9018-71df-49d1-9e03-c1f95d46ba68"><name id="f0cb0874-0516-4f77-98f8-7b68b16991eb"><surname id="c9d2d5c9-71e6-4e77-90d4-85f63a10af4e">Alexandrov</surname> <given-names id="4e28abb7-a5ca-4ac7-b1a2-58b94bc0978a">LB</given-names></name><x>, </x><name id="5cc37d50-18b6-4e09-a197-fb7e5cccdf8c"><surname id="eff61da9-b9fd-4593-9568-05df415e91f6">Nik-Zainal</surname> <given-names id="0a02ec0a-ee17-46fd-ba3a-28246c74e539">S</given-names></name><x>, </x><name id="a0b1462e-4b1e-4172-a083-c0d3ea052f68"><surname id="3dcd70ba-3262-4633-b55d-b0e54e9c664b">Wedge</surname> <given-names id="9d85e537-f274-4be1-b8fd-8f325ff7fbab">DC</given-names></name><x>, </x><etal data-class="RefEtal" id="1afe504f-1596-412f-bb3c-7b2c44caf435">et al</etal></person-group><x>. </x><article-title id="114fec4a-2f9d-4453-a860-2e5e7d298119">Signatures of mutational processes in human cancer</article-title><x>. </x><source id="fa65c951-8d69-49d2-8447-d99acdb647a9">Nature</source><x> </x><year id="c7b0dd8a-6a09-4a12-89d8-1b74e40abde8">2013</year><x>;</x><volume id="f6bb5924-d7fb-47a3-b9bb-1ee384b92c44">500</volume><x>:</x><fpage id="1dae941b-0b4b-4200-8ede-53b82e640bfd">415</fpage><x>–</x><lpage id="3b66e3bd-db89-4cb8-b808-db1d7d1712d4">21</lpage><x>.</x><pub-id pub-id-type="doi" id="170d8661-9b22-4a13-984f-acc9138fe56a">10.1038/nature12477</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R5" id="R5" data-id="R5" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R5" data-validated="true"><label id="fd8e96c2-e84c-4692-8228-5196d2fdc06f">5.</label><element-citation publication-type="journal" id="bdfc015c-b3a8-4f8a-99d8-a1fe3a1e4504"><person-group person-group-type="author" id="7f5c5fa6-877b-48d2-829f-3d509a3ead23"><name id="507466d3-e295-496e-be41-32758f8483c3"><surname id="b9a2a710-8a6b-4630-9eb4-34cdaab27a07">Bonneville</surname> <given-names id="8fc01b9b-1294-414e-b491-9b8aa06a5d32">R</given-names></name><x>, </x><name id="2e49af14-6ad5-4a2e-bba5-10a0ae954dc6"><surname id="dabc27ac-9dff-4e96-bee2-8a5f77126f79">Krook</surname> <given-names id="cfa54305-ab8f-45e8-a7e9-1846a439833c">MA</given-names></name><x>, </x><name id="fca1953d-b77c-4d2b-8f56-91cfb41cdecf"><surname id="4b72a04e-f3b2-476c-894d-f598ac246475">Kautto</surname> <given-names id="129e465b-e595-4136-8542-97738b2fa6ab">EA</given-names></name><x>, </x><etal data-class="RefEtal" id="291c1e48-10ca-4fa6-9b96-d19d89d74715">et al</etal></person-group><x>. </x><article-title id="615ddd4a-330d-4a70-90e6-a7dae2b9f9c3">Landscape of <named-content data-cid="1554706553010" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R81" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="e8c48260-84e2-48d2-bf16-9d680e319872">Microsatellite</named-content><named-content data-cid="1554706553010" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R81" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="8d1c387f-ebf7-470a-8067-bacb394405e3">microsatellite</named-content> <named-content data-cid="1554706553011" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R82" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="d7cd7819-e1fe-4733-bef9-aec06f46c8d4">Instability</named-content><named-content data-cid="1554706553011" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R82" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="b20f7ee6-38bf-47fc-b5d8-b97064d15707">instability</named-content> <named-content data-cid="1554706553012" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R83" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="848c9280-88b6-4e1a-97bc-d076167d2e83">Across</named-content><named-content data-cid="1554706553012" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R83" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="6b3ae272-702a-44b4-97d2-7a11ed59e06b">across</named-content> 39 <named-content data-cid="1554706553013" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R84" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="6c4a9b16-2274-4650-a953-52379b870a29">Cancer</named-content><named-content data-cid="1554706553013" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R84" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="5cbef9af-0a09-4bda-9eec-c66f876e1ee9">cancer</named-content> <named-content data-cid="1554706553014" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R85" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="eaf07004-3d02-479a-8c59-fdb050e14769">Types</named-content><named-content data-cid="1554706553014" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R85" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="d939e3df-51e2-4e6d-a226-603cc65f79ff">types</named-content></article-title><x>. </x><source id="dcc36a36-8005-4ec9-8c97-a99edf47fada">JCO Precis Oncol</source><x> </x><year id="0f6d16e8-c6ee-4148-8652-0df551adb491">2017</year><x>;</x><volume id="a69e08f9-98d2-4a10-88d0-aa5ba05e4ba1">2017</volume><x>.</x></element-citation></ref><ref data-class="jrnlRefText" seqid="R6" id="R6" data-id="R6" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R6" data-doi="10.1093/bioinformatics/btt755" data-validated="true"><label id="04198dec-83e5-4f30-b66a-b5aea2f96aa9">6.</label><element-citation publication-type="journal" id="280deec3-e1c8-46b8-a5ab-0000a523d2a5"><person-group person-group-type="author" id="4cbdaf89-90a4-41fd-9711-2e542c9e4fc0"><name id="a9695fa7-b124-48fa-90d8-3a3a76e9e579"><surname id="4b75efa6-a5f4-49d2-8856-85fdbd3918b1">Niu</surname> <given-names id="ad062728-aac2-4159-8dd7-cc190fc8d715">B</given-names></name><x>, </x><name id="7377cfbd-6a1c-436c-ac3a-2fc8692b5a3b"><surname id="5bdf081a-51a0-449b-96de-2a27b763e118">Ye</surname> <given-names id="5d9c004a-9c6b-476b-b7ba-b597fdfffccc">K</given-names></name><x>, </x><name id="068fc21d-6e79-4757-8375-8ba5fc9d29a0"><surname id="144b9487-cc8b-4628-9db6-24ce5edaaeb5">Zhang</surname> <given-names id="879196ad-7510-4b3a-9531-ee278e4e92fa">Q</given-names></name><x>, </x><etal data-class="RefEtal" id="2adc223d-2c49-499c-ac26-0c54f60f0530">et al</etal></person-group><x>. </x><article-title id="a8f0825a-be24-41c4-be0e-878def24bfb8">MSIsensor: microsatellite instability detection using paired tumor-normal sequence data</article-title><x>. </x><source id="1b475e44-dc93-4ba9-820a-1c6d6cafa676">Bioinformatics</source><x> </x><year id="b2335a0a-e4fd-4bb5-9c3a-21fe8fc68c99">2014</year><x>;</x><volume id="e5077034-bfd0-4710-8a62-2ffa426f2319">30</volume><x>:</x><fpage id="f3551f8a-f86d-401a-9fa6-fdd881557c0f">1015</fpage><x>–</x><lpage id="130d0e31-82ba-4570-b4c4-e67f6fc23b67">6</lpage><x>.</x><pub-id pub-id-type="doi" id="144f4ca5-c26d-4147-9a48-13497890eedc">10.1093/bioinformatics/btt755</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R7" id="R7" data-id="R7" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R7" data-doi="10.1038/nm.4191" data-validated="true"><label id="1eb662b6-6ea4-4be8-ab4d-b8332dffb405">7.</label><element-citation publication-type="journal" id="b9522829-0751-49f9-9f39-c9a88376d9d5"><person-group person-group-type="author" id="9227eaf3-b9ab-410c-8eeb-ac61a744c2da"><name id="e785ceab-f8a2-4911-b7b7-281149ef2b82"><surname id="ffe70e77-0032-48c4-aec5-851368da286a">Hause</surname> <given-names id="aee2d64e-7a3d-4c95-acfa-3707bead4503">RJ</given-names></name><x>, </x><name id="fbf5c147-b993-4cb8-97f5-1667406bec8a"><surname id="a56c860e-eb0f-422f-ba1f-8b61c2e750fe">Pritchard</surname> <given-names id="f64e8c45-f863-42af-801b-dcf1b1b9854a">CC</given-names></name><x>, </x><name id="ac2d6815-2cec-4a1f-a74e-33ede2e15df0"><surname id="3f687754-4d61-4c32-83df-3913026421ab">Shendure</surname> <given-names id="e33b9b4f-df15-484a-b004-86c1d0399f84">J</given-names></name><x>, </x><etal data-class="RefEtal" id="c46a65b4-90b0-4469-831f-3153c4834b7d">et al</etal></person-group><x>. </x><article-title id="e137e495-900e-4537-8b15-58fd311bcdf6">Classification and characterization of microsatellite instability across 18 cancer types</article-title><x>. </x><source id="5eace1f4-7fe6-4654-b197-7d222cdd6fc1">Nat Med</source><x> </x><year id="ce7ba065-9e10-4db5-a8c3-db3fc1e9597e">2016</year><x>;</x><volume id="a715511e-e092-4720-aa14-f61b81b40805">22</volume><x>:</x><fpage id="b115bd11-f843-4a8d-aafb-ed74e4c02a20">1342</fpage><x>–</x><lpage id="399dfd65-eb91-40e8-94c2-1f1cf36080c4">50</lpage><x>.</x><pub-id pub-id-type="doi" id="fc30adc2-5077-4bca-8c12-a98ff32b33eb">10.1038/nm.4191</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R8" id="R8" data-id="R8" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R8" data-doi="10.1093/annonc/mdy495" data-validated="true"><label id="77e32fcb-e00f-4a03-a3dd-53bea481973d">8.</label><element-citation publication-type="journal" id="63a6dff3-e622-47b5-bbaf-b7c5f4c85f03"><person-group person-group-type="author" id="4edb4890-64b1-4e29-b997-6ee57e36ff90"><name id="acdba768-3ca3-460e-8d53-36d902d81782"><surname id="0b9f7ed1-b1b6-4eee-acee-f1eb36431dfa">Chan</surname> <given-names id="d3e9ff94-2552-4e74-87ad-3519bb00f4de">TA</given-names></name><x>, </x><name id="5a75f7b3-bff5-4e7a-a2b3-f9769b0f4af3"><surname id="57c0196d-6089-4d2e-b053-c8565af66d77">Yarchoan</surname> <given-names id="e4fbc7a1-b6f0-43c3-93f4-c998dbac235a">M</given-names></name><x>, </x><name id="a58e0f5d-49d3-4e38-bbfa-4972bd4dfa86"><surname id="1052e0bd-68e0-455f-9700-66117cea2772">Jaffee</surname> <given-names id="1631339d-5f5a-4c8b-83b7-4be56eb78636">E</given-names></name><x>, </x><etal data-class="RefEtal" id="c87aa213-ed9c-4db2-91cc-571820553450">et al</etal></person-group><x>. </x><article-title id="61138907-5a7f-4a0b-9dff-c6baacb74ac7">Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic</article-title><x>. </x><source id="c59e3f3b-5d92-461a-bb3c-210d395cc7d6">Ann Oncol</source><x> </x><year id="916135e4-1e1e-4cf0-9bf3-6e3a1925abaf">2019</year><x>;</x><volume id="153721e0-e50b-401b-8d5e-9e9fc103c9bd">30</volume><x>:</x><fpage id="1dce07e1-ea4d-456f-a889-75ae4ba40222">44</fpage><x>–</x><lpage id="62ba48bf-8d03-414e-ae03-d3197525a05b">56</lpage><x>.</x><pub-id pub-id-type="doi" id="07fb6d6a-2f06-4d43-b7b2-d158af290484">10.1093/annonc/mdy495</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R9" id="R9" data-id="R9" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R9" data-validated="true"><label id="fbe942a0-8366-4f0e-8037-f8b7b61e3e79">9.</label><element-citation publication-type="journal" id="a66a72e3-7f70-452b-b6e3-baedf42b5f12"><person-group person-group-type="author" id="55ab0529-e62c-4f50-93b3-70d9e5bbf451"><name id="2936ce05-a724-4514-919f-66c1729e60b6"><surname id="996efb43-3abd-4a9a-80c1-0f69ee99653d">Davies</surname> <given-names id="4951553f-7024-4092-8ca0-a8cc5dfe3eec">H</given-names></name><x>, </x><name id="8a58a31e-8af4-4dde-9849-739cf1ebce88"><surname id="5a4374c7-2fe9-404f-ab30-6e229ea25a65">Morganella</surname> <given-names id="86c93ca6-f2d2-43d5-b081-df83886e6a40">S</given-names></name><x>, </x><name id="c4a8034c-ff1e-41c5-a489-63f8ff6af48b"><surname id="a34e0b70-b908-4f50-9fb6-da492defefc8">Purdie</surname> <given-names id="52517d4f-ac95-4cf3-81bc-c960903a3054">CA</given-names></name><x>, </x><etal data-class="RefEtal" id="66f89731-56b8-4dd9-a90c-9fdbc8c2d4a6">et al</etal></person-group><x>. </x><article-title id="47551dbc-f730-4bd1-ba4b-dd8839c05e8f">Whole-<named-content data-cid="1554706553015" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="a9b0cdef-eacb-4eee-ab70-51fbf5257b61">Genome</named-content><named-content data-cid="1554706553015" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="c09283f1-2343-4313-bb44-d1906d3db547">genome</named-content> <named-content data-cid="1554706553016" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="fc9423d7-228a-4a26-bd83-8e17fa6a6dea">Sequencing</named-content><named-content data-cid="1554706553016" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="a2896ed4-a815-48e7-87b5-60e9967b5485">sequencing</named-content> <named-content data-cid="1554706553017" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="85fc78bd-4c40-4c5f-a0a7-d1e8f628f738">Reveals</named-content><named-content data-cid="1554706553017" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="7ef0b424-5286-4d4a-bab8-3419180f5aea">reveals</named-content> <named-content data-cid="1554706553018" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="56b1cb98-69e5-4831-abda-1e0a7914b150">Breast</named-content><named-content data-cid="1554706553018" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="38fa9519-5a0f-434c-ba98-df8b6e6871d9">breast</named-content> <named-content data-cid="1554706553019" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="63d1873c-60f1-4205-ab1f-d79d7a0c297a">Cancers</named-content><named-content data-cid="1554706553019" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="8c0b5c40-de6c-4b81-a7de-9a36e6a8dccd">cancers</named-content> with <named-content data-cid="1554706553020" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="8a90f333-6372-4b24-9290-f25c6e968adb">Mismatch</named-content><named-content data-cid="1554706553020" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="f59a2508-28b1-42f4-9f06-390aa06b380e">mismatch</named-content> <named-content data-cid="1554706553021" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="55df5d44-52f5-4585-acbd-f4491b5f5899">Repair</named-content><named-content data-cid="1554706553021" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="29c25863-88e2-499b-b959-bd9f74b2a8ad">repair</named-content> <named-content data-cid="1554706553022" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R108" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="4da6dd71-0a6c-47e0-a851-a6da7dab947e">Deficiency</named-content><named-content data-cid="1554706553022" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R108" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="4a9b1ac9-2e88-4733-b203-3812bdd90da7">deficiency</named-content></article-title><x>. </x><source id="52bfa6b6-2f2a-4dcb-8ea9-fa97d4a4be9a">Cancer Res</source><x> </x><year id="b90b38d2-4329-4bb6-a7f7-d2692b429a14">2017</year><x>;</x><volume id="6fc6a76a-64ac-4af7-8f8b-b89915e38d88">77</volume><x>:</x><fpage id="97cd7c00-1979-4ffb-b43d-f27d72ce16f5">4755</fpage><x>–</x><lpage id="c6ebc2a8-36e6-4d6a-8bc3-080dcbf03830">62</lpage><x>.</x></element-citation></ref><ref data-class="jrnlRefText" id="R10" data-id="R10" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R10" data-doi="10.1200/JCO.18.00283" data-validated="true"><label id="b4822f73-c2da-4c5e-8e35-11bc2ae36593">10.</label><element-citation publication-type="journal" id="1dd0303a-5ba1-46d7-bfcf-8cb77137285b"><person-group person-group-type="author" id="8b972ea3-4dbc-41ba-9f40-06b64822e46d"><name id="93674a50-ee3b-435e-9b3b-c1cd224fb044"><surname id="0c85c34c-7fc2-490b-a5f8-ff09a5f39bcb">Latham</surname> <given-names id="d29a0e63-e359-4598-a553-0c91f8479906">A</given-names></name><x>, </x><name id="d02bf084-258f-44f5-84d1-a05ef729fb1b"><surname id="62026c5d-b88d-4b96-8e63-ff3494a349f3">Srinivasan</surname> <given-names id="f3568bf1-402f-45d2-9050-741c32ab5e41">P</given-names></name><x>, </x><name id="4fef8737-a876-4c62-828a-a4851e61f31f"><surname id="d0d51fd9-3a20-4711-9df5-85af89f677bb">Kemel</surname> <given-names id="7ae4438b-aa7b-4772-afcc-668db8857b9e">Y</given-names></name><x>, </x><etal data-class="RefEtal" id="a794b06d-8dd3-454b-8ed5-6b7abff0b6d3">et al</etal></person-group><x>. </x><article-title id="377bc265-f77d-4f30-bd63-bae813e7640a">Microsatellite <named-content data-cid="1554706553023" id="4fe052e8-3f90-4627-8ed6-484425bc41a7" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">Instability</named-content><named-content data-cid="1554706553023" id="5da0a4ea-1b2c-4b51-920b-71e157b17f59" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">instability</named-content> <named-content data-cid="1554706553024" id="374f3635-0f67-4bef-919a-a2740bc554fc" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">Is</named-content><named-content data-cid="1554706553024" id="7bfd5550-16f6-49fb-9dec-f9b1866a2594" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">is</named-content> <named-content data-cid="1554706553025" id="b64cf8c6-1caf-46eb-99a5-8fd2effb5ea5" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">Associated</named-content><named-content data-cid="1554706553025" id="b3a11ccc-fe59-414d-be25-030624153d2b" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">associated</named-content> <named-content data-cid="1554706553026" id="b94cd199-6872-4eec-8aef-c2b66813ff8c" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">With</named-content><named-content data-cid="1554706553026" id="6d19108b-fc84-4f12-99d4-c1edb61cb090" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">with</named-content> the <named-content data-cid="1554706553027" id="1b6ab9f0-b866-4dab-9b1b-8fee1aab0fc7" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">Presence</named-content><named-content data-cid="1554706553027" id="5fe63244-31ce-4779-a710-81dc0d64124e" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">presence</named-content> of Lynch <named-content data-cid="1554706553028" id="0a577faa-fe68-454b-8eb4-14307b26b3fe" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">Syndrome</named-content><named-content data-cid="1554706553028" id="57670efa-18b6-4654-8214-4e053a92182e" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">syndrome</named-content> <named-content data-cid="1554706553029" id="a08762c8-8363-45cc-97ce-1cdfaee1b6fd" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">Pan</named-content><named-content data-cid="1554706553029" id="de226b55-aa92-41c1-bf43-7d2c5fe82542" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">pan</named-content>-<named-content data-cid="1554706553030" id="98f99006-df4c-496d-ad46-30c9cabcd9d0" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R108" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">Cancer</named-content><named-content data-cid="1554706553030" id="005ff51e-d48c-45b9-b8b1-90777c9b6d26" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R108" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000">cancer</named-content></article-title><x>. </x><source id="a4cedfd1-74e6-4526-8151-946fc3fe9ba7">J Clin Oncol</source><x> </x><year id="dbfe9f85-1a03-4749-94e6-f902338da2b5">2019</year><x>;</x><volume id="2dcfcc0e-a282-4eb8-9c39-daf1f32aaf28">37</volume><x>:</x><fpage id="5875be8b-545b-4eee-b664-dad729c39320">286</fpage><x>–</x><lpage id="c92710e4-d593-4ad6-8bea-7979002fb7ee">95</lpage><x>.</x><pub-id pub-id-type="doi" id="ab81bbfc-6bc6-40a9-82b6-5d3ccdef499a">10.1200/JCO.18.00283</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R11" id="R11" data-id="R11" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R11" data-doi="10.1016/j.ccell.2015.06.012" data-validated="true"><label id="ae0759e8-64a0-4170-8ba7-4e26a9228422">11.</label><element-citation publication-type="journal" id="fbbf7d9c-eca0-46b5-8cca-0875aa348f1c"><person-group person-group-type="author" id="4077c2db-ff18-4dee-a269-5fe8ae26deb5"><name id="40575f89-f660-4b90-93a4-e7541e677be8"><surname id="488b44ba-2654-498f-b0a1-a1986857c78c">Kelderman</surname> <given-names id="23257c00-3bfe-4274-9ff2-521d52ad3ddb">S</given-names></name><x>, </x><name id="a5b70706-68f0-4d1a-80a7-9507d9493f0a"><surname id="9eb93e55-73b7-415e-a746-bfbcc0aee5dc">Schumacher</surname> <given-names id="9af739dd-c21c-48d6-97a9-e4964d225c77">TN</given-names></name><x>, </x><name id="1d8183eb-b902-4a97-8335-5d0825fc28fd"><surname id="0eaeb981-ad98-43d8-8e07-2a4a5e0c5f73">Kvistborg</surname> <given-names id="1b263a93-7ab2-4850-91d4-f81beace1e67">P</given-names></name></person-group><x>. </x><article-title id="06bd9d59-8691-4af5-afe1-b5f51e615e62">Mismatch <named-content data-cid="1554706553032" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="39202231-608e-4d23-bc4f-a8d829235f49">Repair</named-content><named-content data-cid="1554706553032" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="49555942-04d2-4600-8e19-fe74e654ba22">repair</named-content>-<named-content data-cid="1554706553033" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="c0094198-96e6-46d2-8717-79bdb56554ad">Deficient</named-content><named-content data-cid="1554706553033" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="4d17d641-230f-432c-ac13-52357cf5693d">deficient</named-content> <named-content data-cid="1554706553034" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="72ae9e9e-d226-4012-9fe3-188285c4dc50">Cancers</named-content><named-content data-cid="1554706553034" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="80f197eb-f289-42f7-8c0b-bc91c8a0d40b">cancers</named-content> <named-content data-cid="1554706553035" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="b7ab1df7-ed1d-48b3-8fb5-1d6742d9bd18">Are</named-content><named-content data-cid="1554706553035" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="74bc25a5-6211-43e0-b4bd-f8bb57f0c4e6">are</named-content> <named-content data-cid="1554706553036" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="baa6a9a4-7c34-4ea0-9026-db4dadfced01">Targets</named-content><named-content data-cid="1554706553036" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="afce370f-6ffd-49d9-bb1c-66c440e28495">targets</named-content> for <named-content data-cid="1554706553037" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="e9fb4b59-d6e7-4028-85c1-b8e3a78c9ab0">Anti</named-content><named-content data-cid="1554706553037" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="f7cbb26a-8a70-4c9e-80ef-9540b1e74253">anti</named-content>-PD-1 <named-content data-cid="1554706553038" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="07859061-8c10-4206-ba67-6c4afc16546c">Therapy</named-content><named-content data-cid="1554706553038" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="f1e7bfcc-bdf9-4132-b5ac-cef041e45025">therapy</named-content></article-title><x>. </x><source id="be77924f-280e-4a90-9a98-96da275254a4">Cancer Cell</source><x> </x><year id="670c6493-113b-4da4-b825-dbc2dd4487e7">2015</year><x>;</x><volume id="04db5dc9-0d7a-4abb-ab21-9273f7c75d05">28</volume><x>:</x><fpage id="603c9ce0-fa9e-4a51-b738-bf0aa5c54e13">11</fpage><x>–</x><lpage id="ca288223-56e8-4b82-97fb-6eab3d06f71f">13</lpage><x>.</x><pub-id pub-id-type="doi" id="5577c03c-b863-423d-a53a-ad89994f6b18">10.1016/j.ccell.2015.06.012</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R12" id="R12" data-id="R12" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R12" data-doi="10.1038/s41591-018-0198-0" data-validated="true"><label id="b1c9d5b4-e393-45b7-934b-0b10ea45af4c">12.</label><element-citation publication-type="journal" id="6120b579-287d-4796-a4c9-b44b3736aa04"><person-group person-group-type="author" id="d6205b2b-af3f-4fd2-a381-4e1f98312245"><name id="d968031c-ceea-43e9-8699-af4fc3b11005"><surname id="d3d48c8b-cd7f-468e-baa3-e56c52e31274">Blank</surname> <given-names id="e2f006aa-6573-42c4-aded-02130de0c2cc">CU</given-names></name><x>, </x><name id="ab7c6eaa-4750-4eab-8dc2-4f50954041a7"><surname id="1c9eb488-c301-458b-9b30-bc9162459589">Rozeman</surname> <given-names id="fe5c116a-9794-4911-b803-e7fbea5e6aa4">EA</given-names></name><x>, </x><name id="cd6c1735-5258-4410-92db-52bde1883d5f"><surname id="a3e9bd8e-8ebb-45b6-a475-5c6e44c7555d">Fanchi</surname> <given-names id="39cb4e32-0376-42e1-9b79-7b2b977accb6">LF</given-names></name><x>, </x><etal data-class="RefEtal" id="d4c3b368-61b4-40d6-be45-e45467a2edf4">et al</etal></person-group><x>. </x><article-title id="ed36f0c2-3538-4bb5-a355-c076b877c53d">Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</article-title><x>. </x><source id="f36cd41a-8310-46b8-8912-5934d398ecb2">Nat Med</source><x> </x><year id="2a26a8f4-ec66-41f1-a082-11f1c41f18b7">2018</year><x>;</x><volume id="a6057134-0a92-4ab4-a0d8-c3bb5593f97f">24</volume><x>:</x><fpage id="42912510-6ac0-4088-96a5-2a245632d7b3">1655</fpage><x>–</x><lpage id="27831444-f9b7-4721-8c4b-e14f1511cf5e">61</lpage><x>.</x><pub-id pub-id-type="doi" id="3f497fc3-8b39-4ea0-ad8c-a854d5f667a4">10.1038/s41591-018-0198-0</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R13" id="R13" data-id="R13" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R13" data-doi="10.1038/s41591-018-0197-1" data-validated="true"><label id="b8305f07-d930-47be-a74f-79aa311467e5">13.</label><element-citation publication-type="journal" id="a2389cf2-5d16-4f25-81bb-ec1572f3a43c"><person-group person-group-type="author" id="ace5f4db-a44b-483c-9803-754a0fe6cfe9"><name id="6b447110-cc6f-4b69-b628-806315ed84f2"><surname id="fb76457e-0951-433d-a71c-08645b06ab01">Amaria</surname> <given-names id="53729f04-3cc8-4a3c-8d20-3bf4d90ba631">RN</given-names></name><x>, </x><name id="7020851d-4cc3-4259-beef-226312ce3c24"><surname id="77b62ead-8baf-4453-b979-d48ce5111574">Reddy</surname> <given-names id="e1a2c593-ea59-4033-8384-ba4b0e186752">SM</given-names></name><x>, </x><name id="cca183a1-b922-45c3-93f9-aa0dacc7a386"><surname id="3a91b837-eb82-4990-8f07-fcd919f0dd0e">Tawbi</surname> <given-names id="39577abf-36bd-445e-a853-3e475286c05f">HA</given-names></name><x>, </x><etal data-class="RefEtal" id="2d8eeeec-cfde-44cb-922f-39701cb95663">et al</etal></person-group><x>. </x><article-title id="9c8ba917-97b4-4863-b772-ebcd24e2106a">Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma</article-title><x>. </x><source id="330f850a-639e-42b2-a6a8-5a414c7a1660">Nat Med</source><x> </x><year id="644318ef-59a2-4416-9451-5e6b9bfa2dad">2018</year><x>;</x><volume id="6fd0420f-87fc-46d6-a09b-1fceb9a88fdb">24</volume><x>:</x><fpage id="3ff89416-986e-4205-8a7b-c40e1b8e0fa9">1649</fpage><x>–</x><lpage id="cdfed9c2-8e59-4d70-aa13-d8df00c9a886">54</lpage><x>.</x><pub-id pub-id-type="doi" id="0020ff26-1836-43a7-b780-04e5943c2944">10.1038/s41591-018-0197-1</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R14" id="R14" data-id="R14" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R14" data-doi="10.1038/s41591-019-0357-y" data-validated="true"><label id="1923b6de-89f0-4ec4-8350-7912db89e3c5">14.</label><element-citation publication-type="journal" id="08d76bfa-37f9-475d-be3f-054d55711f6d"><person-group person-group-type="author" id="5381fb33-e319-43a3-9e7f-631c893ff9fd"><name id="4a8ebd83-a659-4c33-bcf3-108dfc639754"><surname id="4021a56e-86f5-4b6b-8c04-9b627e56eeed">Huang</surname> <given-names id="6e6bbfd1-268e-41dc-9134-69e2c17b1c0d">AC</given-names></name><x>, </x><name id="a3b1c1c8-3a18-47d2-a0b9-35eea7cc38b2"><surname id="c3ac7b4d-a6a0-4442-aba1-659bc1332c9b">Orlowski</surname> <given-names id="83be9966-6503-4026-b36f-021fa214c287">RJ</given-names></name><x>, </x><name id="bf37a3fe-5f7d-4bec-a2f8-2d89f55307a9"><surname id="2d8e5992-9873-4491-86e2-784bac2e4758">Xu</surname> <given-names id="2fa3d39e-1535-412e-a034-1c777f572fb8">X</given-names></name><x>, </x><etal data-class="RefEtal" id="2b4e8bd1-2a23-4eb7-8cd7-e02722734397">et al</etal></person-group><x>. </x><article-title id="b219df91-6002-46d3-bb29-35d1023167bd">A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma</article-title><x>. </x><source id="0285bc6a-272c-469a-a914-87fdd7120b02">Nat Med</source><x> </x><year id="231406d0-f028-41de-8b21-c23c09fa5889">2019</year><x>;</x><volume id="6d7c1cf0-b698-487d-b1c4-90f8419acfa5">25</volume><x>:</x><fpage id="2bae92e6-82b7-4244-b77c-95833120d405">454</fpage><x>–</x><lpage id="aa987a86-2e4a-406e-932f-4dd31b1c9047">61</lpage><x>.</x><pub-id pub-id-type="doi" id="4591adc2-70a7-401c-b4a0-bbec2bfcb5af">10.1038/s41591-019-0357-y</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R15" id="R15" data-id="R15" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R15" data-validated="true"><label id="934fdc81-8546-4798-8955-9d57b88583ee">15.</label><element-citation publication-type="journal" id="8d13d88b-f837-48f5-8194-8487fc8e7428"><person-group person-group-type="author" id="b7e57dec-6239-4f06-a368-7b2378696b37"><name id="07fdf215-9d5c-49ea-80cd-5acfb4b69775"><surname id="a67c8980-b9e0-4145-9fc1-9bc86e4ad9fd">Forde</surname> <given-names id="c82dcf80-f7f4-4471-b9a1-d34c1cba8d07">PM</given-names></name><x>, </x><name id="38188121-12a0-438d-a577-80c66b4c8d52"><surname id="8ca5e615-d66a-4f90-bf17-57f81f1b7cd9">Chaft</surname> <given-names id="0199956b-eb6c-4462-b818-6b224e8239b6">JE</given-names></name><x>, </x><name id="72f2a0ee-ec06-4a2f-80ab-6a490a49852f"><surname id="026ddc2c-c6c5-4b07-92f4-829f7861d341">Pardoll</surname> <given-names id="8a5f0357-a41b-46bb-9bd4-5f998c997d01">DM</given-names></name></person-group><x>. </x><article-title id="fe3eebdc-37fb-41b7-8184-59988f984501">Neoadjuvant PD-1 <named-content data-cid="1554706553039" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="4ac1270b-e099-4fac-9ab0-7659e1805ec3">Blockade</named-content><named-content data-cid="1554706553039" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="cc4d05d4-bf35-40fa-872e-8845b55183fe">blockade</named-content> in <named-content data-cid="1554706553040" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="be7ab872-c753-4796-b761-f32d754e2f92">Resectable</named-content><named-content data-cid="1554706553040" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="91ad6984-af43-4303-ab41-93c80960d09a">resectable</named-content> <named-content data-cid="1554706553041" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="bc69dda3-3be4-48d8-887f-ebd9ebdecf1f">Lung</named-content><named-content data-cid="1554706553041" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="b50da466-516d-474f-a18b-b3eed2bf3ceb">lung</named-content> <named-content data-cid="1554706553042" content-type="del cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R94" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="264d4fcf-e4a4-4ab0-a358-d5eaef1634e5">Cancer</named-content><named-content data-cid="1554706553042" content-type="ins cts-1" specific-use="1554706553000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/08 12:25 pm" data-track-detail="" data-diff-rid="R94" data-userid="cross-ref" data-username="cross-ref" data-time="1554706553000" id="ea97cbc0-ef73-400c-8a90-7af9dfad558c">cancer</named-content></article-title><x>. </x><source id="79a448a9-faca-4f97-be89-83cafc42e8a7">N Engl J Med</source><x> </x><year id="a36e8b95-9545-49ef-b27d-96f1560d1b6b">2018</year><x>;</x><volume id="48c2fe11-6c2b-46d3-88fd-aaca2fba420c">379</volume><x>:</x><elocation-id id="382091f5-d92b-455c-82dd-ef5f769e6ff7">e14</elocation-id><x>.</x></element-citation></ref></ref-list></back><workflow ftp-file-name="esmoopen-2019-000511" data-job-id="f935a27f-9748-40d1-b4cf-0e99528048c4"><priority>priority</priority><current-stage>Archive</current-stage><paw-stage><previous>Upload for Online First</previous><current>Article Bank</current></paw-stage><word-count/><word-count-without-ref>1825</word-count-without-ref><stage><name>addJob</name><customer-stage-name>Add Job</customer-stage-name><start-date-time/><end-date-time/><start-date>2019-04-05 12:15:02</start-date><duration>0</duration><end-word-count>18</end-word-count><end-word-count-without-ref>18</end-word-count-without-ref><end-date>2019-04-05 12:15:04</end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on/><reason/></assigned><time-log><log><start/><end/><duration/><status/></log></time-log></stage><stage><iteration>1</iteration><start-word-count>18</start-word-count><start-word-count-without-ref>18</start-word-count-without-ref><name>File download</name><customer-stage-name>Clean up</customer-stage-name><start-date>2019-04-05 12:15:04</start-date><duration>0</duration><end-word-count>18</end-word-count><end-word-count-without-ref>18</end-word-count-without-ref><end-date>2019-04-05 12:15:19</end-date><sla-start-date>2019-04-05 12:15:04</sla-start-date><sla-end-date>2019-04-08 12:15:04</sla-end-date><planned-start-date>2019-04-05 12:15:04</planned-start-date><planned-end-date>2019-04-08 12:15:04</planned-end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on>0</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage><stage><iteration>1</iteration><start-word-count>18</start-word-count><start-word-count-without-ref>18</start-word-count-without-ref><name>Convert Files</name><customer-stage-name>Clean up</customer-stage-name><start-date>2019-04-05 12:15:19</start-date><duration>0</duration><end-word-count>353</end-word-count><end-word-count-without-ref>353</end-word-count-without-ref><end-date>2019-04-05 12:15:30</end-date><sla-start-date>2019-04-05 12:15:04</sla-start-date><sla-end-date>2019-04-08 12:15:04</sla-end-date><planned-start-date>2019-04-05 12:15:19</planned-start-date><planned-end-date>2019-04-08 12:15:19</planned-end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on>0</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage><stage><iteration>1</iteration><start-word-count>353</start-word-count><start-word-count-without-ref>353</start-word-count-without-ref><name>Pre-editing</name><customer-stage-name>Clean up</customer-stage-name><start-date>2019-04-05 12:15:30</start-date><duration>18</duration><end-word-count>2217</end-word-count><end-word-count-without-ref>1796</end-word-count-without-ref><end-date>2019-04-08 07:23:28</end-date><sla-start-date>2019-04-05 12:15:04</sla-start-date><sla-end-date>2019-04-08 12:15:04</sla-end-date><planned-start-date>2019-04-05 12:15:30</planned-start-date><planned-end-date>2019-04-09 12:15:30</planned-end-date><status>completed</status><comments/><assigned><to>Gowtham Ram, gowthamram@exeterpm.com</to><by>System, Exeter</by><on>2019-04-08 05:20:30</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Gowtham Ram (PREEDITOR)" role="preeditor" time="1554707966850" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server"/></proof></object><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>05:20:30</start-time><end-date>2019-04-08</end-date><end-time>05:25:43</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Mr. Gowtham Ram null</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>05:27:00</start-time><end-date>2019-04-08</end-date><end-time>05:27:18</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Mr. Gowtham Ram null</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>05:27:52</start-time><end-date>2019-04-08</end-date><end-time>05:27:52</end-time><status type="system">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>06:53:29</start-time><end-date>2019-04-08</end-date><end-time>06:53:29</end-time><status type="system">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>06:57:05</start-time><end-date>2019-04-08</end-date><end-time>06:57:04</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>06:57:27</start-time><end-date>2019-04-08</end-date><end-time>06:59:03</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>07:02:27</start-time><end-date>2019-04-08</end-date><end-time>07:03:30</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>07:08:45</start-time><end-date>2019-04-08</end-date><end-time>07:08:45</end-time><status type="system">open</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>07:08:46</start-time><end-date>2019-04-08</end-date><end-time>07:10:05</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>07:10:57</start-time><end-date>2019-04-08</end-date><end-time>07:12:01</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>07:12:27</start-time><end-date>2019-04-08</end-date><end-time>07:19:49</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>07:20:01</start-time><end-date>2019-04-08</end-date><end-time>07:20:11</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-08</start-date><start-time>07:20:18</start-time><end-date>2019-04-08</end-date><end-time>07:22:59</end-time><status type="system">signed-off</status></log></job-logs><time-tracker><process type="styling">10</process><process type="author-details">5</process><process type="footnotes">5</process><process type="figure-upload">0</process><process type="table-setting">0</process><process type="supplements">0</process><process type="references">5</process><process type="check-rulesets">10</process><process type="others">5</process></time-tracker></stage><stage><iteration>1</iteration><start-word-count>2217</start-word-count><start-word-count-without-ref>1796</start-word-count-without-ref><name>Waiting for CE</name><customer-stage-name>Copy edit</customer-stage-name><start-date>2019-04-08 07:23:28</start-date><duration>0</duration><end-word-count>2217</end-word-count><end-word-count-without-ref>1796</end-word-count-without-ref><end-date>2019-04-08 09:15:03</end-date><sla-start-date>2019-04-08 07:23:28</sla-start-date><sla-end-date>2019-04-09 07:23:28</sla-end-date><planned-start-date>2019-04-08 07:23:28</planned-start-date><planned-end-date>2019-04-09 07:23:28</planned-end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on>0</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage><stage><iteration>1</iteration><start-word-count>2217</start-word-count><start-word-count-without-ref>1796</start-word-count-without-ref><name>Copyediting</name><customer-stage-name>Copy edit</customer-stage-name><start-date>2019-04-08 09:15:03</start-date><duration>119</duration><end-word-count>2219</end-word-count><end-word-count-without-ref>1798</end-word-count-without-ref><end-date>2019-04-09 13:19:30</end-date><sla-start-date>2019-04-08 09:15:03</sla-start-date><sla-end-date>2019-04-09 09:15:03</sla-end-date><planned-start-date>2019-04-08 09:15:03</planned-start-date><planned-end-date>2019-04-09 09:15:03</planned-end-date><status>completed</status><comments/><assigned><to>Maria Eloisa Bite, eloisebite@gmail.com</to><by>Maria Eloisa Bite, eloisebite@gmail.com</by><on>2019-04-09 01:51:12</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Maria (COPYEDITOR)" role="copyeditor" time="1554815072178" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server"/></proof></object><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria Eloisa Bite</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>01:51:27</start-time><end-date>2019-04-09</end-date><end-time>01:51:43</end-time><status type="system">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria Eloisa Bite</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>10:51:23</start-time><end-date>2019-04-09</end-date><end-time>11:54:38</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>11:55:14</start-time><end-date>2019-04-09</end-date><end-time>12:19:17</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:19:19</start-time><end-date>2019-04-09</end-date><end-time>12:19:23</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:21:24</start-time><end-date>2019-04-09</end-date><end-time>12:22:30</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:22:39</start-time><end-date>2019-04-09</end-date><end-time>12:23:26</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:23:30</start-time><end-date>2019-04-09</end-date><end-time>12:26:44</end-time><status type="user">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria Eloisa Bite</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:34:47</start-time><end-date>2019-04-09</end-date><end-time>12:40:43</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:40:49</start-time><end-date>2019-04-09</end-date><end-time>12:41:06</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:41:13</start-time><end-date>2019-04-09</end-date><end-time>12:41:16</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:41:23</start-time><end-date>2019-04-09</end-date><end-time>12:43:42</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:44:11</start-time><end-date>2019-04-09</end-date><end-time>12:44:35</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>12:44:43</start-time><end-date>2019-04-09</end-date><end-time>12:59:53</end-time><status type="user">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria Eloisa Bite</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>13:00:07</start-time><end-date>2019-04-09</end-date><end-time>13:06:18</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>13:16:50</start-time><end-date>2019-04-09</end-date><end-time>13:16:51</end-time><status type="user">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Maria Eloisa Bite</username><useremail>eloisebite@gmail.com</useremail><start-date>2019-04-09</start-date><start-time>13:16:58</start-time><end-date>2019-04-09</end-date><end-time>13:16:58</end-time><status type="user">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>2219</start-word-count><start-word-count-without-ref>1798</start-word-count-without-ref><name>Typesetter Check</name><customer-stage-name>Typeset</customer-stage-name><start-date>2019-04-09 13:19:30</start-date><duration>2</duration><end-word-count>2219</end-word-count><end-word-count-without-ref>1798</end-word-count-without-ref><end-date>2019-04-10 05:47:35</end-date><sla-start-date>2019-04-09 13:19:30</sla-start-date><sla-end-date>2019-04-10 13:19:30</sla-end-date><planned-start-date>2019-04-09 13:19:30</planned-start-date><planned-end-date>2019-04-10 13:19:30</planned-end-date><status>completed</status><comments/><assigned><to>Gowtham Ram, gowthamram@exeterpm.com</to><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Gowtham Ram (TYPESETTER)" role="typesetter" time="1554875079685" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server" reason="none" job-id="4667dd9f-fccb-4a31-ac97-d44674852451"/><pdf user="Gowtham Ram (TYPESETTER)" role="typesetter" time="1554875223630" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server" reason="base-alignment" job-id="9615f410-0342-4c65-a13f-b9a1ce7cc973"/></proof></object><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-10</start-date><start-time>05:42:48</start-time><end-date>2019-04-10</end-date><end-time>05:44:58</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-10</start-date><start-time>05:45:18</start-time><end-date>2019-04-10</end-date><end-time>05:45:37</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-10</start-date><start-time>05:45:41</start-time><end-date>2019-04-10</end-date><end-time>05:46:21</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Gowtham Ram</username><useremail>gowthamram@exeterpm.com</useremail><start-date>2019-04-10</start-date><start-time>05:46:23</start-time><end-date>2019-04-10</end-date><end-time>05:47:20</end-time><status type="system">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>2219</start-word-count><start-word-count-without-ref>1798</start-word-count-without-ref><name>Author Review</name><customer-stage-name>Author proof</customer-stage-name><start-date>2019-04-10 05:47:35</start-date><duration>24</duration><end-word-count>2222</end-word-count><end-word-count-without-ref>1801</end-word-count-without-ref><end-date>2019-04-15 07:30:01</end-date><sla-start-date>2019-04-10 05:47:35</sla-start-date><sla-end-date>2019-04-12 05:47:35</sla-end-date><planned-start-date>2019-04-10 05:47:35</planned-start-date><planned-end-date>2019-04-12 05:47:35</planned-end-date><status>completed</status><comments/><assigned><to>John Haanen, j.haanen@nki.nl</to><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object><article-key><key live="true" email="j.haanen@nki.nl">https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e57a80c10981c7aec79f6a1491c0b041784010d5bed7f7f18853219439376d5e3a4f0617f39c1802b33541ca2ed0d1be0966c47fc5ad</key></article-key><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>John Haanen</username><useremail>j.haanen@nki.nl</useremail><start-date>2019-04-10</start-date><start-time>06:25:51</start-time><end-date>2019-04-10</end-date><end-time>06:25:51</end-time><status type="system">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>John Haanen</username><useremail>j.haanen@nki.nl</useremail><start-date>2019-04-15</start-date><start-time>07:02:41</start-time><end-date>2019-04-15</end-date><end-time>07:13:17</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>John Haanen</username><useremail>j.haanen@nki.nl</useremail><start-date>2019-04-15</start-date><start-time>07:14:38</start-time><end-date>2019-04-15</end-date><end-time>07:28:39</end-time><status type="system">signed-off</status></log></job-logs></stage><chaser-info id="7e0eb6d5-5e31-4633-9a59-4ac8dcff5e54"><chaser stage="authorreview" hour="h48">Fri Apr 12 2019 06:00:06 GMT+0000</chaser><chaser stage="authorreview" hour="h72">Mon Apr 15 2019 06:00:06 GMT+0000</chaser></chaser-info><stage><iteration>1</iteration><start-word-count>2222</start-word-count><start-word-count-without-ref>1801</start-word-count-without-ref><name>Publisher Review</name><customer-stage-name>Production QC</customer-stage-name><start-date>2019-04-15 07:30:01</start-date><duration>20</duration><end-word-count>2247</end-word-count><end-word-count-without-ref>1826</end-word-count-without-ref><end-date>2019-05-08 16:06:47</end-date><sla-start-date>2019-04-15 07:30:01</sla-start-date><sla-end-date>2019-04-16 07:30:01</sla-end-date><planned-start-date>2019-04-15 07:30:01</planned-start-date><planned-end-date>2019-04-16 07:30:01</planned-end-date><status>completed</status><comments/><assigned><to>Tasnia Nizam, tnizam@bmj.com</to><by>System, Exeter</by><on>2019-05-08 15:41:50</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Tasnia (BMJ)" role="publisher" time="1557331454710" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server"/></proof></object><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Tasnia Nizam</username><useremail>tnizam@bmj.com</useremail><start-date>2019-05-08</start-date><start-time>15:41:50</start-time><end-date>2019-05-08</end-date><end-time>15:51:29</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Tasnia</username><useremail>tnizam@bmj.com</useremail><start-date>2019-05-08</start-date><start-time>15:52:03</start-time><end-date>2019-05-08</end-date><end-time>16:01:31</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Tasnia</username><useremail>tnizam@bmj.com</useremail><start-date>2019-05-08</start-date><start-time>16:01:42</start-time><end-date>2019-05-08</end-date><end-time>16:04:04</end-time><status type="system">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>2247</start-word-count><start-word-count-without-ref>1826</start-word-count-without-ref><name>Author Revision</name><customer-stage-name>Revised Proof with author</customer-stage-name><start-date>2019-05-08 16:06:47</start-date><duration>1</duration><end-word-count>2247</end-word-count><end-word-count-without-ref>1826</end-word-count-without-ref><end-date>2019-05-08 20:04:34</end-date><sla-start-date>2019-05-08 16:06:47</sla-start-date><sla-end-date>2019-05-10 16:06:47</sla-end-date><planned-start-date>2019-05-08 16:06:47</planned-start-date><planned-end-date>2019-05-10 16:06:47</planned-end-date><status>completed</status><comments/><assigned><to>John Haanen, j.haanen@nki.nl</to><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object><article-key><key live="true" email="j.haanen@nki.nl">https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e56c9e8815c8d9a4969b22018cdbaa086f0b14d1b383f1e28a1c289b3d37485e11484310b1d41a45b03111e57cf2d0f62f27ed70c1adb7d1</key></article-key><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>John Haanen</username><useremail>j.haanen@nki.nl</useremail><start-date>2019-05-08</start-date><start-time>20:00:55</start-time><end-date>2019-05-08</end-date><end-time>20:02:45</end-time><status type="user">signed-off</status></log></job-logs></stage><stage><iteration>2</iteration><start-word-count>2247</start-word-count><start-word-count-without-ref>1826</start-word-count-without-ref><name>Publisher Review</name><customer-stage-name>Production QC</customer-stage-name><start-date>2019-05-08 20:04:34</start-date><duration>6</duration><end-word-count>2247</end-word-count><end-word-count-without-ref>1826</end-word-count-without-ref><end-date>2019-05-17 09:43:55</end-date><sla-start-date>2019-05-08 20:04:34</sla-start-date><sla-end-date>2019-05-09 20:04:34</sla-end-date><planned-start-date>2019-05-08 20:04:34</planned-start-date><planned-end-date>2019-05-09 20:04:34</planned-end-date><status>completed</status><comments/><assigned><to>Tasnia Nizam, tnizam@bmj.com</to><by>System, Exeter</by><on>2019-05-17 09:36:23</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Tasnia (BMJ)" role="publisher" time="1558086074023" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server"/><pdf user="Tasnia (BMJ)" role="publisher" time="1558086230179" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server"/></proof></object><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Tasnia Nizam</username><useremail>tnizam@bmj.com</useremail><start-date>2019-05-17</start-date><start-time>09:36:23</start-time><end-date>2019-05-17</end-date><end-time>09:42:26</end-time><status type="user">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>2247</start-word-count><start-word-count-without-ref>1826</start-word-count-without-ref><name>Validation Check</name><customer-stage-name>Upload for Online First</customer-stage-name><start-date>2019-05-17 09:43:55</start-date><duration>3</duration><end-word-count>2246</end-word-count><end-word-count-without-ref>1825</end-word-count-without-ref><end-date>2019-05-20 05:18:13</end-date><sla-start-date>2019-05-17 09:43:55</sla-start-date><sla-end-date>2019-05-20 09:43:55</sla-end-date><planned-start-date>2019-05-17 09:43:55</planned-start-date><planned-end-date>2019-05-20 09:43:55</planned-end-date><status>completed</status><comments/><assigned><to>Asha Narayanan, ashan@exeterpm.com</to><by>System, Exeter</by><on>2019-05-20 05:14:19</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Asha Narayanan</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-05-20</start-date><start-time>05:14:19</start-time><end-date>2019-05-20</end-date><end-time>05:17:32</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-05-20</start-date><start-time>05:18:04</start-time><end-date>2019-05-20</end-date><end-time>05:18:04</end-time><status type="system">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>2246</start-word-count><start-word-count-without-ref>1825</start-word-count-without-ref><name>Final Deliverables</name><customer-stage-name>Upload for Online First</customer-stage-name><start-date>2019-05-20 05:18:13</start-date><duration>4</duration><end-word-count>2246</end-word-count><end-word-count-without-ref>1825</end-word-count-without-ref><end-date>2019-05-21 10:32:58</end-date><sla-start-date>2019-05-20 05:18:13</sla-start-date><sla-end-date>2019-05-21 00:00:00</sla-end-date><planned-start-date>2019-05-20 05:18:13</planned-start-date><planned-end-date>2019-05-21 00:00:00</planned-end-date><status>completed</status><comments/><assigned><to>Usha Venkatesh, usha.venkatesh@exeterpremedia.com</to><by>Usha Venkatesh, usha.venkatesh@exeterpremedia.com</by><on>2019-05-21 06:59:04</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Usha (TYPESETTER)" role="typesetter" time="1558434607161" path="http://kriya2.kriyadocs.com/resources/bmj/esmoopen/esmoopen-2019-000511/proofing/esmoopen-2019-000511.pdf?method=server" reason="others" description="rfo" job-id="7e8fd275-825d-406a-8a60-1ac305e4dfcd"/></proof></object><job-logs><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha Venkatesh</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>06:59:06</start-time><end-date>2019-05-21</end-date><end-time>07:00:24</end-time><status type="user">logged-off</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha Venkatesh</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>10:17:42</start-time><end-date>2019-05-21</end-date><end-time>10:19:10</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>10:19:22</start-time><end-date>2019-05-21</end-date><end-time>10:19:43</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>10:21:20</start-time><end-date>2019-05-21</end-date><end-time>10:22:20</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>10:29:18</start-time><end-date>2019-05-21</end-date><end-time>10:29:18</end-time><status type="system">open</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>10:29:18</start-time><end-date>2019-05-21</end-date><end-time>10:30:26</end-time><status type="system">in-active</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>10:32:04</start-time><end-date>2019-05-21</end-date><end-time>10:32:04</end-time><status type="system">open</status></log><log data-doi="esmoopen-2019-000511" data-project="esmoopen" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-05-21</start-date><start-time>10:32:05</start-time><end-date>2019-05-21</end-date><end-time>10:32:05</end-time><status type="system">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>2246</start-word-count><start-word-count-without-ref>1825</start-word-count-without-ref><name>Upload for Online First</name><customer-stage-name>Upload for Online First</customer-stage-name><start-date>2019-05-21 10:32:58</start-date><duration>0</duration><end-word-count>2246</end-word-count><end-word-count-without-ref>1825</end-word-count-without-ref><end-date>2019-05-21 12:00:16</end-date><sla-start-date>2019-05-21 10:32:58</sla-start-date><sla-end-date>2019-05-22 10:32:58</sla-end-date><planned-start-date>2019-05-21 10:32:58</planned-start-date><planned-end-date>2019-05-22 10:32:58</planned-end-date><status>completed</status><held-stage/><hold-state/><comments/><assigned><to/><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object><job-logs/></stage><stage><iteration>1</iteration><start-word-count>2246</start-word-count><start-word-count-without-ref>1825</start-word-count-without-ref><name>Archive</name><customer-stage-name>Article Bank</customer-stage-name><start-date>2019-05-21 12:00:16</start-date><end-date>2019-05-21 00:00:00</end-date><sla-start-date>2019-05-21 12:00:16</sla-start-date><sla-end-date>2019-05-21 00:00:00</sla-end-date><planned-start-date>2019-05-21 12:00:16</planned-start-date><planned-end-date>2019-05-21 00:00:00</planned-end-date><status>completed</status><comments/><assigned><to/><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage></workflow><production-notes><note type="workflow"><id>9b31cd32-6d99-4475-b973-1ddf61655311</id><fullname>Workflow</fullname><created>2019-04-05 12:15:02</created><content>Job created on 2019-04-05 12:15:02</content></note><note id="ecfb0b21-ca06-49dc-8667-f463d91f1f10" type="workflow"><id>ecfb0b21-ca06-49dc-8667-f463d91f1f10</id><fullname>Workflow</fullname><created>2019-04-05 12:15:04</created><content>Article signed-off from addJob to File download</content></note><note id="584bf59f-bf8e-4344-b076-d7f751d99038" type="workflow"><id>584bf59f-bf8e-4344-b076-d7f751d99038</id><fullname>Workflow</fullname><created>2019-04-05 12:15:19</created><content>Article signed-off from File download to Convert Files</content></note><note id="73b871f7-fd14-4a54-a50e-3f2f476ff9cb" type="workflow"><id>73b871f7-fd14-4a54-a50e-3f2f476ff9cb</id><fullname>Workflow</fullname><created>2019-04-05 12:15:21</created><content>Payment and license info has been updated {"license":"CC-BY-NC","copyrightStatement":"CC-BY-NC","paymentMethod":"APC Waived","paymentStatus":"no","currentStage":"Convert Files","holdType":"NoHold","holdStatus":"true","matchStage":"Convert Files"}</content></note><note id="83a7cfdd-5428-47c6-ad30-bcddcc071bbb" type="email"><id>83a7cfdd-5428-47c6-ad30-bcddcc071bbb</id><fullname>Workflow</fullname><created>2019-04-05 12:15:30</created><content><email-content><mail-id>65e5f919-09ad-ced8-f79a-c9fd1814e720@exeterpremedia.com</mail-id><mail-subject>Job Notification: Article 10.1136/esmoopen-2019-000511 loaded </mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><mail-body><p>Dear typesetter</p><p>The article '<span class="article-id">10.1136/esmoopen-2019-000511</span>' is now ready for editing.</p><p>Thank you,</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="ee3e0607-e609-4c18-ba35-dcc822fa6e81" type="workflow"><id>ee3e0607-e609-4c18-ba35-dcc822fa6e81</id><fullname>Workflow</fullname><created>2019-04-05 12:15:30</created><content>Article signed-off from Convert Files to Pre-editing</content></note><note id="cd3d7cfe-ed0a-46f3-a4e2-a8f3b28b0f9b" type="workflow"><id>cd3d7cfe-ed0a-46f3-a4e2-a8f3b28b0f9b</id><fullname>Gowtham Ram</fullname><created>2019-04-08 07:23:28</created><content>Article signed-off from Pre-editing to Waiting for CE</content></note><note id="8bb3bc47-04d4-4732-8e70-ec7ff52d29ef" type="paw"><id>8bb3bc47-04d4-4732-8e70-ec7ff52d29ef</id><fullname>Gowtham Ram</fullname><created>2019-04-08 07:23:30</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Clean up to Copy edit</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Clean up"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Clean up"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Copy edit"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Copy edit"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-08T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-10T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="7cf7bd32-d696-4e5b-85df-ac4278ede797" type="email"><id>7cf7bd32-d696-4e5b-85df-ac4278ede797</id><fullname>Gowtham Ram</fullname><created>2019-04-08 07:23:30</created><content><email-content><mail-id>0b8d2feb-9aef-830b-09dc-ce74e2f086b1@exeterpremedia.com</mail-id><mail-subject>Ready for Copyediting - 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>production.esmoopen@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p>This article is ready for copyediting. Please assign the copy editor in paw.</p><p>Thank you</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="a17403cf-a8f3-40ac-a858-cf3aa62c2775" type="workflow"><id>a17403cf-a8f3-40ac-a858-cf3aa62c2775</id><fullname>Workflow</fullname><created>2019-04-08 09:15:03</created><content>Article signed-off from Waiting for CE to Copyediting</content></note><note id="1f501eb8-ebf8-4a04-a804-675f5e1539cd" type="paw"><id>1f501eb8-ebf8-4a04-a804-675f5e1539cd</id><fullname>Workflow</fullname><created>2019-04-08 09:15:04</created><content><div class="jsonresp"><div class="note-head">PAW skipped: Article skipped to move from Copy edit to Copy edit</div></div></content></note><note id="e462ca06-f6b6-4612-af6f-e797ddc3fc81"><id>98facb9f-19f3-48dd-b848-c7353bad98d7</id><fullname>Automation</fullname><created>2019-04-08 09:15:04</created><content>Article assigned to: <b>EXETER</b> for copyediting</content></note><note id="efbb6a02-7981-43a2-954c-666483836b9b" type="email"><id>efbb6a02-7981-43a2-954c-666483836b9b</id><fullname>Workflow</fullname><created>2019-04-08 09:15:05</created><content><email-content><mail-id>e9cba88e-5ad6-2c7a-da0a-cdd246781cdd@exeterpremedia.com</mail-id><mail-subject>Copyediting for 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><mail-body><p>Dear Exeter</p><p>This article is ready for copyediting.</p><p>Kindly note, the online editing system is currently not supported on Internet Explorer. Please use <a href="https://www.google.com/chrome/">Google Chrome</a> to access the article.</p><p>Thank you</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="d47cdf11-9214-401b-ab15-43cee3668f72" type="workflow"><id>d47cdf11-9214-401b-ab15-43cee3668f72</id><fullname>Maria Eloisa Bite, eloisebite@gmail.com</fullname><created>2019-04-09 01:51:12</created><content>Assigned to : Maria Eloisa Bite, eloisebite@gmail.com</content></note><note id="7b385f2a-7f30-4a90-b4e5-fa2271cd96ae" type="workflow"><id>7b385f2a-7f30-4a90-b4e5-fa2271cd96ae</id><fullname>Maria Eloisa Bite</fullname><created>2019-04-09 01:51:12</created><content>Success:Purchase Order created</content></note><note id="7919f525-0914-41ee-8019-d4e8490dbfa3" type="workflow"><id>7919f525-0914-41ee-8019-d4e8490dbfa3</id><fullname>Maria Eloisa Bite</fullname><created>2019-04-09 13:19:30</created><content>Article signed-off from Copyediting to Typesetter Check</content></note><note id="53a7efd2-4adf-48c0-b109-c5182b515101" type="workflow"><id>53a7efd2-4adf-48c0-b109-c5182b515101</id><fullname>Maria Eloisa Bite</fullname><created>2019-04-09 13:19:30</created><content>Article assigned to Gowtham Ram, gowthamram@exeterpm.com</content></note><note id="c6da8f2d-a595-41ac-8b3e-5611b5fce155" type="paw"><id>c6da8f2d-a595-41ac-8b3e-5611b5fce155</id><fullname>Maria Eloisa Bite</fullname><created>2019-04-09 13:19:32</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Copy edit to Typeset</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Copy edit"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Copy edit"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Typeset"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Typeset"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-09T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-12T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="65b85dc7-bec8-40c9-8a58-13053801071c" type="email"><id>65b85dc7-bec8-40c9-8a58-13053801071c</id><fullname>Maria Eloisa Bite</fullname><created>2019-04-09 13:19:33</created><content><email-content><mail-id>1e6d46ff-835d-82bf-4996-08d7551ddccd@exeterpremedia.com</mail-id><mail-subject>Edited files to be typeset 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><mail-body><p><span class="article-id">10.1136/esmoopen-2019-000511</span></p><p>Dear Typesetter</p><p>The above article has been sent to you for typesetting.</p><p>Best wishes</p><p>Production Office</p></mail-body></email-content></content></note><note id="bd85b7fb-12bc-4e67-a785-f29bf3f51eb3" type="workflow"><id>bd85b7fb-12bc-4e67-a785-f29bf3f51eb3</id><fullname>Gowtham Ram</fullname><created>2019-04-10 05:47:35</created><content>Article signed-off from Typesetter Check to Author Review</content></note><note id="fa497e6a-442c-4c52-a3fd-e107b90bfe6e" type="paw"><id>fa497e6a-442c-4c52-a3fd-e107b90bfe6e</id><fullname>Gowtham Ram</fullname><created>2019-04-10 05:47:38</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Typeset to Author proof</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Typeset"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Typeset"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Author proof"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Author proof"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-10T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-12T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="28e6d858-1cd1-4976-8f78-fdc6ddd6f89b" type="email"><id>28e6d858-1cd1-4976-8f78-fdc6ddd6f89b</id><fullname>Gowtham Ram</fullname><created>2019-04-10 05:47:39</created><content><email-content><mail-id>08b20d42-ea7a-9c63-dd38-224345c31dba@exeterpremedia.com</mail-id><mail-subject>Proof of your article for ESMO Open - 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>j.haanen@nki.nl</to><cc>bmj@exeterpremedia.com,production.esmoopen@bmj.com</cc><mail-body><p>Dear <span class="name">John Haanen</span>,</p><p>I’m pleased to provide the proof of your article, which is available on our author proofing system here:</p><p><a style="background: #FF5722;padding: 3px 6px;border-radius: 3px;color: #fff !important;" href="https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e57a80c10981c7aec79f6a1491c0b041784010d5bed7f7f18853219439376d5e3a4f0617f39c1802b33541ca2ed0d1be0966c47fc5ad">LINK</a></p><p>Please submit any corrections then ensure you click ‘Approve’ to complete the author proofing process. Signing off the paper will send the article back to the Production team so they can make any changes.</p><p>Please note, the online author proofing system cannot be used in the browser Internet Explorer. Please review your proofs in <a href="https://www.google.com/chrome/">Google Chrome</a>.</p><p>A PDF version of the proof is available to download and review, but all corrections must be submitted using the online system. Please contact us at production.esmoopen@bmj.com if you need any help using this.</p><p>This is the only opportunity you will have to correct your article before publication, so please review it carefully. Please ensure you respond to queries listed in the article. Minor errors cannot be corrected after publication and any serious scientific errors will result in a formal correction.</p><p>Reprints: If you wish to purchase reprints of your article, please fill in the <a href="http://authors.bmj.com/wp-content/uploads/2018/10/Standard_reprint_form_2018.pdf">reprint form</a>.</p><p>Thanks in advance.</p><p><span class="journal-title">ESMO Open</span> Production Team</p></mail-body></email-content></content></note><note id="c6a48bee-76d8-4b6a-b997-9d8844fa507e"><id>9aaca596-ca21-4381-9a39-e1a504e77528</id><fullname>Automation</fullname><created>2019-04-12 06:00:10</created><content><email-content><mail-id>fb319ca8-0775-4771-7044-50a16ddacbc4@exeterpremedia.com</mail-id><mail-subject>Proof of your article for ESMO Open - 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>j.haanen@nki.nl</to><bcc>bmj@exeterpremedia.com,production.esmoopen@bmj.com</bcc><cc/><mail-body><p>Dear <span class="name">John  Haanen</span>,</p><p>The proof for your article has been available to review at <a href="https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e57a80c10981c7aec79f6a1491c0b041784010d5bed7f7f18853219439376d5e3a4f0617f39c1802b33541ca2ed0d1be0966c47fc5ad" target="_blank">https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e57a80c10981c7aec79f6a1491c0b041784010d5bed7f7f18853219439376d5e3a4f0617f39c1802b33541ca2ed0d1be0966c47fc5ad</a> for 2 days. We see you have started editing your proofs via this link.</p><p>Please submit any corrections then ensure you click ‘Approve’ to complete the author proofing process. Signing off the paper will send the article back to the Production team so they can make any changes.</p><p>Please note, the online author proofing system cannot be used in the browser Internet Explorer. Please review your proofs in Google Chrome.</p><p>A PDF version of the proof is available to download and review, but all corrections must be submitted using the online system. Please contact us at production.esmoopen@bmj.com if you need any help using this.</p><p>If you need to replace any figures or supplementary files, DO NOT attempt to upload them to the system but please send them to the Production Editor at production.esmoopen@bmj.com. We will provide a further PDF proof for you to check if they have been replaced.</p><p>This is the only opportunity you will have to correct your article before publication, so please review it carefully. Please ensure you respond to queries listed in the article. Minor errors cannot be corrected after publication and any serious scientific errors will result in a formal correction.</p><p>Thanks in advance.</p><p><span class="journal-title">ESMO Open</span> Production team</p></mail-body></email-content></content></note><note id="15561636-4b50-47c0-813a-1dccafd0bb8d"><id>21736a98-4998-440c-afe5-f2949ba6055d</id><fullname>Automation</fullname><created>2019-04-12 06:00:10</created><content>Author chaser sent after 48 hours</content></note><note id="decd26c3-d585-4aa6-a0e5-8fae8de1d6ff"><id>c2d6aba3-51d9-4f2d-8869-329e3321888e</id><fullname>Automation</fullname><created>2019-04-15 06:00:09</created><content><email-content><mail-id>3f705070-cbe4-d497-f048-15ea8c272931@exeterpremedia.com</mail-id><mail-subject>Proof of your article for ESMO Open - 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>j.haanen@nki.nl</to><bcc>bmj@exeterpremedia.com,production.esmoopen@bmj.com</bcc><cc/><mail-body><p>Dear <span class="name">John  Haanen</span>,</p><p>The proof for your article has been available to review at <a href="https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e57a80c10981c7aec79f6a1491c0b041784010d5bed7f7f18853219439376d5e3a4f0617f39c1802b33541ca2ed0d1be0966c47fc5ad" target="_blank">https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e57a80c10981c7aec79f6a1491c0b041784010d5bed7f7f18853219439376d5e3a4f0617f39c1802b33541ca2ed0d1be0966c47fc5ad</a> for 3 days. We see you have started editing your proofs via this link</p><p>Please submit any corrections then ensure you click ‘Approve’ to complete the author proofing process. Signing off the paper will send the article back to the Production team so they can make any changes.</p><p>Please note, the online author proofing system cannot be used in the browser Internet Explorer. Please review your proofs in Google Chrome.</p><p>A PDF version of the proof is available to download and review, but all corrections must be submitted using the online system.  Please contact us at production.esmoopen@bmj.com if you need any help using this.</p><p>If you need to replace any figures or supplementary files, DO NOT attempt to upload them to the system but please send them to the Production Editor at production.esmoopen@bmj.com. We will provide a further PDF proof for you to check if they have been replaced.</p><p>This is the only opportunity you will have to correct your article before publication, so please review it carefully. Please ensure you respond to queries listed in the article. Minor errors cannot be corrected after publication and any serious scientific errors will result in a formal correction.</p><p>Thanks in advance.</p><p><span class="journal-title">ESMO Open</span> Production team</p></mail-body></email-content></content></note><note id="e190c8ab-4817-4662-8c58-dd484b11f39c"><id>9a17f40a-4bde-4576-855a-f24dd8b261b8</id><fullname>Automation</fullname><created>2019-04-15 06:00:09</created><content>Author chaser sent after 72 hours</content></note><note id="f0fea49e-e7f2-4613-8ee7-2eac3cf840a5" type="workflow"><id>f0fea49e-e7f2-4613-8ee7-2eac3cf840a5</id><fullname>John Haanen</fullname><created>2019-04-15 07:30:01</created><content>Article signed-off from Author Review to Publisher Review</content></note><note id="6b478dda-99bd-4911-9700-18feca92c5be" type="email"><id>6b478dda-99bd-4911-9700-18feca92c5be</id><fullname>John Haanen</fullname><created>2019-04-15 07:30:04</created><content><email-content><mail-id>7c0ab6d0-cc5b-73be-3c46-e6df86ae54ba@exeterpremedia.com</mail-id><mail-subject>Author corrections completed for esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>production.esmoopen@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p>The corresponding author has finished reviewing the proof, the Production Editor should now sign in to Kriya 2 and review the corrections.</p><p>Thank you,</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="18a5c040-4929-4e65-90f0-2478bd06330d" type="paw"><id>18a5c040-4929-4e65-90f0-2478bd06330d</id><fullname>John Haanen</fullname><created>2019-04-15 07:30:04</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Author proof to Production QC</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Author proof"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Author proof"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Production QC"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Production QC"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-15T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-17T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="f38e83ef-1d54-49aa-9681-5864b8b83c14" type="workflow"><id>f38e83ef-1d54-49aa-9681-5864b8b83c14</id><fullname>Tasnia Nizam</fullname><created>2019-05-08 16:06:47</created><content>Article signed-off from Publisher Review to Author Revision</content></note><note id="97ec2372-735c-4b3f-ac4e-c965b6444ccd" type="paw"><id>97ec2372-735c-4b3f-ac4e-c965b6444ccd</id><fullname>Tasnia Nizam</fullname><created>2019-05-08 16:06:49</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Production QC to Revised Proof with author</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Production QC"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Production QC"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Revised Proof with author"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Revised Proof with author"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-05-08T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-05-10T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="d89e84ec-6bd3-4f6d-87fc-9a9d3cc75cce" type="email"><id>d89e84ec-6bd3-4f6d-87fc-9a9d3cc75cce</id><fullname>Tasnia Nizam</fullname><created>2019-05-08 16:06:50</created><content><email-content><mail-id>5fb55f48-b52c-934a-48f0-a7b0f390c87d@exeterpremedia.com</mail-id><mail-subject>Revised proof - 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>j.haanen@nki.nl</to><cc>bmj@exeterpremedia.com,production.esmoopen@bmj.com</cc><mail-body><p>Dear <span class="name">John Haanen</span>,</p><p>The revised proof of your article is now available to check at:</p><p><a style="background: #FF5722;padding: 3px 6px;border-radius: 3px;color: #fff !important;" href="https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b97e2744957c320e9bd2d0c9f6f242a652c0252f8ce60ab80ce5d59d021aaf1d05f81e1ff7eadcf3a6688d9002acbe3eef4e56c9e8815c8d9a4969b22018cdbaa086f0b14d1b383f1e28a1c289b3d37485e11484310b1d41a45b03111e57cf2d0f62f27ed70c1adb7d1">LINK</a>.</p><p>Please submit any corrections then ensure you click ‘Approve’ to complete the author proofing process. If you have additional changes, please mark these up on the system before signing off and a member of the Production team will add those in before we publish your paper.</p><p>Please be aware that:</p><ul><li><p>The online author proofing system is currently not supported using Internet Explorer. Please review your proofs using <a href="https://www.google.com/chrome/">Google Chrome</a>.</p></li></ul><p>A PDF version of the proof is available to download and review, but all corrections must be submitted using the online system. Please contact us at production.esmoopen@bmj.com if you need any help using this.</p><p>As before, please make your changes using the online system and then review your updated PDF proof once this is complete.</p><p>Best wishes,</p><p><span class="journal-title">ESMO Open</span> Production Team</p><p> production.esmoopen@bmj.com </p></mail-body></email-content></content></note><note id="9fb531e7-122e-4cc3-86a5-e3d0ec35e540" type="workflow"><id>9fb531e7-122e-4cc3-86a5-e3d0ec35e540</id><fullname>John Haanen</fullname><created>2019-05-08 20:04:34</created><content>Article signed-off from Author Revision to Publisher Review</content></note><note id="2e1cf991-6ec4-48eb-baa4-dab9071f0296" type="paw"><id>2e1cf991-6ec4-48eb-baa4-dab9071f0296</id><fullname>John Haanen</fullname><created>2019-05-08 20:04:36</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Revised Proof with author to Production QC</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Revised Proof with author"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Revised Proof with author"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Production QC"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Production QC"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-05-08T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-05-10T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="a86750ff-0c46-4a54-a218-95d27a154a45" type="email"><id>a86750ff-0c46-4a54-a218-95d27a154a45</id><fullname>John Haanen</fullname><created>2019-05-08 20:04:37</created><content><email-content><mail-id>65961cb6-51a4-ee78-620e-f71ba05d7df8@exeterpremedia.com</mail-id><mail-subject>Author corrections completed for esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>production.esmoopen@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher<br/></p><p>Author corrections have been completed and approved for <span class="article-id">esmoopen-2019-000511</span>. </p><p>Thank you,</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="38248647-4600-4ffa-bdbf-55b5660678c9" type="workflow"><id>38248647-4600-4ffa-bdbf-55b5660678c9</id><fullname>Tasnia Nizam</fullname><created>2019-05-17 09:43:55</created><content>Article signed-off from Publisher Review to Validation Check</content></note><note id="a5f836c0-2161-4761-9baf-bbeef1472a58" type="paw"><id>a5f836c0-2161-4761-9baf-bbeef1472a58</id><fullname>Tasnia Nizam</fullname><created>2019-05-17 09:43:59</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Production QC to Upload for Online First</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Production QC"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Production QC"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Upload for Online First"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Upload for Online First"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-05-17T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-05-20T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="fb72263e-51cc-4aef-a137-566421bd6c60" type="email"><id>fb72263e-51cc-4aef-a137-566421bd6c60</id><fullname>Tasnia Nizam</fullname><created>2019-05-17 09:43:59</created><content><email-content><mail-id>16bd1f1c-6f8a-201f-7a90-1d232af2be82@exeterpremedia.com</mail-id><mail-subject>10.1136/esmoopen-2019-000511: Article has been moved to validation check</mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><cc>sasikala@exeterpremedia.com</cc><mail-body><p>Dear Typesetter</p><p>Article requires further changes. Please update and send back to final deliverables.</p><p>Best wishes</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="4fcb4eb3-a35c-43b4-ada7-2c557eb79c00"><id>88a333a4-c9a6-477d-b830-410d923ec95c</id><fullname>Automation</fullname><created>2019-05-17 10:15:03</created><content>Approved email received for this article</content></note><note id="26076895-5a26-4a1b-8e21-d720413d53ce" type="workflow"><id>26076895-5a26-4a1b-8e21-d720413d53ce</id><fullname>Asha Narayanan</fullname><created>2019-05-20 05:18:13</created><content>Article signed-off from Validation Check to Final Deliverables</content></note><note id="8f125b44-fd5e-44ab-922d-bb6c6035ab86" type="paw"><id>8f125b44-fd5e-44ab-922d-bb6c6035ab86</id><fullname>Asha Narayanan</fullname><created>2019-05-20 05:18:15</created><content><div class="jsonresp"><div class="note-head">PAW skipped: Article skipped to move from Upload for Online First to Upload for Online First</div></div></content></note><note id="d68c04c7-0b8a-451c-9add-e7d51c980647" type="email"><id>d68c04c7-0b8a-451c-9add-e7d51c980647</id><fullname>Asha Narayanan</fullname><created>2019-05-20 05:18:16</created><content><email-content><mail-id>5b56a797-b9b6-1d1d-39c5-61143e215f31@exeterpremedia.com</mail-id><mail-subject>Upload for Online First approved for 10.1136/esmoopen-2019-000511</mail-subject><from>bmj@exeterpremedia.com</from><to>production.esmoopen@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p><span class="article-id">10.1136/esmoopen-2019-000511</span> has been approved for Upload for Online First.</p><p>Best wishes</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="ebd83a3e-7427-4627-9004-844d3ef0b476" type="workflow"><id>ebd83a3e-7427-4627-9004-844d3ef0b476</id><fullname>Usha Venkatesh, usha.venkatesh@exeterpremedia.com</fullname><created>2019-05-21 06:59:04</created><content>Assigned to : Usha Venkatesh, usha.venkatesh@exeterpremedia.com</content></note><note id="98f56521-0dc4-4fff-802b-ffe489e6021e" type="workflow"><id>98f56521-0dc4-4fff-802b-ffe489e6021e</id><fullname>Usha Venkatesh</fullname><created>2019-05-21 10:32:58</created><content>Article signed-off from Final Deliverables to Upload for Online First</content></note><note id="877112a5-b408-4f86-abbd-4b129b955f7d" type="email"><id>877112a5-b408-4f86-abbd-4b129b955f7d</id><fullname>Usha Venkatesh</fullname><created>2019-05-21 10:33:01</created><content><email-content><mail-id>26052ac1-84a1-b27d-d2df-f4d6b68b1103@exeterpremedia.com</mail-id><mail-subject>10.1136/esmoopen-2019-000511: Article has been uploaded to HighWire Express site</mail-subject><from>bmj@exeterpremedia.com</from><to>production.esmoopen@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p>We have uploaded the article on the HighWire Express site.</p><p>Best wishes</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note><note id="930afa8f-d67c-4288-af3b-66e8c3b88fc2"><id>cd23b1b0-ecc9-4452-a000-4b9ec47412c6</id><fullname>Automation</fullname><created>2019-05-21 12:00:07</created><content>Published</content></note><note id="5e5a61f4-31fa-4e14-b07e-c77c905f8f72" type="workflow"><id>5e5a61f4-31fa-4e14-b07e-c77c905f8f72</id><fullname>Workflow</fullname><created>2019-05-21 12:00:16</created><content>Article signed-off from Upload for Online First to Archive</content></note><note id="631a110d-76b1-4973-b394-a1ffd157a971" type="paw"><id>631a110d-76b1-4973-b394-a1ffd157a971</id><fullname>Workflow</fullname><created>2019-05-21 12:00:28</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Upload for Online First to Article Bank</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"Not processed: PAW stage and current stage"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ArticleStageTypeName":</span> <span class="string">"Upload for Online First"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticle"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"esmoopen"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"esmoopen-2019-000511"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">2.5</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Dr. John Haanen"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Upload for Online First"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-05-17T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="null">null</span>, <br/><span class="key">"Ended":</span> <span class="string">"2019-05-21T12:00:00"</span> } ] }</pre></div></div></content></note><note id="7afc2d5c-2d4f-482d-a024-2f063467542f" type="email"><id>7afc2d5c-2d4f-482d-a024-2f063467542f</id><fullname>Workflow</fullname><created>2019-05-21 12:00:29</created><content><email-content><mail-id>64f5918e-724a-d812-9456-2dc712094dfa@exeterpremedia.com</mail-id><mail-subject>10.1136/esmoopen-2019-000511: Article has been moved to Archive</mail-subject><from>bmj@exeterpremedia.com</from><to>production.esmoopen@bmj.com</to><mail-body><p>Dear Publisher</p><p>The uploaded article has been moved to Archive.</p><p>Best wishes</p><p style="font-size:10.0pt;">kriyā@BMJ</p></mail-body></email-content></content></note></production-notes></article>